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General introduction and outline of the thesis
Type 2 diabetes (T2DM) represents a serious threat to human health in almost 
every country in the world. In 2005, the World Health Organization estimated 
that 1.1 million people died as a result of diabetes-related complications and this 
represents almost certainly an underestimation. Moreover, it is estimated that this 
number will increase worldwide by approximately 50% between 2005 and 2030 
[1]. T2DM develops as a consequence of the complex interaction between genetic 
predisposition and behavioral and environmental risk factors. In this respect, high 
fat, energy dense diets and physical inactivity, both of which promote obesity, are 
among the main non-genetic determinants [2]. Until recently, T2DM was a disease 
that only affected middle-aged and older adults. Now, a growing number of young 
adults, adolescents and even children are diagnosed with obesity-related T2DM 
[3,4]. 
Obesity, in particular central obesity, is strongly associated with insulin resistance. 
Under physiologic conditions, the amount of insulin secreted by the pancreatic 
beta-cells matches the increased insulin demand in order to maintain glucose levels 
within the normal range [5]. However, when insulin demand exceeds the capacity 
of beta cells to secrete insulin, glucose levels will rise into the pre-diabetic states, 
i.e. impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) (Figure 
1) [6,7]. Consequently, the rise in glucose levels, in pre-diabetic states and T2DM, 
is the result of both insulin resistance and beta-cell dysfunction [6,7]. Although a 
certain percentage of individuals with IFG and/or IGT may revert to normoglycemia, 
the absolute annual risk for individuals with IFG and/or IGT to develop T2DM ranges 
from 5 to 10% [8]. This high risk for individuals with IFG and/or IGT to progress 
to T2DM prompted us to perform the studies described in this thesis, giving us 
more insight in the underlying pathology (Part 1) and the protective effect of RAS 
blockade in this high risk population (Part 2).
In addition to impairments in glucose metabolism, individuals with IFG and/or 
IGT often display several concurrent cardiometabolic abnormalities, including 
hyperinsulinemia, dyslipidemia and hypertension. The close relationship between 
impaired glucose metabolism and dyslipidemia has been described extensively. 
As such, insulin resistance is characterized by an impaired adipose tissue function 
and an inability to buffer the daily influx of dietary fat entering the circulation 
by suppressing the release of non-esterified fatty acids (NEFA) and increasing 
the clearance of triacylglycerol [9]. This leads to chronically elevated NEFA and 
triglyceride levels [10] and accumulation of lipids and lipid metabolites in non-
adipose tissues such as skeletal muscle, liver and pancreas [11,12]. This ectopic 
fat accumulation is a strong marker of insulin resistance in skeletal muscle and 
the liver [11,13], and may impair insulin secretion in pancreatic beta-cells [12,14]. 
The harmful effect of chronically elevated NEFA levels has been referred to as 
lipotoxicity [15] and is not only seen in T2DM but has also been documented in 
individuals with IFG and/or IGT [13]. 
Chapter 1
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General introduction and outline of the thesis
Figure 1. Development of type 2 diabetes. In the presence of obesity-related insulin resistance, insulin secretion 
by the pancreatic beta-cells is increased to maintain glucose levels within the normal range. However, when 
insulin demand exceeds the capacity of beta cells to secrete insulin, glucose levels will rise into the prediabetic 
states and T2DM. Abbreviations: IGM, impaired glucose metabolism; T2DM, type 2 diabetes.
Part 1 of this thesis contains three different studies on the pathophysiology of 
impaired glucose metabolism. In specifi c, Chapter 2 gives an overview into 
how disturbances in lipid metabolism may interfere with beta-cell function as 
investigated in both preclinical studies and studies in humans. The evidence for 
lipotoxicity in humans is critically addressed including the data presented in 
Chapter 3. In this chapter a cross-sectional study investigating the effect of fat 
accumulation in the pancreas and its relation to beta-cell dysfunction is described. 
In the last chapter of Part 1 (Chapter 4), data regarding disturbances in skeletal 
muscle fatty acid handling in individuals with impaired glucose metabolism are 
described, to further identify the pathophysiology of insulin resistance in these 
different pre-diabetic states. 
There is an urgent need for approaches to prevent or treat the cardiometabolic 
syndrome and T2DM. The Finnish Diabetes Prevention Study outlined that a 
lifestyle intervention focusing on diet and physical activity (moderate exercise of at 
least 30 minutes a day, 5 days a week) reduced the incidence of T2DM by 58 percent 
in individuals at high risk to develop T2DM [16]. Although lifestyle intervention 
delayed the onset of T2DM, the Diabetes Prevention Program Outcomes Study 
showed that after 10 years the cumulative incidence of T2DM was still approximately 
40 percent in the lifestyle intervention group [17]. Consequently, early identifi cation 
of individuals who will progress to T2DM is essential in preventing the disease. 
Furthermore, the United Kingdom Prospective Diabetes Study (UKPDS) has clearly 
shown that in T2DM, over the years, HbA1c rises, regardless of the therapy given 
[18,19]. Also, this landmark study has clearly demonstrated that once T2DM is 
diagnosed, beta-cell function declines at an annual rate of 4% [20], which drives 
the observed worsening of glycemic control. Interestingly, ever since the core 
studies in the UKPDS have been concluded, several novel blood-glucose lowering 
agents have been introduced to the market, such as the thiazolidinediones and 
more recently, the glucagon-like peptide (GLP-1) receptor agonists and dipeptidyl 
peptidase (DPP)-4 inhibitors. However, according to most current guidelines, the use 
1
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of essentially the same drug classes as used in the UKPDS, i.e. sulphonylurea and 
metformin are still being advocated. These agents are indeed still the cornerstone of 
current oral blood-glucose lowering therapy in T2DM. Inasmuch these agents lower 
blood glucose, partly via improved insulin sensitivity, and relieve the symptomatic 
burden of T2DM, they do not halt the relentless deterioration of beta-cell function 
and as such the progression of the disease. Consequently, identifying therapeutic 
targets to improve, delay or restore pancreatic beta-cell dysfunction in addition to 
improvements in insulin sensitivity is today still considered an unmet clinical need. 
Already in populations at high risk to develop T2DM, such as IFG and/or IGT, a wide 
range of disturbances of beta-cell function can be found with an estimated loss 
of function up to 45% [6]. Thus, preservation or restoration of beta-cell function in 
this stage, where sufficient function is still left to be salvaged, seems essential to 
delay or prevent T2DM in this high risk population. Furthermore, the presence of 
insulin resistance increases insulin demand in these pre-diabetic states. However, 
at present, limited (pharmacological) therapies are available that in addition to 
improvements in insulin sensitivity, effectively prevent or slow down beta-cell 
function decline in these pre-diabetic subjects as well as in those with overt T2DM. 
In recent years, the role of renin-angiotensin blockers, i.e. angiotensin converting 
enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB), in the delayed 
onset of T2DM has been described [21,22]. 
The renin-angiotensin system (RAS) consists of several compounds, i.e. the liver-
derived angiotensinogen, which is cleaved by the renal-synthesized peptide renin 
into angiotensin I (AngI), that is converted by lung-derived angiotensin-converting 
enzyme into angiotensin II (AngII) [23]. Classically, the RAS is known for its systemic 
effects, in particular its role in the regulation of blood pressure, electrolyte and fluid 
homeostasis. Furthermore, in the past few years, a local RAS has been localized 
in almost any kind of tissue, including heart, blood vessels, kidney, brain, nerve 
fibres, pancreas, adipose tissue and skeletal muscle [24]. Consequently, AngII 
actions are not solely cardiovascular but also include metabolic effects as well as 
the promotion of inflammation, fibrosis, cell proliferation and apoptosis via the 
angiotensin type 1 receptor [24,25] and anti-inflammation, antiproliferation and 
tissue regeneration via the angiotensin type 2 receptor [26] in these tissues. 
RAS activation has also been implicated in the development of insulin resistance 
and beta-cell dysfunction (Figure 2) [27-29]. In large-scaled randomized clinical trials 
blockade of RAS, with an ACEi or ARB, delayed the onset of T2DM in non-diabetic 
subjects with hypertension [19,20]. Unfortunately, in these studies the onset of 
T2DM was generally not considered as a prespecified endpoint. Recently, two large-
scaled prospective trials, the DREAM trial (Diabetes Reduction Assessment with 
Ramipril and Rosiglitazone Medication [30] and the NAVIGATOR trial (Nateglinide 
and Valsartan in Impaired Glucose Tolerance Outcomes Research [31]), specifically 
showed the potential of RAS blockade to delay the onset of T2DM in individuals with 
IFG and/or IGT. However, the underlying mechanisms are incompletely understood. 
Chapter 1
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Therefore, Part II of this thesis focuses on the role of the RAS in metabolism. 
Chapter 5 gives an overview of the proposed mechanisms of how RAS blockade 
may delay the onset of T2DM, with a specific focus on beta-cell function and insulin 
sensitivity. In Chapter 6, we test the hypothesis that RAS blockade, using the ARB 
valsartan, will improve insulin sensitivity and beta-cell function in individuals with 
IFG and/or IGT. As reviewed in Chapter 5, the underlying mechanisms of improved 
beta-cell function and insulin sensitivity after RAS blockade are multifactorial 
and may include reduced oxidative stress and islet fibrosis in pancreatic islets, 
as well as improvements in adipose tissue function, alterations in adipokines 
and pro-inflammatory cytokines and increased adipose tissue blood flow, which 
in turn together may contribute to reduced ectopic fat deposition and improved 
insulin sensitivity. Furthermore, RAS blockade may directly affect skeletal muscle 
insulin signaling and affect skeletal muscle mitochondrial function. The evidence 
for these underlying mechanisms is mainly based on rodent data. Therefore, in this 
thesis, we investigated the effect of the ARB valsartan on microvascular function 
(Chapter  7), adipose tissue function (Chapter 8) and body composition and fat 
distribution (Chapter 9), to further clarify underlying mechanisms in individuals 
who are at high risk to develop T2DM.
General introduction and outline of the thesis
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ABSTRACT
Purpose of review
Type 2 Diabetes Mellitus (T2DM) is characterized by impaired insulin secretion. 
Chronically increased levels of plasma nonesterified fatty acids (NEFA) and 
triglyceride-rich lipoproteins impair beta-cell function, a process referred to as 
lipotoxicity. Furthermore, when NEFA supply exceeds metabolic capacity, lipids 
accumulate in non-adipose tissues, such as pancreatic islets, inducing organ 
dysfunction. The purpose of this review is to describe the mechanisms underlying 
lipotoxicity in vitro, to discuss the evidence for lipotoxicity in vivo and to address 
whether pancreatic lipid accumulation interferes with insulin secretion in humans.
Recent findings
Although numerous in vitro studies have shown that chronically elevated NEFA 
levels induce beta-cell dysfunction and apoptosis, studies in humans are less 
conclusive. It has been acknowledged that concurrent hyperglycemia amplifies 
the adverse effects of elevated plasma NEFA levels on beta-cell function, therefore 
glucolipotoxicity should be the preferred term. Lipid accumulation in pancreatic 
islets impaired beta-cell secretory capacity in leptin-deficient rodents. In humans, 
recent studies employing non-invasive MR- and CT-technology, lipid accumulation 
in the pancreas was increased in subjects with impaired glucose metabolism and 
T2DM. However, there was no clear association with beta-cell function.
Summary
To date, it is difficult to provide evidence that intra-islet lipid accumulation truly 
exists in humans and that it is indeed causal to beta-cell dysfunction. Additional 
research is warranted to further detail the nature and role of pancreatic lipid 
content in humans, its consequence for the postulated processes pertinent 
to glucolipotoxicity and its contribution to the progressive nature of beta-cell 
dysfunction in (pre)diabetes.
Chapter 2
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1. Introduction 
Type 2 Diabetes Mellitus (T2DM) is characterized by impaired insulin secretion 
against a background of obesity-related insulin resistance. Beta-cell failure is a 
prerequisite for the development of hyperglycemia and T2DM, and its progressive 
character determines the course of the disease with deterioration of glycemic 
control over time despite any treatment given [1,2]. Under physiological conditions, 
insulin secretion matches insulin demand. Thus, in insulin resistant states, healthy 
beta-cells augment insulin secretion to maintain glucose levels within the normal 
range. In order to be able to increase beta-cell function for a prolonged period of 
time, the number of islets, or beta-cell mass, is expanded [3]. In T2DM, the ability 
of beta cells to adequately meet the instantaneous need for insulin to maintain 
glucose homeostasis is compromised. Currently, the inadequate insulin secretion 
in T2DM is due to a combination of two components: i.e. a reduction in beta-cell 
mass and function, with an impaired insulin response to glucose stimuli as the 
most prominent defect [4].
In numerous studies, chronically elevated nonesterified fatty acids (NEFA) levels 
and triglyceride-rich lipoproteins (TRL) have been implied in the pathogenesis of 
both insulin resistance and beta-cell dysfunction. As such, elevated fasting NEFA 
levels were shown to increase the risk to develop T2DM, independent of their 
effects on insulin sensitivity [5]. Indeed, in vitro, prolonged exposure of human 
islets to NEFA resulted in marked beta-cell dysfunction, characterized by decreased 
insulin gene expression, blunted glucose-stimulated insulin secretion (GSIS) and 
increased apoptosis rates. These detrimental effects of NEFA on beta-cell function 
have been referred to as lipotoxicity [6].
 
In vivo, increased NEFA and triacylglycerol (TG) levels are frequently encountered 
in obese patients, and if present in excess of metabolic needs, may accumulate 
in non-adipose tissue, i.e. skeletal muscle, liver, heart and pancreas. In skeletal 
muscle, liver and heart muscle, lipid accumulation was associated with organ 
dysfunction [7]. The association between lipid accumulation in the pancreas 
and islet-cell function is less clear (Figure 1). Whereas in vivo studies in rodent 
models with deficient leptin-signaling have demonstrated an association between 
pancreatic lipid accumulation and deterioration of beta-cell function [8], studies in 
humans have produced more conflicting data [9,10,11,12,13].
In this review we will outline how chronically elevated levels of NEFA may impair 
beta-cell function in vitro. In addition, evidence for the existence of (gluco)lipotoxicity 
in vivo in humans will be discussed. In the final section of the review, in vivo studies 
that have additionally assessed pancreatic steatosis in different populations per se 
and its possible relation with endocrine function will be addressed.
2
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Figure 1. Intra-organ fat accumulation and associated organ dysfunction. Increased NEFA, TG and TRL plasma 
levels induce adipose tissue expansion, but may also lead to intra-organ fat accumulation in the pancreas, skeletal 
muscle, liver and heart muscle. Although clear associations are described between fat accumulation and organ 
dysfunction for skeletal muscle, liver and the heart, this is at present unclear for the pancreas. Abbreviations: 
EGP: endogenous glucose production; NEFA: nonesterifi ed fatty acids; TG: triacylglycerol; TRL: triglyceride-rich 
lipoproteins. 
2.1 Lipotoxicity: multiple mechanisms
The term lipotoxicity refers to the detrimental effects of chronically elevated NEFA 
levels on beta-cell function and mass, characterized by decreased insulin secretion, 
diminished insulin synthesis and increased beta-cell apoptosis [14]. A number 
of mechanisms have been proposed underlying the NEFA-mediated effects on 
the beta cells. These include endoplasmic reticulum (ER) stress, oxidative stress, 
mitochondrial uncoupling and dysfunction, islet infl ammation and beta-cell 
apoptosis (Figure 2). Since most evidence is derived from in vitro studies, caution has 
to be taken in extrapolating these concepts to the situation in humans. In addition, 
it should be emphasised that the pathophysiological mechanisms of lipotoxicity 
described below are derived from studies investigating the chronic effects of NEFA 
exposure on beta-cell function. It is, on the other hand, well recognised that acute 
NEFA exposure may enhance insulin secretion.
2.1.1 Endoplasmic reticulum stress
The ER is a dynamic cell organelle and responsible for the synthesis of almost all 
secreted proteins. In the ER, proteins are translated, folded and assessed for quality 
before they are released. An imbalance between protein production and folding 
capacity on one hand, and cellular demands on the other, may lead to ‘ER stress’, a 
state characterized by an excess of misfolded proteins inside the ER. To restore ER 
homeostasis, a protective mechanism is activated, known as the unfolded protein 
response (UPR). The UPR attempts to reduce the amount of new protein synthesis, 
to increase folding capacity, and to degrade terminally misfolded proteins. When 
the UPR fails to alleviate ER stress, however, the UPR triggers apoptosis [15].
Numerous studies have demonstrated that chronically elevated NEFA levels induce 
ER stress in both pancreatic beta-cell lines and cultured human islets. Incubation 
with the saturated NEFA palmitate, and to a lesser extent with the monounsaturated 
NEFA oleate, induced an ER stress response with activation of the three major 
hyperglycemia
2
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signalling pathways of the UPR: 1) inositol requiring ER-to-nucleus signal kinase-1 
(IRE-1), 2) PKR-like ER kinase (PERK) and 3) activating transcription factor (ATF)6 
[15,16,17,18]. In addition, NEFA activate C/EBP homologous protein (CHOP) and 
c-Jun N-terminal kinase (JNK), key signals in the apoptosis pathway, through the 
UPR. Indeed, palmitate-induced apoptosis could partially be reversed by increasing 
ER folding capacity [18]. The mechanisms by which NEFA induce ER stress are 
currently unclear, however, it is suggested that NEFA may deplete ER Ca2+ stores, 
thereby reducing the protein folding capacity of the ER [19,20].
 
Evidence that ER stress may also be present in humans came from a number 
of studies. In beta-cells from pancreatic sections obtained from T2DM patients, 
distended ER was found using electron microscopy, and markers for both ER 
stress and apoptosis, including CHOP, were increased as compared to non-diabetic 
patients [15,18,21]. However, since T2DM patients experience hyperglycemia, which 
may also induce ER stress [22], it is diffi cult to tease out the specifi c contribution of 
NEFA relative to glucose to ER stress in these studies.
Figure 2. Overview of the pathophysiological mechanisms underlying NEFA-induced beta-cell dysfunction 
in vitro. Hyperlipidemia, in the presence or absence of hyperglycemia, impairs beta-cell function through 
distinct pathways, which are detailed in the text. Abbreviations: ATF6: activating transcription factor 6; bcl2: 
B-cell leukaemia 2; CHOP: C/EBP homologous protein; IRE1: inositol requiring ER-to-nucleus signal kinase-1; IL: 
interleukin; iNOS: inducible nitric oxide synthase; JNK: c-Jun N-terminal kinase; NF-kB: nuclear factor-kB; NO: 
nitric oxide; PERK: PKR-like ER kinase; ROS: reactive oxygen species; UPR: unfolded protein response.
2.1.2 Oxidative stress and mitochondrial dysfunction
Oxidative stress refers to a persistent imbalance between the production of reactive 
oxygen species (ROS) and antioxidant capacity. Since beta cells have very low 
levels of antioxidant enzymes, they are particularly vulnerable to oxidative stress. 
Although at physiological levels, ROS are involved in important cellular processes, 
increased levels of ROS are detrimental for beta-cell function. Mitochondria, critical 
regulators of both GSIS and beta-cell mass, play an essential role in oxidative 
stress. ROS are formed in mitochondria during nutrient oxidation in the electron 
transport chain, thus, in times of excessive nutrient supply and oxidation, ROS 
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levels will concurrently increase. Mitochondria are not only the primary source of 
ROS production within the beta cell, but they also act as the primary target of ROS, 
which were shown to damage mitochondrial DNA and mitochondrial membrane 
proteins, and to decrease the ability of mitochondria to produce ATP, resulting in 
reduced GSIS [23,24].
Several studies have found that increased NEFA levels impair beta-cell function 
by inducing oxidative stress. Both in isolated human [25] and rat [26] islets, and in 
cultured beta-cell lines [27,28], NEFA were shown to generate ROS and to reduce 
insulin secretion and insulin content, and to increase apoptosis rates. A 2-day [29] 
and 4-day [30] infusion of healthy rats with oleate or intralipid decreased GSIS both 
in vivo and ex vivo in perfusion experiments, with increased markers for oxidative 
stress and reduced insulin gene expression [30].
 
Further evidence for a role of oxidative stress in lipotoxicity comes from studies, in 
which antioxidant strategies were implemented. Treatment with anti-oxidants such 
as N-acetyl cysteine partially prevented NEFA-induced reductions in GSIS in rats 
in vivo [29,30] and prevented NEFA-induced impairment of both GSIS and insulin 
gene expression in vitro [28,30]. In humans, however, beneficial effects of anti-
oxidant treatment on beta-cell function, are yet to be established [31].
An additional pathway through which NEFA and ROS may impair mitochondrial 
dysfunction is related to uncoupling. Both NEFA and ROS activate uncoupling 
protein 2 (UCP-2), which uncouples the electrochemical gradient produced by the 
respiratory chain from ATP synthesis [32,33]. Although uncoupling of oxidative 
phosphorylation may protect beta cells against additional ROS production and 
oxidative stress [34], ATP synthesis necessary for insulin secretion, is also reduced 
[35]. Therefore, increased uncoupling through upregulated UCP-2 expression may 
contribute to the harmful effects of NEFA and ROS on beta-cell function [32].
2.1.3 Lipotoxicity and islet inflammation
In the last two decades it has become increasingly clear that inflammatory 
processes play an important role in the progressive beta-cell dysfunction and 
apoptosis rates in islets of T2DM patients [36]. Several studies suggest that NEFA 
may induce inflammatory responses in beta-cells. Both in MIN6 cells and human 
islets, chronic incubation with palmitate and oleate activated genes involved in 
inflammation and immunity, and induced the expression of various chemokines, 
as determined by microarray analysis [37,38]. Additional studies revealed that 
NEFA increase the expression of the cytokines interleukin (IL)-1, IL-6 and IL-8. These 
effects were shown to be mediated through the IL-1 receptor and through toll-like 
receptors (TLR) [39]. NEFA may thus directly induce inflammation and activate an 
immune response within beta cells.
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2.1.4 Lipotoxicity and apoptosis
In addition to perturbing beta-cell function, chronically elevated levels of NEFA 
induce beta-cell apoptosis in vitro. As discussed above, NEFA may induce 
apoptosis through multiple pathways, i.e. secondary to ER stress (via CHOP and 
JNK activation), through mechanisms related to oxidative stress and mitochondrial 
dysfunction, and by inducing an inflammatory response in beta cells. Additional 
mechanisms as to how NEFA may induce beta-cell death have been reported. 
Saturated NEFA such as palmitate can serve as substrate for de novo ceramide 
synthesis, a sphingolipid that has been shown to be a potent inducer of apoptosis 
by activating nuclear factor (NF)-kB following inducible nitric oxide synthase 
(iNOS) upregulation. As such, inhibitors of ceramide and NOS were able to prevent 
NEFA-induced apoptosis [36]. Monounsaturated NEFA such as oleate, which do 
not serve as precursors for ceramide, are usually less cytotoxic than saturated 
NEFA [40,41]. Finally, NEFA were shown to regulate two proteins directly involved 
in apoptosis. NEFA increased the expression of pro-apoptotic cysteine-aspartic 
proteases (caspases) and reduced the expression of the protein B-cell leukemia 
(Bcl)-2 which facilitates cell survival [42].
3. Lipotoxicity: interplay with glucotoxicity 
In the previous section, we have described the mechanisms that underlie the 
deleterious effects of NEFA on beta cells in vitro, resulting in reduced beta-cell 
function and increased beta-cell apoptosis. However, it is currently being debated 
whether lipotoxicity can exist without the simultaneous presence of hyperglycemia. 
Several in vitro studies could only measure toxic effects of NEFA when combined 
with hyperglycemia [43,44]. In Zucker diabetic fatty (ZDF) rats, reduction of glucose 
levels with phlorizin treatment was able to prevent the decrease in insulin gene 
mRNA levels characteristic for these leptin-deficient rodents, whereas lowering of 
TG levels by bezafibrate treatment had no effect [14]. The biochemical basis for 
these observations was earlier proposed by Prentki and Corkey [45]. Elevated 
glucose levels in the beta cell may form malonyl-CoA following oxidation in 
mitochondria, which in turn prevent NEFA oxidation by impairing NEFA transport 
into mitochondria, resulting in accumulation of long-chain acyl-CoA esters in the 
cytoplasm, stimulating esterification of NEFA and glycerol into diacylglycerol (DAG) 
and TAG. The increased formation of lipid intermediates is thought to adversely 
affect beta-cell function either directly or via the generation of lipid-derived signals 
or metabolites, such as ceramide, that may enhance apoptosis by inducing iNOS 
[36,46]. Future studies should tease out the relative contribution of hyperlipidemia 
and hyperglycemia per se, as well as their synergistic effects, to the development 
and progression of beta-cell function in glucometabolic disorders. 
4. Lipotoxicity in vivo in humans 
As outlined above, several in vitro studies indicate that increased levels of 
NEFA, both in the presence and absence of hyperglycemia, impair intrinsic beta-
cell function and increase apoptosis. Studies on the effects of increased NEFA 
levels in vivo in humans have raised more controversial data. It seems clear that 
physiological NEFA levels are essential to sustain normal beta-cell function [47]. 
The effect of raising NEFA levels above normal values on beta-cell function has 
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rendered different results in the performed studies, dependent on achieved NEFA 
plasma levels, duration of NEFA infusion and the population that was studied. 
Acute elevation of plasma NEFA concentrations enhanced [48,49] or had no effect 
[50,51] on GSIS in healthy individuals. More prolonged infusion (48-72 hr), similarly 
generated opposite reports. Sustained NEFA infusion was shown to improve 
[52,53,54], not to affect [48] or to impair [55,49] parameters of beta-cell function in 
healthy volunteers. However, in obese subjects [56,57], patients with T2DM [58] and 
normoglycemic subjects with a strong family history of T2DM [53], prolonged NEFA 
infusion was shown to impair GSIS. In addition, a reduction of circulating NEFA 
concentrations with acipimox improved beta-cell function in relatives of T2DM 
patients [59]. These data suggest that increments in plasma NEFA concentrations 
in healthy humans do not impair GSIS and do not seem very “lipotoxic”, but that 
NEFA become the preferred substrate for insulin secretion, a process referred to 
as lipoadaptation [14]. However, in subjects susceptible for T2DM, there may be 
evidence for a role of hyperlipidemia in the pathogenesis of beta-cell dysfunction. 
As such, it was recently demonstrated that fasting plasma glucose (FPG) was closely 
associated with lipid-induced reduction of beta-cell function in obese subjects with 
impaired glucose tolerance (IGT) or T2DM as compared to obese normoglycemic 
controls [60].
 
In addition to NEFA, TG and very-low density lipoprotein (VLDL)-cholesterol 
levels may also induce lipotoxicity in compromised populations. As such, it was 
demonstrated that increased levels of these lipids were associated with a decline in 
islet graft survival in Type 1 Diabetes Mellitus islet transplant recipients [61]. 
5. Pancreatic steatosis: evidence for effects on endocrine function? 
In vivo, excess circulating NEFA are esterified and stored in adipose tissue. However, 
when NEFA or TRL levels exceed the metabolic capacity of adipose tissue, TG 
overflow will be directed to other organs, where it may impair its function. As such, 
in skeletal muscle tissue, increased lipid content was associated with impaired 
insulin-stimulated glucose uptake [62]. In the liver, fat content positively correlated 
with glucose production [63]. Finally, in the heart, myocardial steatosis was shown 
to be an independent predictor of diastolic dysfunction in subjects with T2DM [64]. 
Given these effects of intra-organ lipid accumulation, it was recently explored 
whether lipids may also accumulate in the pancreas, and whether a relation may 
exist between intra-islet lipid accumulation and beta-cell dysfunction (Figure 1).
In ZDF rats, it was reported that TG accumulation in islets precedes the development 
of hyperglycemia [8]. It is hypothesized that these TG may serve as a pool for the 
generation of NEFA and other toxic intermediates in lipid metabolism, such as DAG 
and ceramide, which could interfere with beta-cell function [65]. As such, in lipid laden 
islets isolated from ZDF rats, ceramide levels were augmented leading to increased 
NO-mediated beta-cell apoptosis [66]. In contrast, in purified healthy rat beta-cells, 
an inverse relation between TG accumulation and NEFA-induced cytotoxicity was 
reported [67]. The authors proposed that esterification of NEFA could serve as a 
protective mechanism by preventing a cellular rise in toxic lipid intermediates [67]. 
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This was in line with a previous study which demonstrated that promotion of TG 
accumulation protects against lipotoxicity as induced by saturated fatty acids [68]. 
Similarly, in different strains of rodents, intra-islet TG accumulation was positively 
associated with insulin secretion during ex vivo perfusion experiments [69]. These 
studies seem to suggest that accumulated TG are rather inert and that these TG 
may rather reflect a general derangement in lipid metabolism. This is supported 
by the notion that pancreatic TG accumulation in the latter study was positively 
correlated with insulin resistance [69]. 
A number of studies have recently investigated pancreatic lipid accumulation in 
humans [9,10,11,12,13]. Although one study reported that pancreatic fat content 
may only increase in relation to age and BMI [11], and may not be affected by 
the presence of metabolic disorders, other studies have reported differently. In the 
study performed by Tushuizen [12] and Lingvay [10], pancreatic fat content was 
higher in T2DM patients as compared to age-and BMI-matched controls. In addition, 
subjects with impaired fasting glucose (IFG) and/or IGT had more pancreatic lipid 
accumulation as compared to age- and BMI-matched normoglycemic controls 
[9,10,13]. The different methodology used to quantify pancreatic lipid accumulation 
could explain these conflicting results. Whereas Saisho et al [11] used computed 
tomography (CT) to measure pancreatic fat volume, in the other studies lipid 
content was assessed using magnetic resonance spectroscopy (1H-MRS), which 
was shown to correlate well with intra-islet TG content as measured by biochemical 
assays in rodents [10]. 
Three of the above-mentioned studies related pancreatic fat content to parameters 
of beta-cell function [9,12,13]. In non-diabetic subjects, inverse relations between 
pancreatic lipid content and various model-derived parameters of beta-cell function 
were observed. These correlations, however, were not present in T2DM patients 
[12]. Heni et al recently reported negative correlations between pancreatic fat 
content and markers for beta-cell function derived from an oral glucose tolerance 
test in IFG/IGT subjects, but could not confirm the negative correlations in healthy 
subjects [9]. More recently, we related pancreatic lipid accumulation to beta-cell 
function, measured by the gold standard hyperglycemic clamp, in subjects with 
IFG and/or IGT and age- and BMI-matched controls [13]. Interestingly, no relations 
between pancreatic fat accumulation and clamp-derived secretion parameters 
were observed. An inverse relation between pancreatic lipid accumulation and 
the disposition index (which corrects insulin secretion for insulin sensitivity) was 
observed. However, this inverse relation was not distinctive since similar relations 
were seen between liver fat content or visceral fat and the disposition index. In 
addition, positive correlations were found between the different abdominal fat 
parameters and insulin resistance, as was previously observed in rodents [69].
 
To summarize, in addition to aging and increasing BMI, pancreatic lipid content 
increases with deterioration of the glucometabolic state in humans. There is 
however no clear evidence that these lipids interfere with beta-cell function. Rather, 
accumulated lipids in the pancreas seem inert and, in our opinion, do not seem a 
direct cause for lipotoxicity in humans.
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Conclusion
Chronically elevated levels of NEFA, TRL and TG lead to impaired glucose 
metabolism, since they have been associated with both insulin resistance and 
beta-cell dysfunction. The adverse effects of prolonged increased NEFA levels on 
beta-cell function (lipotoxicity) were, however, primarily demonstrated in in vitro 
studies. In humans, the concept of lipotoxicity as a cause for beta-cell dysfunction, 
is currently unsettled. The negative effects of prolonged supraphysiological 
NEFA infusion on beta-cell function could only be demonstrated in populations 
with pre-existent impaired glucose metabolism. Also, pancreatic lipid content 
was highest in individuals with T2DM, and higher in those with impaired glucose 
metabolism relative to normoglycemic subjects. These observations point towards 
concurrent hyperglycemia to be instrumental for lipids to become deleterious 
in the development and progression of beta-cell dysfunction in glucometabolic 
disorders. Therefore we propose that glucolipotoxicity should be the preferred 
term to designate the processes associated with the dysmetabolic features of 
T2DM. Additional research is warranted to further detail the nature and role of 
pancreatic lipid content in humans, its consequence for the postulated processes 
pertinent to glucolipotoxicity and its contribution to the progressive nature of beta-
cell dysfunction in (pre)diabetes.
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ABSTRACT
Background
We hypothesized that ectopic fat deposition, in particular pancreatic fat accumulation, 
is related to beta-cell dysfunction in individuals with impaired glucose metabolism, 
i.e. impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). 
Methods
Sixty-four age- and BMI-matched individuals with normal glucose tolerance 
(NGT, n=16, 60% males), IFG (n=29, 52% males) or IFG/IGT (n=19, 63% males), 
underwent a) combined hyperinsulinemic-euglycemic and hyperglycemic clamp, 
with subsequent arginine-stimulation to quantify insulin sensitivity and C-peptide 
secretion b) Proton-magnetic resonance (MR) spectroscopy, to assess pancreatic 
(PFC) and liver (LFC) fat content and c) MRI, to quantify visceral (VAT) and 
subcutaneous (SAT) adipose tissue. The disposition index (DI) was used to estimate 
insulin sensitivity-adjusted beta-cell function.
Results 
IFG and IFG/IGT were more insulin resistant (P<0.001) compared to NGT. Individuals 
with IFG/IGT had lowest values of glucose- and arginine-stimulated C-peptide 
secretion (both P<0.03) and DI (P<0.001), relative to IFG and NGT. PFC and LFC 
gradually increased between NGT, IFG and IFG/IGT (P=0.02 and P=0.01, respectively), 
whereas VAT and SAT were similar between groups. No direct associations were 
found between PFC, LFC, VAT and SAT and C-peptide secretion. DI was inversely 
correlated with PFC, LFC and VAT (all P<0.05). 
Conclusion
PFC was increased in individuals with IFG and/or IGT, without a direct relation with 
beta-cell function.
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Introduction
Chronically elevated non-esterified fatty acids (NEFA) have been implicated in the 
pathogenesis of beta-cell dysfunction [1]. In vitro, prolonged exposure to elevated 
levels of NEFA result in decreased insulin gene expression, blunted glucose-
stimulated insulin secretion (GSIS) and increased apoptosis [2,3]. These deleterious 
effects of NEFA have been referred to as lipotoxicity [4,5]. In vivo, while acute 
infusion of intralipids was shown to enhance [6,7], prolonged infusion of intralipids 
was shown to impair glucose-stimulated insulin secretion [7,8]. In visceral obesity, 
excessive NEFA and lipid supply may exceed the oxidative capacity, which, in 
the presence of an impaired lipid storage capacity of adipose tissue, will lead to 
lipid accumulation in non-adipose tissues [9,10]. Furthermore, this ectopic lipid 
accumulation may result in functional impairments, including insulin resistance 
in skeletal muscle and liver, and decreased diastolic function of the heart [11-13]. 
At present, it is unclear whether lipid accumulation occurs in pancreatic islets and 
whether this contributes to beta-cell dysfunction. In leptin-deficient rodent models, 
lipid accumulation in pancreatic islets was associated with deterioration of beta-
cell mass and function [4,14]. However, data in humans are less conclusive.
 
First, it is under debate whether in glucometabolic disorders, pancreatic lipid 
accumulation exist independent of factors such as aging and obesity. Previously, 
increased pancreatic lipid accumulation, quantified by proton-magnetic resonance 
spectroscopy (1H-MRS), was reported in age- and BMI-matched individuals with 
impaired glucose metabolism [15] and type 2 diabetes mellitus [16] compared 
to healthy controls. In contrast, increased pancreatic lipid content has also been 
reported only to associate with aging and obesity, without a relation to glucose 
tolerance [17]. 
Second, it is unclear whether pancreatic lipid accumulation associates with beta-
cell dysfunction. It could be hypothesized that the accumulated pancreatic lipids 
may act as a source of NEFA or other lipid-derived metabolites, interfering with 
beta-cell function through lipotoxic pathways. In our previous study, pancreatic 
fat content was inversely associated with model-derived parameters of beta-cell 
function, assessed during an oral glucose tolerance test (OGTT), in healthy but 
not in T2DM men [16]. Similarly, in subjects with impaired glucose metabolism, an 
inverse relationship of pancreatic fat content and insulin secretion during an OGTT 
was described [18]. However, although OGTT derived beta-cell function provides 
valuable information on various aspects of beta-cell dynamics, the gold-standard 
measurement of beta-cell function is the hyperglycemic clamp method [19], which 
was used in the present study. For measurements of pancreatic fat content, we 
employed 1H-MRS. Although, this method cannot discriminate between intra-islet 
lipid accumulation and lipid accumulation outside of the islets, 1H-MRS-measured 
pancreatic fat content was validated against the gold-standard biochemical staining 
[15]. Furthermore, 1H-MRS-measured fat content closely paralleled that of intra-
islet fat content [20]. Consequently, 1H-MRS is considered to be the most reliable 
and validated method to assess pancreatic fat content in vivo. 
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In this study, we assessed pancreatic fat content and the association with clamp-
measured beta-cell function in individuals with impaired glucose metabolism, i.e. 
those with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) 
and healthy controls. Additionally, insulin sensitivity, liver fat content, visceral and 
subcutaneous adipose tissue were assessed. 
Research design and methods
Study population
Overweight Caucasian individuals with a family history of T2DM were recruited by 
advertisements in local news papers. After obtaining written informed consent, 149 
individuals underwent a 2-hour 75-gram OGTT during a screening visit. Individuals 
with IFG (fasting plasma glucose (FPG) ≥6.1 and <7.0 mmol/l) and/or individuals 
with IFG (FPG ≥5.6 and <7.0 mmol/l) and a family history of T2DM (i.e. first- and 
second- degree relatives), and/or IGT (2-hour plasma glucose level ≥7.8-11.1 mmol/l) 
were eligible. Individuals were only allowed to use blood pressure lowering or 
lipid lowering medication (statins). Twenty-nine individuals with IFG (52% males), 
3 individuals with isolated IGT and 16 individuals with combined IFG/IGT (63% 
males) were enrolled; 16 NGT (60% males) individuals, matched for age, gender 
and BMI served as controls. Claustrophobia, excess alcohol intake (>20 units/
week), history of diabetes, hepatitis and/or pancreatitis, abnormal liver and renal 
function tests (>2 times upper limits of normal) and recent (<3 months) changes 
in weight (≥5%) were exclusion criteria. The local ethics committee approved the 
study and the investigation conformed to the principles outlined in the Declaration 
of Helsinki.
 
Study design
Within one month after inclusion, participants arrived at the research institute after 
an overnight fast (from 10:00PM the previous evening). All participants underwent 
a 1H-MRS and a combined hyperinsulinemic-euglycemic and hyperglycemic clamp 
procedure, with additional arginine stimulation.
Pancreas and liver 1H-MRS 
Magnetic resonance imaging (MRI), for determination of abdominal fat 
compartments, and 1H-MRS, to quantify fat content in the liver and the pancreas, 
were performed in the supine position using a 1.5 T whole-body system equipped 
with spine and body phased-array coils (Sonata; Siemens, Erlangen, Germany). 
All scans were performed by a single investigator (NJZ). To diminish respiratory 
artefacts spectroscopic volumes-of-interest (VOIs) were positioned on respiratory-
triggered coronal and axial T2-weighted HASTE images. A respiratory-triggered 
PRESS sequence was used for 1H-MRS acquisition (repetition time TR ≥3 s, 
determined by respiration interval, echo time TE 30 ms, 8 measurements with one 
acquisition each were stored separately). Pancreatic fat content was measured in 
the distal part of the pancreas using an oblique 2.5 cm3 (2.5 x 1.0 x 1.0 cm) VOI, 
avoiding the spleen vessels and the lateral margin of the pancreas. Three 8 cm3 
(2.0 x 2.0 x 2.0 cm) VOIs were positioned in the liver (right anterior, right posterior 
and medial or left anterior) avoiding major blood vessels, intra-hepatic bile ducts, 
and the lateral margin of the liver. All 8 separate spectra per VOI were quantified 
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with LCModel, and subsequently combined for the analyses of the mean pancreas 
and liver spectra [16,21]. Fat content was defined as the signal intensities at 0.9 
and 1.3 ppm (methyl- and saturated methylene protons of triglycerides) relative 
to the signal intensity of water at 4.65 ppm. Occasionally, one or two out of eight 
measurements were discarded due to obvious visceral fat contamination. To 
determine reproducibility, 1H-MRS measurements of pancreatic and liver fat content 
were performed twice in the same individuals (n = 10) during two independent 
sessions separated by more than ten minutes. The mean intra-subject coefficient of 
variation (CV) between two repeated pancreatic fat measurements was 14% with a 
pearson correlation coefficient (r) of 0.95. The CV between two assessments of liver 
fat was 4%, with r=0.99.
Visceral and subcutaneous adipose tissue compartments
Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were 
measured by MRI as described previously [22]. Briefly, sagittal and coronal slices 
were used to localize anatomic sites for image acquisition (L4–L5). Three T1-
weighted transverse spin-echo images (TR 40  ms, TE 13 ms, 10 mm slice thickness, 
20 mm spacing, 1 image per breath hold) were obtained. Quantification of VAT 
and SAT were performed using an image analysis program, running on a Sparc10 
workstation (Sun Microsystems, Palo Alto, CA, USA). A seed point was placed in a 
fat depot, and using a seed-growing procedure, this fat depot can be circumscribed 
by the selection of a pixel intensity range. The areas were expressed in cm2 and 
the average area of the three transverse images was used for statistical analyses. 
Processing of MRI data and calculation of SAT and VAT was performed by a single 
experienced investigator (MHM).
Combined clamp procedures 
A modified combined hyperinsulinemic-euglycemic and hyperglycemic clamp, 
with subsequent arginine-stimulation, was performed as previously described [23] 
to assess insulin sensitivity and secretion. In brief, during the hyperinsulinemic-
euglycemic clamp the insulin infusion rate was maintained at 40 mU/min/m2 body 
surface area for 120 minutes. Insulin sensitivity was defined as the glucose infusion 
rate (M-value, mg⋅kg-1⋅min-1), during the last 30 minutes of the hyperinsulinemic-
euglycemic clamp, with blood glucose levels at a steady state of 5.0 mmol/L. An 
hour after the hyperinsulinemic-euglycemic clamp, the hyperglycemic clamp was 
started with an intravenous glucose bolus, increasing glucose levels to 15.0 mmol/L. 
Blood glucose levels were sustained at a steady-state of 15 mmol/L, with variable 
20% glucose infusion. During the hyperglycemic clamp blood was collected 
to measure insulin and C-peptide levels and first- and second-phase glucose 
stimulated C-peptide secretion was assessed. First-phase C-peptide secretion was 
calculated as the C-peptide area under the curve (AUC, nmol⋅min/L) during the first 
ten minutes after the intravenous glucose bolus. Second phase C-peptide secretion 
was calculated as the C-peptide AUC during 70 minutes following first-phase 
C-peptide secretion. Subsequently, a 5-gram arginine bolus was administered to 
measure maximum C-peptide secretory capacity at a steady-state blood glucose 
concentration of 15 mmol/L [24]. Combined hyperglycemia and arginine-stimulated 
beta-cell secretory capacity was calculated as the C-peptide AUC during the first 
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10 minutes after the arginine bolus (AIRarg). Insulin sensitivity adjusted beta-cell 
function, the disposition index (DI, (pmol⋅min/L)⋅(mg⋅kg-1⋅min-1)), was calculated by 
multiplying first-phase insulin secretion and M-value [25].
Biochemical analyses
Fasting plasma glucose (FPG) concentrations were determined using a hexokinase 
method (Gluco-quant, Roche Diagnostics, Mannheim, Germany). Glycated 
hemoglobin (HbA1c) was measured by cation exchange chromatography (Menarini 
Diagnostics, Florence, Italy; reference values: 4.3-6.1%). Total cholesterol, HDL-
cholesterol and NEFA in the fasting state (NEFAfast) and during the hyperinsulinemic-
euglycemic clamp (NEFAins), were determined using an enzymatic colorimetric 
method.
Statistical analyses 
Data are expressed as mean ± standard deviation (SD) or, in case of skewed 
distribution, as median (interquartile range, IQR) for numerical variables and as 
proportions for categorical variables. Group differences were tested by analysis 
of variances (ANOVA) with Bonferroni post-hoc analyses. Differences in non-
normally distributed variables of subject characteristics were tested with Kruskal-
Wallis test. In the analyses isolated IGT and combined IFG/IGT were taken together, 
excluding the isolated IGT individuals from the analyses did not alter the results. 
Spearman’s correlations were used to evaluate the relation between pancreatic fat 
content, liver fat content, VAT, SAT and NEFAins with beta-cell function and relevant 
glucometabolic determinants (i.e. age, BMI, HDL-cholesterol, triglycerides, FPG 
and insulin sensitivity). Multivariable regression analyses were used to assess 
independent determinants of pancreatic fat, and to evaluate effect modification 
by group (i.e. NGT, IFG, IFG/IGT, tested by adding the interaction term pancreatic 
fat content x group). A P-value <0.1 was considered to indicate effect modification. 
Statistical analyses were performed using SPSS for windows version 15.0 (SPSS, 
Chicago, IL, USA). A P-value <0.05 was considered statistically significant.
Results
Subject characteristics 
Baseline characteristics of the study population are summarized in Table 1. There 
were no differences between groups with respect to age, BMI, waist and lipid profile. 
Individuals with impaired glucose metabolism had higher blood pressure, HbA1c, 
FPG and fasting plasma insulin (FPI) compared to NGT. NEFAfast were increased in 
IFG; NEFAins were highest in IFG/IGT compared to controls.
Pancreatic fat, liver fat, VAT and SAT
Pancreatic fat content gradually increased with deterioration of glucose metabolism: 
NGT: 7.6% (2.9-13.4) vs. IFG: 12.1% (5.1-17.5) vs. IFG/IGT: 22.4% (7.3-36.2). Similarly, 
liver fat content increased between NGT, IFG and IFG/IGT. However, VAT and SAT 
did not differ between the three groups (all Figure 1).
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Controls (n=16) IFG (n=29) IFG/IGT (n=19) P -trend
Sex, %males 60 52 63 0.668
Age, years 54.8 ± 7.3 57.0 ± 8.0 56.2 ± 6.4 0.655
Body mass index, kg/m2 27.5 ± 3.0 28.7 ± 3.7 28.2 ± 3.6 0.481
Waist circumference, cm 98.3 ± 10.2 101.3 ± 10.3 100.6 ± 11.4 0.575
Systolic blood pressure, mmHg 123 ± 7 132 ± 13 a 131 ± 9 a 0.033
Diastolic blood pressure, mmHg 79 ± 6 83 ± 6 85 ± 7 a 0.024
Fasting plasma glucose, mmol/L 5.0 ± 0.3 6.3 ± 0.4 a 6.2 ± 0.6 a <0.001
Fasting plasma insulin, pmol/L 44 (30-49) 64 (49-89) a 74 (48-97) b 0.003
Plasma glucose 2-h, mmol/L 5.0 ± 1.5 6.3 ± 0.9 b 9.5 ± 1.1 bc <0.001
HbA1c, % 5.4 ± 0.3 5.8 ± 0.3 
a 5.8 ± 0.3 a <0.001
Alkaline Phosphatase, U/L 64 (62-74) 78 (73-88) a 72 (54-82) 0.012
Gamma-GT, U/L 24 (20-30) 32 (22-44) 31 (20-42) 0.145
ALT, U/L 29 (17-42) 28 (22-37) 28 (20-43) 0.804
Total cholesterol, mmol/L 5.3 ± 0.8 5.3 ± 1.0 5.3 ± 1.0 0.985
HDL-C, mmol/L 1.6 ± 0.4 1.3 ± 0.4 1.4 ± 0.5 0.247
LDL-C, mmol/L 3.2 ± 0.9 3.3 ± 0.8 3.1 ± 0.8 0.820
Plasma triglycerides, mmol/L 1.2 ± 0.5 1.5 ± 0.7 1.7 ± 0.9 0.169
NEFAfast, mmol/L 0.45 (0.31-0.53) 0.52 (0.45-0.7) 
a 0.53 (0.35-0.65) 0.100
NEFAins, mmol/L 0.03 (0.02-0.04) 0.05 (0.03-0.07) 0.06 (0.04-0.08) 
a 0.095
M-value, mg⋅kg-1⋅min-1 9.4 (6.9-11.3) 5.0 (4.0-5.6) b 5.3 (3.4-5.8) b <0.001
Blood pressure lowering therapy, % 0 22 29 0.084
Lipid lowering medication, % 0 7 0 0.298
Table 1. Clinical and biochemical characteristics. Values are mean ± SD or median (interquartile range). ALT, 
alanine transaminase; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; NEFAfast, fasting non-esterified fatty acids; 
NEFAins, NEFA during hyperinsulinemic-euglycemic clamp; 
a P<0.05, compared to CO; b P<0.001, compared to CO; 
c P<0.001, IFG/IGT compared to IFG. 
Pancreatic fat, liver fat and VAT were positively associated with age, BMI, FPG 
and triglycerides and negatively related to HDL-cholesterol (Table 2). In addition 
NEFAins associated with increased liver fat content, triglycerides, VAT and FPG and 
decreased HDL-cholesterol (Table 2).
Using multivariate analysis, independent determinants of pancreatic fat content 
were assessed. Since group (i.e. NGT, IFG and/or IFG/IGT) was not an effect modifier 
(P>0.1), the analysis was performed in the total study population. However, to correct 
for possible confounding, group was added to the model. Age, BMI, 2-hour plasma 
glucose levels and HDL-cholesterol were significant determinants of pancreatic fat 
content (adjusted R-square of the model: 0.33, Pmodel=0.001, unstandardized beta 
(b) group: b=5.8, P=0.073; Age: b=0.38, P=0.062; BMI: b=1.16, P=0.025; 2-h plasma 
glucose level: b=0.29, P=0.05; HDL-cholesterol: b=-11.6, P=0.01). 
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Figure 1. Pancreatic fat content (A), liver fat content (B), visceral adipose tissue (C) and subcutaneous adipose 
tissue (D) in normoglycemic healthy controls, IFG, IFG/IGT.
Values are mean ±SD; NGT (white bar), IFG (grey bar) and IFG/IGT (black bar).
PFC
(%)
LFC 
(%)
VAT 
(cm2)
SAT 
(cm2)
TG 
(mmol/L)
NEFAins 
(mmol/L)
Age, years 0.413 b 0.333 a 0.175 0.124 -0.071 -0.194
BMI, kg/m2 0.471 b 0.423 b 0.468 b 0.716 b 0.300 a 0.155
HDL-C, mmol/L -0.356 a -0.494 b -0.473 b 0.043 -0.423 b -0.426 b 
Triglycerides, mmol/L 0.231 a 0.226 a 0.271 a 0.128 - 0.343 a
NEFAfast, mmol/L 0.018 0.070 -0.086 0.074 -0.104 0.077
NEFAins, mmol/L 0.084 0.335
a 0.186 -0.029 0.343b -
FPG, mmol/L 0.264 a 0.296 a 0.116 0.035 0.229 0.329 a 
M-value, mg⋅kg-1⋅min-1 -0.301 a -0.562 b -0.291 a -0.266 a -0.368 b -0.577 b 
1st-phase, nmol⋅min/L 0.075 0.022 0.012 0.087 0.137 0.101
2nd-phase, nmol⋅min/L 0.197 0.268 0.095 0.068 0.232 0.257
AIRarg, nmol⋅min/L 0.248 0.249 0.089 0.014 0.199 0.184
DI, (pmol⋅min/L)⋅(mg⋅kg-1⋅min-1) -0.249 a -0.274 a -0.310 b -0.140 -0.097 -0.269 a
Table 2. Univariate correlations between abdominal fat measurements, beta-cell function and insulin sensitivity. 
r, Spearman’s correlation coefficient; BMI, body mass index; HDL-C, HDL-cholesterol; FPG, fasting plasma 
glucose; FPI, fasting plasma insulin; LFC, liver fat content; PFC, pancreatic fat content; VAT, visceral adipose 
tissue area; SAT, subcutaneous abdominal adipose tissue area; NEFAfast, fasting NEFA; NEFAins, NEFA during 
hyperinsulinemic-euglycemic clamp; 1st-phase, AUC of glucose stimulated first phase C-peptide secretion; 
2nd-phase, AUC of glucose stimulated second phase C-peptide secretion; AIRarg, AUC of C-peptide response to 
Arginine at 15 mmol/L glucose level; DI, disposition index; a P<0.05; b P<0.01. 
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Clamp-measured aspects of beta-cell function, insulin sensitivity and disposition index
Differences in C-peptide secretion between the three groups are shown in Figure 
2; IFG individuals had decreased first-phase C-peptide secretion compared to 
NGT. In IFG/IGT, both glucose- and arginine-stimulated C-peptide secretion were 
diminished, compared to IFG and NGT. As expected, IFG and IFG/IGT were more 
insulin resistant compared to controls (M-value, IFG/IGT: 5.3 mg⋅kg-1⋅min-1 (3.4-5.8) 
vs. IFG: 5.0 mg⋅kg-1⋅min-1 (4.0-5.6) vs. NGT 9.4 mg⋅kg-1⋅min-1 (6.9-11.3), Ptrend<0.001). 
The disposition index, decreased with deterioration of glucose metabolism: NGT: 
1958 (pmol⋅min/L)⋅(mg⋅kg-1⋅min-1) (1779-2887) vs. IFG: 773 (pmol⋅min/L)⋅(mg⋅kg-
1⋅min-1) (404-1129) vs. IFG/IGT: 483 (pmol⋅min/L)⋅(mg⋅kg-1⋅min-1) (331- 730) (P<0.001).
 
Figure 2. C-peptide concentrations during the hyperglycemic clamp with subsequent arginine stimulation in 
NGT (white bar/dot), IFG (grey bar/squares) and IFG/IGT (black bar/triangles). Data are mean ± SD; 1st phase, first-
phase C-peptide response to glucose; 2nd phase, second-phase C-peptide response to glucose; AIRarg, C-peptide 
response to arginine at 15 mmol/l glucose concentration. See ‘Research design and methods’ for calculations of 
beta-cell function parameters.
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Associations of ectopic fat with variables of beta-cell function, insulin sensitivity 
and disposition index
No significant correlations were found between pancreatic fat content and glucose- 
or arginine-stimulated C-peptide secretion (Table 2). Pancreatic fat content, liver fat 
content, VAT, SAT and triglycerides were inversely associated with insulin sensitivity 
(Table 2). There was an inverse relationship between pancreatic fat content and 
DI (Table 2). However, in multivariable regression analyses, this association did 
not sustain after adjustment for age and BMI (data not shown). Similarly, inverse 
associations were observed between liver fat content, VAT and NEFAins and the DI. 
Discussion
The present study demonstrates that the impairments in beta-cell function in 
individuals with IFG and IFG/IGT, are accompanied by fat accumulation in the 
pancreas. However, a relation between pancreatic fat accumulation and beta-cell 
function could not be established. The ectopic fat depots showed strong inverse 
relations with insulin sensitivity. 
Our participants were well matched for age and BMI and classified based on 
impairments in fasting and post load glucose levels. VAT did not alter between 
the three groups, where there was an increase in liver fat content. The discrepancy 
between VAT and liver fat content has been described previously, outlining liver 
fat content as a more accurate marker in the detection of metabolic derangements 
than visceral adipose tissue in obese subjects [26,27].
In obesity and insulin resistant states, in the additional presence of adipose tissue 
dysfunction with impaired lipid storage capacity, lipids will accumulate in non-
adipose tissues [10]. This ectopic lipid accumulation enhances with aging, obesity 
and glucometabolic disorders [28,29]. However, whether the latter also applies 
to the pancreas is currently under debate. Previously, we and others showed a 
gradual increase in 1H-MRS-measured pancreatic fat content with deterioration of 
glucose metabolism (ranging from NGT, IFG and/or IGT and T2DM) [15,16,18]. In 
contrast, Saisho et al. [19] found no relation between computed tomography (CT) 
measured pancreatic fat content and glucometabolic disorders. In the current study, 
we were able to confirm our previous findings, showing an increase in pancreatic 
fat content in individuals with IFG and/or IGT compared to age- and BMI-matched 
normoglycemic controls. Similar to Lingvay et al. [15], post-load glucose levels were 
independently associated with pancreatic fat content, delineating an independent 
relation with glucometabolic changes. These data outline the reciprocal association 
of glucose and fatty acid metabolism, where increasing glucose availability may 
promote the shuttling of fatty acids into esterification to triglycerides, rather than 
to oxidation, leading to intracellular triglyceride accumulation [30]. Therefore, in 
glucometabolic disorders both hyperglycemia and hyperlipidemia may contribute 
to ectopic lipid accumulation and organ dysfunction. Differences between our 
results and the findings of Saisho et al., are possibly due to the use of different 
techniques to assess pancreatic fat content. Saisho et al. used CT, measuring lipid 
content primarily outside the parenchyma, whereas we used 1H-MRS, measuring 
lipid content within the parenchyma [31].
Chapter 3
3
Opzet Proefschrift-def 25052011.indd   46 25-05-11   16:27
47
Excessive pancreatic lipid content may enter a continuous vicious cycle of hydrolysis 
and fatty acid re-esterification, thereby generating toxic intermediates (i.e. 
ceramide, diacylglycerol), which may induce beta-cell dysfunction and apoptosis 
[32,33]. These are among the lipotoxic mechanisms that have been shown to exist in 
pancreatic islets in vitro and in rodents in vivo [3-5,33]. Conclusive data in humans 
in vivo, regarding the occurrence of lipotoxicity as a causal factor of beta-cell 
dysfunction is lacking. Studies with prolonged intralipid infusions show conflicting 
results, since an increase [34], no effect [35] or a decrease [36] in GSIS, are all 
described. However, these studies measured the effect of infused lipids rather than 
lipids stored in the pancreas. We and others, related pancreatic lipid accumulation 
to OGTT-measured beta-cell function [15,16,18]. Although inverse relations were 
seen with beta-cell function, data was not conclusive. OGTT-derived beta-cell 
function provides valuable information, however, the gold-standard measurement 
for beta-cell function is the hyperglycemic clamp method. Therefore, in this study 
we related clamp-measured beta-cell function to pancreatic fat content.
Based on our previous study, where we found an inverse relation between 
pancreatic fat content and OGTT-derived beta-cell function in non-diabetic men 
[16], we expected to find an inverse relation with beta-cell function in subjects with 
IFG and/or IGT. However, we could not establish a relation between pancreatic 
fat content and direct measurements of beta-cell function. Several explanations 
for the lack of association with unadjusted C-peptide secretion variables may be 
postulated. Although 1H-MRS measures parenchymal triglyceride accumulation, 
1H-MRS cannot discriminate between intra- and inter-islet fat accumulation [31]. 
Since beta cells constitute only 2% of the total pancreas mass [37], 1H-MRS 
measured lipid deposition in the pancreas is most likely located outside beta cells, 
e.g. in exocrine or stromal cells or in adipocytes infiltrating the pancreas. This 
infiltrating adipose tissue is presumably closely associated with visceral fat which 
is known to be metabolically active and release NEFA and adipocytokines [38], all 
of which may subsequently adversely affect islet structure, survival and beta-cell 
function. Unfortunately, in this study these contributing factors were not assessed. 
Regardless, determination of circulating factors, will not allow to establish their 
origin and therefore will not enable us to discriminate between the contribution of 
the different fat compartments to beta-cell dysfunction.
Finally, it has been suggested that triglyceride depositions reflect a protective buffer, 
diverting excess NEFA from metabolic pathways leading to lipotoxicity affecting 
beta-cell function and survival. Instead, NEFA are channelled into lipid stores in 
non-adipose tissue, including the pancreas. Therefore, although pancreatic lipid 
content reflects derangements in lipid metabolism, it is unknown whether these 
depositions in fact are inert or harmful.
 
In the current study we focused on individuals with impaired glucose metabolism, 
a population that is characterized by defects in both beta-cell function and insulin 
sensitivity [39]. Subjects with impaired glucose metabolism showed altered 
C-peptide secretion during the combined clamp procedure as well as a higher 
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degree of insulin resistance, as compared to normoglycemic controls. It is widely 
accepted that insulin resistant states, such as obesity, are accompanied by increased 
insulin secretion. Therefore, correcting C-peptide secretion for accompanying 
insulin resistance (DI), might give additional information [40]. In our study, 
subjects with IFG and IFG/IGT showed a gradual decrease in the DI, compared to 
NGT. The DI was inversely associated with pancreatic and liver fat content, VAT 
and SAT. This suggests an inverse relation between derangements in glucose and 
lipid metabolism and beta-cell function. However, the DI is based on both insulin 
secretion and insulin sensitivity. Since all fat compartments were inversely related 
to insulin sensitivity, the relation between DI and fat compartments might be driven 
by decreased insulin sensitivity. 
Taken together, in individuals with impaired glucose metabolism, pancreatic fat 
content is increased compared to healthy controls, independent of aging and 
obesity. In this study, we could not establish a direct relation between pancreatic 
fat content and diminished beta-cell function in subjects with impaired glucose 
metabolism. Longitudinal studies are needed to gain more insight in the sequence 
of events and the contributing role of ectopic fat, that may occur during the 
progressive decline in beta-cell function. 
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ABSTRACT
Background
The pre-diabetic states, impaired fasting glucose (IFG) and/or impaired glucose 
tolerance (IGT), are the precursors of type 2 diabetes mellitus (T2DM). It is 
suggested that IFG, IGT and IFG/IGT represent distinct pathophysiological pathways 
towards T2DM, with partial overlap in both progressive loss of beta-cell function 
and peripheral insulin sensitivity. We investigated insulin sensitivity and beta-
cell function in healthy controls (NGT), IFG, IGT and IFG/IGT. Secondly, skeletal 
muscle fatty acid handling was assessed in a sub-study to elucidate underlying 
mechanisms for diminished postprandial insulin sensitivity. 
Methods
In this multi-center study, insulin sensitivity and beta-cell function were assessed in 
102 individuals with IFG (n=48), IGT (n=12), IFG/IGT (n=26) and NGT (n=16), using 
a hyperinsulinemic-euglycemic and hyperglycemic clamp with additional arginine 
stimulation and a 75g-oral glucose tolerance test. Fasting and postprandial skeletal 
muscle fatty acid handling was examined using the forearm balance technique 
(n=35).
Results
IFG, IGT and IFG/IGT subjects had lower insulin sensitivity with no differences 
between groups, and lower impaired beta-cell function compared with NGT 
controls. The early postprandial increase in triacylglycerol (TAG) concentration was 
higher (iAUC0-2h IFG: 238.4±26.5, IGT: 234.0±41.0 and NGT: 82.6±13.8 mmol·l
-1·min-1, 
both P<0.05) and early TAG extraction was increased (AUC0-2h IFG: 56.8±9.0, IGT: 
52.2±12.0 and NGT: 3.8±15.4 nmol·100 ml-1·min-1, P<0.05 and P=0.057 respectively) 
in both IFG and IGT subjects.
Conclusion 
IFG, IGT and IFG/IGT subjects have lower insulin sensitivity and impaired beta-
cell function compared with age and BMI-matched NGT controls. The increased 
postprandial TAG response and higher muscle TAG extraction in both IFG and IGT 
compared to NGT, may lead to ectopic fat accumulation in the skeletal muscle, 
thereby contributing to insulin resistance.
Chapter 4
4
Opzet Proefschrift-def 25052011.indd   56 25-05-11   16:27
57
Skeletal muscle lipid handling and glucose tolerance
Introduction
The pre-diabetic states, impaired fasting glucose (IFG), impaired glucose tolerance 
(IGT) and a combination (IFG/IGT), are the precursors of type 2 diabetes mellitus 
(T2DM) and are fueling this epidemic worldwide. The risk to progress to T2DM 
differs between these groups, with the lowest risk in IFG, followed by IGT and the 
highest risk in IFG/IGT compared to normal glucose tolerance (NGT) subjects [1-5]. 
Furthermore, impaired glucose metabolism (IGM) is associated with increased risk 
of cardiovascular events [6,7]. To provide a basis for the development of tailored 
strategies to prevent or delay the onset of T2DM and cardiovascular diseases, it 
is important to obtain more insight into the pathogenesis of IFG, IGT and IFG/IGT. 
Several  studies suggest that IFG, IGT and IFG/IGT represent distinct 
pathophysiological pathways towards T2DM, with only partial overlap [8-10] in both 
progressive loss of beta-cell function and peripheral and hepatic insulin sensitivity 
[5]. However, there are still discrepancies between studies regarding differences 
in insulin sensitivity in subjects with IGM, which may partly be due to differences 
in methodology. In general, studies that used the gold-standard hyperinsulinemic-
euglycemic clamp to assess insulin sensitivity, have found lower peripheral insulin 
sensitivity in IGT but not in IFG subjects compared to NGT [8,10-14]. In contrast, 
insulin sensitivity has been shown to be lower in both IFG and IGT subjects when 
estimated based on an oral glucose tolerance test (OGTT) or HOMAIR [15-17]. 
The underlying mechanisms for impairments in insulin sensitivity in subjects with 
IGM are not yet fully understood. Skeletal muscle and adipose tissue are important 
organs in regulating fatty acid (FA) metabolism. There is substantial evidence that 
impairments in skeletal muscle and adipose tissue function may contribute to the 
development of insulin resistance and T2DM [18, 19]. In insulin resistant conditions, 
the capacity of the adipose tissue to store lipids (especially in the postprandial state) 
becomes insufficient, which could lead to an increased supply of free fatty acids (FFA) 
and triacylglycerol (TAG) to non-adipose tissues such as skeletal muscle and the liver 
(‘lipid overflow’ hypothesis) [18,19]. Consequently, when the uptake of FFA exceeds 
the capacity or the need to oxidize fat in skeletal muscle, the FFA are stored, leading to 
ectopic fat accumulation, which is associated with insulin resistance [20,21]. We have 
previously demonstrated that skeletal muscle fatty acid oxidation is diminished in 
T2DM [22,23] during exercise and ß-adrenergic stimulation and, interestingly, these 
impairments were already present in IGT subjects [24]. Furthermore, obese IGT 
subjects showed an impaired capacity to switch from fat to carbohydrate oxidation 
in the postprandial state as compared to obese NGT controls [18]. 
The present study was performed to investigate insulin sensitivity in subjects with 
NGT, IFG, IGT and IFG/IGT using the gold-standard hyperinsulinemic-euglycemic 
clamp, a 75g OGTT and HOMAIR. Secondly, skeletal muscle fatty acid handling 
was assessed in a sub-study to elucidate underlying mechanisms for diminished 
postprandial insulin sensitivity in IFG and IGT compared to NGT. A unique aspect of 
this study is that all groups were matched for age, BMI, blood pressure and gender 
distribution. This approach has not been frequently conducted and provides insight 
into differences ascribed to glucometabolic state. 
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Materials and methods
The current study was conducted within the framework of the PRESERVE 
(PancREatic beta-cell dySfunction rEstoRed by Valsartan Effects) study, which is a 
controlled, multi-center trial, carried out in two different centers in the Netherlands 
(VU University Medical Center, Amsterdam and Maastricht University, Maastricht). 
The Medical-Ethical Committee at each center approved the study protocol and all 
subjects gave their written informed consent before participating in the study.
Subjects
Caucasian male and female subjects were recruited by advertisements in local 
newspapers. Based on a standard 2h 75 g OGTT during screening, 16 NGT 
(fasting plasma glucose (FPG) ≤ 6.1 mmol/L (or ≤ 5.6 mmol/L and a family history 
of T2DM), 2h plasma glucose < 7.8 mmol/L), 48 IFG (FPG ≥ 6.1-7.0 mmol/L (or 
≥ 5.6-7.0 mmol/L and a family history of T2DM), 2h plasma glucose ≤ 7.8 mmol/L), 
12 IGT (FPG < 6.1 mmol/L (< 5.6 mmol/L with history of T2DM), 2h plasma glucose 
≥ 7.8-11.1 mmol/L) and 26 IFG/IGT subjects were identified. Subjects with a blood 
pressure >140/90  mmHg were treated with amlodipine 5 mg. If blood pressure 
persisted >140/90 mmHg, the amlodipine dosage was increased to 10 mg. If this 
did not lower blood pressure to a level lower then 140/90, hydrochlorothiazide 
12.5 mg and/or carvedilol 25 mg was added. Only subjects with a blood pressure 
< 140/90 mmHg were included in the study. None of the 102 subjects were taking any 
medications known to affect glucose metabolism. Exclusion criteria were excess 
alcohol intake (>20 units/week), history of diabetes, hepatitis and/or pancreatitis, 
abnormal liver and renal function tests (>2 times the upper limits of normal) and 
recent (< 3 months) changes in weight (±3 kg).
Study design
Subjects came to the research center at 0800h after an overnight fast (from 
2200h the previous evening). All subjects underwent a whole dual-energy X-ray 
absorptiometry (DXA, Hologic, QDR4500; Hologic, Waltham, MA) to measure body 
composition, a 2h 75g OGTT (t0, t10, t20, t30, t60, t90 and t120 min), a combined 
hyperinsulinemic-euglycemic and hyperglycemic clamp procedure with additional 
arginine stimulation. In a subset of these subjects (n=35), fasting and postprandial 
skeletal muscle fatty acid handling was examined at Maastricht University Medical 
Center. All measurements were completed within 5 weeks after screening.
Clamp
A combined hyperinsulinemic-euglycemic and hyperglycemic clamp, with 
subsequent arginine stimulation, was performed to assess insulin sensitivity [25] 
and insulin secretion [26]. A cannula was inserted retrogradely into a superficial 
dorsal hand vein, which was heated in a hot-box (60ºC) to obtain arterialized venous 
blood. In the contra lateral arm, a second cannula was introduced anterogradely in 
an antecubital vein of the forearm for the variable infusion of 20% glucose (IVAC560 
pump, IVAC, San Diego, CA) and insulin (40 mU/m2/min, Actrapid, Novo Nordisk 
Farma BV, Alphen aan den Rijn, The Netherlands, using a Harvard microinfusion 
pump, Plato BV, Diemen, The Netherlands). Arterialized blood samples were 
collected every five minutes to determine glucose concentration (EML 105, 
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Radiometer, Copenhagen, Denmark). The amount of glucose infused was adjusted 
to maintain euglycemia at 5.0 mmol/L. After the hyperinsulinemic-euglyemic part 
of the clamp (t120 min) insulin infusion was discontinued for 60 minutes, while 
glucose was maintained at 5.0 mmol/L. After the hyperinsulinemic-euglycemic 
clamp, a hyperglycemic clamp was performed. To quantify insulin secretion, blood 
glucose concentration was rapidly raised to 15.0 mmol/L by administering a 50% 
glucose bolus in 2 min (adjusted for body weight) followed by a variable 20% 
glucose infusion to maintain 15.0 mmol/L blood glucose for the next 110 min. 80 
min after induction of hyperglycemia, 5g arginine dissolved in 50 ml was infused 
over 45 sec to measure maximum insulin secretory capacity (t260), while the 
glucose concentration was maintained at 15.0 mmol/L.
Postprandial study
Forearm skeletal muscle metabolism was studied in a subset (n=35). A cannula was 
inserted retrogradely into a superficial dorsal hand vein, which was heated in a hot-
box (60ºC) to obtain arterialized venous blood. In the contra lateral arm, a second 
catheter was introduced retrogradely in an antecubital vein of the forearm for 
sampling of deep venous blood draining forearm skeletal muscle. Arterialized and 
deep venous blood samples were simultaneously collected at three baseline time 
points (t-30, t-15 and t0 min) and at six time points (t30, t60, t90, t120, t180 and t240 
min) after consumption of a standardized high-fat mixed meal (t0 min), containing 
2.6 MJ, consisting of 61E% fat (35.5E% saturated FAs, 18.8E% monounsaturated 
FAs and 1.7E% polyunsaturated FAs), 33E% carbohydrate and 6E% protein. Subjects 
were asked to consume the test meal within 5 min. At the same time points as 
the blood-sampling, forearm blood flow (FBF) was measured by venous occlusion 
plethysmography (EC5R plethysmograph; Hokanson, Bellevue, WA) to calculate 
substrate fluxes across the forearm, as previously described [23]. 
Biochemical methods
Plasma glucose concentrations were determined using a hexokinase method 
(Gluco-quant, Roche Diagnostics, Mannheim, Germany). FFA (Wako NEFA C kit, 
Sopar Biochemicals, Koekelberg, Belgium) was analyzed using standard enzymatic 
techniques automated on a Cobas Fara centrifugal spectrophotometer (Roche 
Diagnostica, Basel, Switzerland). Plasma TAG (Sigma; Diffchamb, Västa Frölunda, 
Sweden) and lactate (ABX Diagnostics, Montpellier, France) were analyzed 
enzymatically on a Cobas Mira automated spectrophotometer (Roche Diagnostica). 
Glycated hemoglobin (HbA1c) was measured by cation exchange chromatography 
(Menarini Diagnostics, Florence, Italy; reference values: 4.3-6.1%). Insulin and 
C-peptide concentrations were quantified using an immunometric assay (Siemens, 
USA). The intra-assay precision ranged from 3-4% over a mean range from 20 to 
1500 pmol/l for insulin and from 4-5% over a mean range from 0.13 to >0.5 nmol/L 
for C-peptide.
Skeletal muscle lipid handling and glucose tolerance
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Calculations
Insulin sensitivity was calculated with the use of fasting measurements, HOMAIR 
[27], during the OGTT, the insulin sensitivity index (ISI) [8,28] and OGIS [29] and 
during the hyperinsulinemic-euglycemic clamp, the M-value. 
During the hyperinsulinemic-euglycemic clamp, the M-value was calculated 
based on the last 30 min (steady-state) and after adjustments for steady state 
insulin concentration (M/I). First and second-phase C-peptide secretion during 
the hyperglycemic clamp was calculated as area under the curve (AUC180-190 min 
and AUC190-260 min, respectively) divided by the AUC180-190 min and AUC190-260 min glucose, 
respectively. Arginine-stimulated C-peptide secretion (AIRarg) was calculated as 
the incremental AUC260-270 min above the fasting C-peptide concentration divided by 
the AUC260-270 min glucose concentration. The disposition index (DI1st-phase, DI1st/2nd-phase 
and DIArg260-290), was determined by multiplying first, first and second-phase, and 
arginine-stimulated insulin secretion with the M-value.
During the postprandial study, plasma flow was calculated by multiplying FBF 
with ((1-hematocrite)/100). A positive flux indicates net uptake across forearm 
muscle, whereas a negative flux indicates net release. For comparing postprandial 
responses, the AUC and incremental AUC (iAUC) were calculated for early (0-2h), 
mid (2-4h) and total (0-4h after meal ingestion). 
Body composition was measured by DEXA. Upper body fat was determined by the 
trunk region, and lower body fat was determined by the left and right leg region. 
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). To obtain normal 
distribution, all variables that were not normal distributed were ln transformed. 
ANCOVA was applied to test for group differences in this multicenter study with 
gender and center as covariate. In the postprandial study, one-way analysis 
of variance (ANOVA) was used to test for group differences, since adjustment 
for gender did not affect the results. All statistical analyses were run on SPSS 
version 16.0 (SPSS, Chicago. IL. USA). A P-value <0.05 was considered statistically 
significant.
Results
Study 1: Insulin sensitivity and beta-cell function 
Subjects’ characteristics 
Baseline characteristics of the subjects are summarized in Table 1. There were no 
differences between subjects with NGT, IFG, IGT and IFG/IGT with respect to age, 
BMI, total body fat percentage, W/H ratio, blood pressure and lipid profile (Table 1). 
OGTT: Insulin sensitivity
Insulin sensitivity, determined by ISI and OGIS was significantly lower in the 
IFG, IGT and IFG/IGT compared to NGT subjects (Table 2). However, HOMAIR was 
significantly higher only in the IFG/IGT compared to NGT subjects (Table 2).
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Clamp: Insulin sensitivity, C-peptide secretion and disposition index
IFG, IGT and IFG/IGT subjects had lower insulin sensitivity during the 
hyperinsulinemic-euglycemic clamp compared to NGT (M-value: 4.3±0.2, 3.5±0.7, 
3.8±0.4, 9.4±0.7 mg·min-1·kg-1, respectively, ANCOVA P<0.001; Bonferroni P<0.001 
for all), but no significant differences were found between subjects with IGM. 
Differences in C-peptide secretion are shown in Table 2. In addition, IFG, IGT and 
IFG/IGT subjects had lower first-phase C-peptide secretion compared to NGT 
subjects. IFG/IGT subjects also showed severe defects in second-phase C-peptide 
secretion and a trend towards impaired C-peptide secretion during stimulation 
with the strong insulin-secretagogue arginine. The DI (first-phase, first/second-
phase and arginine-stimulated phase) was significantly lower in IFG, IGT and IFG/
IGT compared with NGT subjects (Table 2).
No significant gender differences were found in insulin sensitivity, insulin secretion 
and disposition index (data not shown).
NGT IFG IGT IFG/IGT
n 16 48 12 26
Gender, m/f 10/6 25/23 6/6 14/12
Age, yrs 54.4±1.8 58.0±1.0 57.8±1.6 57.5±1.4
Height, cm 177.5±2.0 172.8±1.3 170.8±2.3 172.6±1.9
Weight, kg 86.8±3.1 87.2±2.1 92.8±5.1 88.2±2.7
BMI, kg/m2 27.5±0.7 29.1±0.6 31.9±1.8 29.6±0.8
WHR 0.93±0.02 0.98±0.01 0.99±0.03 0.97±0.1
Systolic BP, mmHg 123±2 130±2 129±3 131±2
Diastolic BP, mmHg 79±2 81±1 85±2 83±2
Fasting glucose, mmol/L 5.4±0.1 6.3±0.1† 5.8±0.2‡ 6.6±0.1†§
Glucose 2h, mmol/L 5.7±0.3 7.5±0.3* 8.3±0.7† 9.4±0.5†‡
HbA1C, % 5.5±0.1 5.9±0.1* 5.6±0.1‡ 6.0±0.1†§
Fasting insulin, pmol/L 52.2±5.5 80.3±6.6 114.5±22.8 97.7±8.4*
Total body fat, % 26.9±1.8 31.0±1.2 34.6±2.0 31.2±1.4
Trunk fat, % 50.5±1.2 53.0±0.8 52.9±1.7 55.1±0.9*
Lower body fat, % 31.7±1.2 30.2±0.8 30.4±1.7 28.7±0.8
HDL, mmol/L 1.5±0.10 1.3±0.05 1.4±0.19 1.3±0.08
LDL, mmol/L 3.3±0.23 3.4±0.12 3.5±0.36 3.3±0.19
Triglycerides, mmol/L 1.2±0.12 1.4±0.11 1.3±0.17 1.8±0.18
Table 1. Characteristics of the study population. BMI, body mass index; WHR, waist/hip ratio; BP, blood pressure; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein. Values are mean ± SEM; *P<0.05, vs. NGT;
†P<0.001, vs. NGT; ‡P<0.05, vs. IFG; §P<0.05, vs. IGT.
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NGT
 (16)
IFG 
(48)
IGT 
(12)
IFG/IGT 
(26)
OGTT
Mean glucose. mmol/L 7.1±0.2 8.6±0.2† 8.3±0.5* 9.9±0.3†‡
Mean insulin, pmol/L 349.5±47.1 532.7±48.3 658.2±106.9 566.7±79.6
ISI 5.8±0.6 3.5±0.3* 3.2±0.6* 2.7±0.3†
HOMAIR 1.8±0.2 3.1±0.3 4.4±1.0 4.0±0.4*
OGIS, ml·min-1·m-2 396±13 305±8† 304±28* 292±11†
CLAMP
M-value, mg·kg-1·min-1 8.1±0.7 4.3±0.2† 3.2±0.6† 3.7±0.4†
M/I, mg·kg-1·min-1/pmol·L-1 0.017±0.0017 0.007±0.0004† 0.006±0.0014† 0.006±0.0007†
1st-phase C-peptide secretion, 
(nmol·min·L-1)/(mmol/L) 
0.27±0.03 0.18±0.01† 0.19±0.01* 0.15±0.01†
2nd-phase C-peptide secretion, 
(nmol·min·L-1)/(mmol/L)
0.17±0.02 0.15±0.01 0.13±0.02 0.11±0.01*
AIRarg, (nmol·min·L
-1)/(mmol/L) 2.43±0.19 2.17±0.95 1.86±0.22 1.84±0.13#
DI 1st-phase, 
(nmol·min·L-1)·(mg·min-1·kg-1)
21091±2157 9186±769† 9124±1646† 5416±534†‡
DI 1st and 2nd-phase, 
(nmol·min·L-1)·(mg·min-1·kg-1)
211890±22463 100910±7722† 80905±11753† 73218±8524†
DI Arg260-290, 
(nmol·min·l-1)·(mg·min-1·kg-1)
598±70 267±15† 183±27† 191±18†
Table 2. Insulin sensitivity, insulin secretion and DI determined by OGTT and clamp. OGTT, oral glucose tolerance 
test; ISI, insulin sensitivity index; HOMAIR, homeostasis model assessment for insulin resistance; OGIS, oral 
glucose insulin sensitivity; 1st-phase, AUC 1st-phase C-peptide secretion divided by AUC glucose; 2nd-phase, AUC 
2nd-phase C-peptide secretion divided by AUC glucose ; AIRarg, AUC C-peptide response to arginine divided by 
AUC glucose; DI, Disposition Index. Values are mean ± SEM; *P<0.05, vs. NGT; †P<0.001, vs. NGT; ‡P<0.05, vs. 
IFG; #P=0.064, NGT vs. IFG/IGT.
Study 2: Postprandial study
Subjects’ characteristics 
Baseline characteristics of the subjects that participated in the sub-study to examine 
skeletal muscle fatty acid handling are shown in Table 3. Groups were matched for 
age and BMI. IGT had a lower M-value compared to NGT and IFG subjects (2.5±0.2, 
4.8±0.3 and 4.9±0.6 mg·min-1·kg-1 respectively, ANOVA P=0.004; Bonferroni P<0.05 
for both), but the difference in insulin sensitivity between IFG and IGT subjects 
did not reach statistical significance. Of note, NGT subjects that participated in the 
postprandial study had a higher BMI and were more insulin resistant as compared 
to the total group of NGT subjects in study 1.
Postprandial insulin sensitivity and circulating metabolites
Arterialized plasma glucose and insulin concentrations during fasting and 
postprandial conditions are shown in Figure 1. Despite the significant higher 
arterialized plasma insulin concentrations during the postprandial period in IFG 
and IGT compared to NGT subjects (AUC0-4h 9851±1125, 10425±884 and 5983±684 
pmol·l-1 respectively, ANOVA P<0.05; Bonferroni P<0.05 for IFG and P=0.08 for IGT) 
Chapter 4
4
Opzet Proefschrift-def 25052011.indd   62 25-05-11   16:27
63
(Figure 1B), no signifi cant differences were found in arterialized plasma glucose 
concentrations (AUC0-4h 1575±24, 1568±19 and 1612±41 mmol·l
-1 respectively, 
ANOVA P=0.622) (Figure 1A). Similarly, there were no differences in net forearm 
muscle glucose uptake (AUC0-4h 162±22, 101±14 and 135±25 mmol·100ml
-1·min-1 
respectively, ANOVA P=0.148) (Figure 2A) in IFG and IGT when compared to NGT 
subjects. 
NGT (6)
6 male
IFG (18)
9 male
IGT (11)
7 male
Age, years 55.0±3.1 58.0±1.8 58.3±2.8
BMI, kg/m2 32.3±0.9 30.6±1.5 32.7±0.7
WHR 1.01±0.02 1.05±0.03 1.03±0.01
Fasting glucose, mmol/L 5.5±0.2 5.9±0.1 5.9±0.1
M-value, mg·kg-1·min-1 4.8±0.3* 4.9±0.6† 2.5±0.2
Table 3. Subjects’ characteristics of the sub-study. WHR, waist/hip ratio. Values are mean ± SEM; *P<0.05, vs. IGT; 
†P<0.05, vs. IGT.
Figure 1. Fasting and postprandial plasma glucose, insulin, FFA and TAG in NGT, IFG and IGT subjects during 
fasting and postprandial state. Fasting and postprandial plasma glucose (A), insulin (B), FFA (C) and TAG (D) in 
NGT, IFG and IGT subjects during fasting and postprandial state. FFA, free fatty acids; TAG, triacylglycerol.
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Fasting arterialized plasma FFA and TAG concentrations were comparable between 
groups. Arterialized plasma FFA concentrations decreased during the fi rst 2h 
after intake of the mixed-meal, and returned to near baseline values after 4h in all 
groups (Figure 1C). There was no difference in the postprandial decrease of plasma 
FFA concentration in the period from t0-90 min (iAUC0-90 min) between NGT, IFG and 
IGT subjects (-207.5±18.5, -264.6±24.0 and -221.8±15.8 mmol·l-1·min-1 respectively, 
P=0.118).
However, the early postprandial TAG response (iAUC0-2h) was signifi cantly higher in 
the IFG and the IGT (ANOVA P<0.05; Bonferroni both P<0.05) compared to the NGT 
subjects (iAUC0-2h 238.4±26.5, 234.0±41.0 and 82.6±13.8 mmol·l
-1·min-1 respectively) 
(Figure 1D).
Figure 2. Fasting and postprandial net glucose, lactate, FFA and TAG fl ux across skeletal muscle in NGT, IFG and 
IGT subjects. Fasting and postprandial net glucose (A), lactate (B), FFA (C) and TAG fl ux (D) across skeletal muscle 
in NGT, IFG and IGT subjects. FFA, free fatty acids; TAG, triacylglycerol.
Forearm muscle metabolism
Baseline FBF was signifi cantly lower in the NGT compared to the IFG and IGT 
subjects (1.3±0.2, 2.3±0.1 and 2.1±0.2 ml·100 ml tissue-1·min-1, respectively, 
P=0.006). However, FBF did not change in either group after intake of the high-fat 
mixed-meal.
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Net fasting glucose, lactate, FFA and TAG fluxes across forearm muscle were not 
significantly different between groups. Net lactate flux across forearm muscle 
increased during the first hour after the intake of the meal, and decreased to near 
baseline values after 4h in all groups (Figure 2B). Furthermore, net FFA flux across 
the forearm decreased during the first 90 min of the early postprandial phase, 
indicating reduced FFA uptake by forearm muscle, without significant differences 
between groups (Figure 2C). Interestingly, net TAG extraction across forearm 
muscle was significantly higher in IFG and IGT (ANOVA P<0.05; Bonferroni P<0.05 
and P=0.057 respectively) compared to NGT subjects during the early postprandial 
phase (AUC0-2h 56.8±9.0, 52.2±12.0 and 3.8±15.4 nmol·100 ml
-1·min-1 respectively) 
(Figure 2D). 
The early increase in plasma TAG concentration after intake of a high-fat mixed-
meal was strongly correlated with early net TAG extraction across skeletal muscle 
(r=0.716, P<0.001). In addition, fractional extraction of TAG tended to be higher in 
subjects with IGM (P=0.065).
Discussion
Individuals with IGM are at increased risk of developing T2DM [1-5]. However, the 
pathophysiological pathways that ultimately lead to T2DM may differ between IFG, 
IGT and IFG/IGT subjects. The present study demonstrated that IFG, IGT and IFG/
IGT had lower insulin sensitivity and impaired beta-cell function compared to age 
and BMI-matched NGT subjects. The sub-study showed lower peripheral insulin 
sensitivity in IGT and increased insulin concentrations after a mixed meal without 
alterations in glucose concentrations and forearm glucose uptake, indicating lower 
postprandial insulin sensitivity in IFG and IGT compared to age and BMI-matched 
NGT controls. This was accompanied by an increased postprandial TAG extraction 
in both groups, suggesting that an increased muscle fat storage may play a role 
in the progression towards impaired insulin sensitivity and subsequently the 
development of T2DM in both IFG and IGT subjects.
Insulin sensitivity
Clamp and OGTT-derived peripheral insulin sensitivity
Insulin sensitivity was lower in IFG, IGT and IFG/IGT subjects compared with 
age and BMI-matched NGT controls, either measured with the hyperinsulinemic-
euglycemic clamp, the OGTT or derived from fasting measurements.
Consistent with our findings, impairments in insulin-stimulated glucose disposal 
in IGT and IFG/IGT subjects have been observed in many studies [8,10,12-
14,17,30,31]. However, findings are inconsistent in individuals with isolated IFG, 
having either normal [8,10-13] or lower insulin sensitivity [14,17,30-33] compared 
to NGT controls. Some discordance between these studies may result from the 
use of surrogate markers (e.g. HOMAIR and OGTT-derived parameters), rather than 
direct measurements of insulin sensitivity (hyperinsulinemic-euglycemic clamp). 
However, findings remain conflicting when limiting consideration to clamp studies, 
showing both lower [14,31,34] and comparable [8,10,13] insulin sensitivity in IFG 
compared with NGT subjects. A possible explanation for these discrepancies, in 
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addition to differences in methodology, could be differences in clinical staging 
(e.g. number of years with IGM) and the (in)comparability of study groups; in 
many previous reports subjects with IGM were older, had higher body weight and 
more metabolic abnormalities compared to the control group [8,10,11,14,17,31,32]. 
The unique aspect of the present study is that all groups were matched for age, 
BMI, blood pressure and gender distribution. This approach provides insight into 
differences ascribed to impairments in glucose metabolism per se. 
Postprandial insulin sensitivity
The postprandial net glucose flux across forearm muscle was not significantly 
different between groups, despite significantly higher postprandial insulin 
concentrations in IFG and IGT compared to NGT subjects. These data indicate 
postprandial skeletal  muscle insulin  resistance  in  IFG and IGT subjects compared 
with NGT controls. Although the hyperinsulinemic-euglycemic clamp is the gold 
standard for measuring insulin sensitivity, meal-derived insulin sensitivity is not 
only an insulin challenge but reflects a postprandial effect because it involves the 
oral route of delivery, the associated incretin hormone secretion, and the presence 
of non-glucose nutrients stimulation during ingestion of a mixed meal and is, 
therefore, a more physiological test.
Forearm muscle metabolism
There is substantial evidence that disturbances in skeletal muscle fatty acid 
handling may play an important role in the etiology of insulin resistance and T2DM. 
The present study is to our knowledge the first to examine skeletal muscle fatty 
acid handling in NGT, IFG and IGT subjects matched for age and BMI. As expected, 
net glucose uptake across forearm muscle significantly increased, whereas net 
FFA uptake significantly decreased after intake of the mixed-meal in all groups, 
reflecting a shift from fat to carbohydrate utilization in the early postprandial period. 
The increase in plasma TAG concentrations during the early postprandial period 
was significantly higher in both IFG and IGT compared to NGT subjects. Net TAG 
extraction across forearm muscle was also significantly higher in these subjects 
during the early postprandial phase. Interestingly, we demonstrated that early 
increase in plasma TAG concentration after intake of the high-fat mixed-meal was 
strongly associated with early net TAG extraction across skeletal muscle, indicating 
that TAG supply to the skeletal muscle may determine TAG extraction. These results 
are in line with the recent findings of our group [35], showing that insulin resistant 
men have an increased postprandial forearm muscle TAG uptake.
 
The higher TAG extraction could be related to postprandial hyperinsulinemia in the 
IGM group, which may underlie higher skeletal muscle LPL activity. Furthermore, 
the fatty acid transporter CD36 is acutely upregulated during insulin stimulation 
[36]. Thus, increased CD36 content in skeletal muscle, as a consequence of 
hyperinsulinemia, may also contribute to higher TAG extraction in subjects with 
IGM.
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A reduced fatty acid oxidation, alterations in skeletal muscle fatty acid delivery and 
uptake may contribute to excessive fat storage in skeletal muscle. Therefore, the 
observed disturbances in TAG handling in IFG and IGT may lead to increased lipid 
storage in skeletal muscle in the postprandial period, which is closely associated 
with insulin resistance and may contribute to the progression of overt T2DM [20,21]. 
Further research is necessary to elucidate underlying mechanisms such as skeletal 
muscle fatty acid oxidation and intramuscular lipid storage in these groups.
Insulin secretion
T2DM is characterized by beta-cell dysfunction against a background of impaired 
insulin sensitivity. Similar to impaired insulin sensitivity, beta-cell dysfunction 
may already be present in subjects with IGM. However, only few studies have 
measured first- and second-phase C-peptide secretion with the hyperglycemic 
clamp comparing IFG, IGT and IFG/IGT with NGT controls [8,11,14,37]. The present 
study demonstrated that first-phase C-peptide secretion was lower in subjects with 
impaired glucose metabolism compared to age and BMI-matched NGT subjects. 
IFG/IGT subjects also showed severe defects in second-phase C-peptide secretion 
and a trend towards impaired C-peptide secretion during stimulation with the 
strong insulin-secretagogue arginine, which is consistent with longitudinal studies 
showing a higher risk of progression to T2DM in the combined IFG/IGT subjects 
compared with IFG and IGT [2]. 
In conclusion, the present study demonstrated that IFG, IGT and IFG/IGT subjects 
have lower peripheral insulin sensitivity and impaired beta-cell function compared 
with age and BMI-matched NGT controls. The decreased postprandial insulin 
sensitivity was accompanied by higher postprandial TAG concentration and 
increased TAG extraction across skeletal muscle in IFG and IGT. These impairments 
may lead to increased fat storage in the skeletal muscle and contribute to the 
progression of overt T2DM in these individuals.
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ABSTRACT
Agents interfering with the renin-angiotensin system (RAS) were consistently 
shown to lower the incidence of type 2 diabetes (T2DM), as compared to other 
antihypertensive drugs, in hypertensive high-risk populations. The mechanisms 
underlying this protective effect of RAS blockade using angiotensin converting 
enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) on glucose 
metabolism are not fully understood. In this paper, we will review the evidence 
from randomized-controlled trials and discuss the proposed mechanisms as to 
how RAS interference may delay the onset of T2DM. In particular, since T2DM is 
characterized by beta-cell dysfunction and obesity-related insulin resistance, we 
address the mechanisms that underlie RAS blockade-induced improvement in 
beta-cell function and insulin sensitivity. 
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Introduction 
Type 2 diabetes mellitus (T2DM) is characterized by impairments in insulin 
secretion by the beta cells (beta-cell dysfunction) and obesity-related disturbances 
in insulin action in target tissues (insulin resistance) [1]. In susceptible individuals, 
with increasing body weight and physical inactivity, insulin sensitivity decreases 
gradually. This imposes progressive stress on the compromised beta cell. Over 
time, insulin secretion cannot keep up with the increasing demand and glucose 
levels start to rise into the pre-diabetic range leading to impaired fasting glucose 
(IFG) and/or impaired glucose tolerance (IGT) [2]. In a population-based study in 
the Netherlands (the Hoorn-study) the prevalence of impaired glucose metabolism 
(IGM) in a randomly-selected population (age 40-65 years) was 16% [3]. Similarly, 
in a European population-based study, the DECODE study (Diabetes Epidemiology: 
Collaborative Analysis of Diagnostic Criteria in Europe), the prevalence of IGM 
between the age of 30-59 was <15%, increasing to 15-30% above the age of 60 years 
[4]. Although people with IGM were 0.33 (95% confidence interval 0.23-0.43) times 
as likely to be normoglycemic after 1 year compared to people with normal glucose 
tolerance [5], individuals with IGM had an absolute annual risk of progression to T2DM 
of approximately 5-10% [5]. As such, identification and treatment of individuals with 
IGM seems essential in the battle against T2DM. The Finnish Diabetes Prevention 
Study outlined that lifestyle changes, i.e. weight reduction via dietary changes and 
moderate exercise of at least 30 minutes a day, reduced the incidence of T2DM by 
58% in individuals at high risk to develop T2DM [6]. Although lifestyle intervention 
delayed the onset of T2DM, the Diabetes Prevention Program Outcomes Study 
showed that after 10 years the cumulative incidence of T2DM was still approximately 
40% in the lifestyle intervention group [7].
 
Inasmuch as lifestyle-intervention may postpone the onset of T2DM, once the 
disease occurs, the currently available pharmacological blood-glucose lowering 
interventions are not able to delay progressive beta-cell dysfunction in T2DM 
patients [8]. Recently, the introduction of therapies based on the incretin hormone 
GLP-1, which improve islet-cell function in rodents and humans and preserve 
functional beta-cell mass in rodents, has sparked hope for the potential future 
prevention of beta-cell function decline in high-risk individuals [9,10]. Also, in this 
context, the dramatic effects of bariatric surgical procedures should be mentioned, 
which were shown to cure/resolve T2DM in morbidly obese T2DM patients [11,12]. 
The latter therapies are beyond the scope of this review.
In recent years, the use of pharmacological interventions blocking the renin-
angiotensin system (RAS) have been related to delayed onset of T2DM in high-
risk populations [13,14]. Evidence mainly derived from rodent and cell experiments 
suggests that improvements of insulin sensitivity, through improved adipose 
tissue function and direct effects on insulin signaling in skeletal muscle, and 
improved beta-cell function by ameliorated islet perfusion and anti-fibrotic effects, 
were among the proposed mechanisms by which RAS blocking agents may reduce 
T2DM risk [15-18]. Here, we will review the evidence from clinical trials, showing 
the protective effects of pharmacological RAS blockade, and discuss the underlying 
mechanisms as demonstrated in preclinical and clinical studies.
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The renin-angiotensin system (RAS) 
The RAS consists of several key components: the hepatic-derived angiotensino-
gen, which is cleaved by the renal-synthesized peptide renin into angiotensin I. An-
giotensin I is converted by the lung-derived angiotensin-converting enzyme (ACE) 
into angiotensin II (AngII) [19], which mainly exerts its effect via two receptors: the 
angiotensin type 1 (AT1R) and the angiotensin type 2 (AT2R) receptor. Classically, 
the RAS is known for its systemic effect on blood pressure, electrolyte and fluid 
regulation [19]. However, over the past few years, RAS components have been 
localized in almost any tissue, including heart, blood vessels, kidney, brain, nerve 
fibres, pancreas, adipose tissue and skeletal muscle [20]. Consequently, RAS com-
ponents, primarily AngII, not only exert cardiovascular effects but also have multi-
ple autocrine and/or paracrine effects on other tissues resulting in the promotion of 
inflammation, fibrosis, cell proliferation and apoptosis via the AT1R [20,21] and in 
anti-inflammatory, and antiproliferatory effects and tissue regeneration mediated 
by the AT2R [22]. 
The renin-angiotensin system and type 2 diabetes
RAS activation has been related to both insulin resistance and beta-cell dysfunction 
[23-26]. As such, in rodents, the presence of hyperglycemia increased expression of 
RAS components, including AngII, in pancreatic islets, adipose tissue and skeletal 
muscle [27,28]. Furthermore, AngII diminished insulin secretion in pancreatic beta-
cells [29] and impaired insulin sensitivity in adipose and skeletal muscle tissue 
[30-32]. In large clinical trials blockade of RAS with an angiotensin-converting 
enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) delayed the onset of 
T2DM in subjects with hypertension [33-35]. Based on multiple meta-analyses, it is 
suggested that treatment with an ACEi or ARB reduces the incidence of  T2DM by 22-
30% [13,36]. However, in most of the trials investigating the effect of RAS blockade 
on the incidence of T2DM, the onset of T2DM was not a prespecified endpoint. 
Recently, two large-scaled prospective trials (the Diabetes Reduction Assessment 
with Ramipril and Rosiglitazone Medication, DREAM trial [37], and the Nateglinide 
and Valsartan in Impaired Glucose Tolerance Outcomes Research, NAVIGATOR 
trial [38]), specifically addressed the potential of the ACEi ramipril and the ARB 
valsartan, respectively, on incident T2DM in normotensive individuals with IGM. In 
the DREAM trial, ramipril (15 mg QD), given for 3 years, non-significantly reduced 
the incidence of T2DM by 9%. At 3 years, individuals treated with ramipril were 
more likely to revert from impaired to normal glucose metabolism (hazard ratio, 
1.16; 95%CI: 1.07-1.27; P=0.001) and their post-load glucose levels were significantly 
reduced compared to placebo (7.50 mmol/L vs. 7.80 mmol/L, ramipril vs. placebo, 
respectively, P=0.01) [37]. In the NAVIGATOR trial, valsartan (160 mg QD), given 
for 5 years, not only reduced fasting and post-load glucose after an oral glucose 
tolerance test (OGTT), but also reduced the incidence of  T2DM by 14% (P<0.001) [38]. 
Since valsartan was given in addition to lifestyle modification, its true protective 
potential regarding the incidence of T2DM might be an underestimation. However, 
the underlying mechanisms are incompletely understood. Here, we discuss the 
possible effects of RAS blockade on beta-cell function and insulin sensitivity. 
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Figure 1. Overview of the mechanisms underlying AngII-induced beta-cell dysfunction and impaired insulin 
sensitivity and the effect of RAS blockade in vitro. AngII (solid arrows), in the presence or absence of 
hyperglycemia, impairs beta-cell function and insulin sensitivity through several pathways, which are detailed in 
the text. The effect of RAS blockade is shown in dashed arrows. Abbreviations: CTGF, connective tissue growth 
factor; GLUT4, glucose transporter type 4, HsCRP, high-sensitive C-reactive protein; IL: interleukin; IRS, insulin 
receptor substrate; MCP, monocyte chemotactic protein; NADPH, nicotinamide adenine dinucleotide phosphate; 
PAI, plasminogen activator inhibitor; PI3K, phosphatidylinositol-3-kinase; PPAR, Peroxisome proliferator-
activated receptor; ROS, reactive oxygen species; TGF, transforming growth factor; TNF, tumor necrosis factor; 
UCP, uncoupling protein.
The renin-angiotensin system and beta-cell function
In the development of T2DM, beta cell failure is a prerequisite and deterioration 
of beta cell function as well as loss of functional beta-cell mass are important 
determinants of the development and the progressive course of the disease. In 
addition to the vascular distribution of AT1R in the pancreas, the involvement 
of RAS in insulin synthesis/release was suggested by the presence of AT1R on 
pancreatic beta-cells [27,39]. In rodents, hyperglycemia induced an upregulation of 
RAS components in pancreatic islets [27] and AngII diminished islet blood fl ow and 
impaired insulin secretion [23,29]. Furthermore, RAS blockade with an ACEi or ARB 
counteracted these effects and increased insulin secretion and glucose tolerance 
[15,18,29,40]. Together, these data indicate that the pancreatic islet RAS is not only 
involved in islet blood fl ow but may also be directly involved in insulin secretion. 
Molecular mechanisms explaining these observations have been addressed in 
vitro and in vivo in animal models of T2DM, and may include increased oxidative 
stress, infl ammation and islet fi brosis.
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Oxidative stress and inflammation 
The disproportionate activation of RAS as seen in animal models of T2DM, 
is associated with increased activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, which is a major source of reactive oxygen species 
(ROS) [41,42]. Since beta cells have low levels of endogenous antioxidants, they 
are susceptible to ROS-induced damage [43], and consequently RAS-mediated 
ROS production may alter beta-cell structure, impair function and contribute to the 
development of T2DM [44-47]. Furthermore, ROS activates uncoupling protein 2 
(UCP-2), which uncouples the electrochemical gradient produced by the respiratory 
chain from ATP synthesis [48,49]. Enhanced UCP-2 expression can be protective 
against oxidative damage, but, on the other hand ATP synthesis is essential for 
insulin secretion. Therefore, upregulated UCP-2 expression may contribute to the 
deleterious effects of ROS on beta-cell function. In vivo in db/db mice, RAS blockade 
with an ARB selectively inhibited oxidative stress via down regulation of NADPH 
oxidase [27,50,51] and suppression of UCP-2 [51,52] with improved mitochondrial 
function [15,50,52]. Together, this increased insulin secretion and diminished 
apoptosis. Finally, the AngII-induced oxidative stress may trigger inflammatory 
processes, resulting in an upregulation of inflammatory mediatiors, such as 
interleukin (IL)-1, tumor necrosis factor (TNF)-alpha and monocyte chemoattractant 
protein (MCP)-1 [53]. Inflammation in pancreatic islets has been related to the 
progression of beta-cell dysfunction and apoptosis in T2DM [54]. Blockade of RAS 
with an ARB ameliorated the inflammatory profile and improved beta-cell function 
in male Wistar rats fed a high-fat diet [52]. 
Islet fibrosis
An intact pancreatic islet structure is required for normal islet function [55]. However, 
due to hyperglycemia and the formation of hyperglycemia and hyperlipidemia-
related toxic intermediates, T2DM is associated with prominent fibrosis within the 
islet interstitium [18]. Due to the islet fibrosis, cell-to-cell contact and communication 
is impaired and this reduces the secretory function of the beta cells. In different 
tissues, including the pancreas, an upregulation of RAS has been related to 
increased fibrosis [56]. Via the AT1R, AngII induced apoptosis and upregulation of 
the cytokine transforming growth factor (TGF)-beta and connective tissue growth 
factor (CTGF). Together, an upregulation of TGF-beta and CTGF results in matrix 
accumulation and fibrosis [18,57]. In rodents, RAS blockade downregulated TGF-
beta and CTGF, thereby decreasing islet fibrosis [18,50,57]. In addition to the anti-
inflammatory effects of RAS blockade, these alterations resulted in improved islet 
structure, mass and function with increased insulin secretion [18,50,51,57]. 
Evidence in humans 
Notwithstanding the extensive data derived from rodent studies, evidence from 
human investigations is limited and less conclusive. In human pancreatic beta cells 
the presence of a local RAS has been identified and hyperglycemia was found to 
increase the expression of RAS components [39,58-60]. Similar to rodent models, 
hyperglycemia impaired insulin secretion and induced activation of NADPH oxidase, 
in pancreatic islets from individuals without T2DM in vitro, resulting in increased 
ROS production [58]. Treatment with an ACEi protected these human pancreatic 
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islets from the functional damage induced by hyperglycemia [58]. However, the 
profibrotic effect of pancreatic RAS activation in the development of T2DM has not 
yet been established in human pancreatic islets. 
In vivo, short-term (6-weeks) RAS blockade with the ARB valsartan (80mg twice daily) 
did not affect beta-cell function, assessed with a hyperglycemic clamp, in subjects 
with IGT [61]. In contrast, 3 months treatment with the ARB candesartan (8mg once 
daily) increased first-phase insulin secretion following an OGTT in subjects with 
IGT and hypertension [62]. A similar effect was measured after treatment with the 
ACEi captopril for 4 months (mean dose 81±12 mg/day) in patients with essential 
hypertension, who showed an increase in early-phase insulin secretion in response 
to intravenous glucose administration compared to placebo [63]. Recently, in a 
randomized placebo-controlled trial we investigated the effect of 26-weeks high-
dose valsartan (320mg QD) on multiple aspects of beta-cell function using the gold-
standard hyperglycemic clamp method and a frequently sampled OGTT. We found 
an increase in clamp-measured glucose-stimulated insulin secretion [64] and, in 
line with the findings of Suzuki et al. [62], an increase in first-phase insulin secretion 
during an OGTT. The discrepant findings between the results from both Suzuki et 
al. [62] and our group and the study of Bokhari et al. [61] who did not find an effect 
on clamp-measured beta-cell function, may be explained by differences in the 
compound used, the exposure-time, methodology, dosage and study population. 
As stated above, the processes underlying RAS blockade-induced improvements 
in beta-cell function are based on rodent data and should, as much as possible, be 
established in humans.
 
The renin-angiotensin system and insulin sensitivity at a multi-organ level
As stated above, components of the RAS have been identified in many different 
organs, most notably in those playing a significant role in metabolism and insulin 
sensitivity, including the liver, skeletal muscle and adipose tissue. In this review, 
we focus on the effects of disproportionate RAS activation and RAS blockade on 
insulin sensitivity in skeletal muscle and adipose tissue. 
The renin-angiotensin system and skeletal muscle 
As the major tissue for insulin mediated glucose disposal, skeletal muscle is 
crucial in the development of insulin resistance. The skeletal muscle expresses and 
secretes many components of the RAS, including angiotensinogen (AGT) [65], AngII 
and AT1R [66]. Local RAS components may affect insulin sensitivity via changes 
in muscle blood flow but also directly via interference with insulin signaling and 
mitochondrial function. 
Muscle blood flow 
A reduction in muscle blood flow reduces nutrient, hormone and oxygen delivery, 
including glucose and insulin, and may contribute to insulin resistance [67]. The 
well-known vasoconstrictive effect of AngII was present in the gastrocnemius and 
forearm, since AngII decreased blood flow in healthy normal weight and obese 
male individuals [68,69]. In accordance, RAS blockade resulted in an increase in 
forearm blood flow [67,70], thereby increasing glucose and insulin delivery to 
Protective effect of RAS blockade in the onset of type 2 diabetes
5
Opzet Proefschrift-def 25052011.indd   79 25-05-11   16:27
80
skeletal muscle, which in turn may lead to increased glucose utilization. Similarly, 
in rodents, AngII was shown to impair microvascular skeletal muscle blood flow 
and glucose uptake [42]. Furthermore, ARB treatment prevented or improved 
microvascular dysfunction in spontaneously hypertensive and Sprague-Dawley rats 
[71-73]. However, limited data are available regarding the effect of RAS blockade 
on the microcirculation in humans. Previously, our group did not find an effect 
of 26-weeks valsartan treatment on skin microvascular function and structure in 
individuals with IGM [74]. Importantly, the effect of RAS blockade on microvascular 
structure and function might be more pronounced in other populations, such 
as (untreated) hypertensive patients, or after longer treatment duration. These 
possibilities should be addressed in future studies. 
Skeletal muscle insulin signaling and mitochondrial function
Insulin resistant states are characterized by reduced insulin-stimulated tyrosine 
phosphorylation of the insulin receptor (IR) and IR substrate (IRS)-1 and reduced 
activation of phosphatidylinositol-3-kinase (PI3K)/Akt pathway [75-77]. This leads to 
defects in glucose transporter type 4 (GLUT4) translocation [78] from the intracellular 
space to the plasma membrane, resulting in impaired glucose uptake in the myocyte. 
Based on rodent data, it has been proposed that increased expression of RAS 
components, as seen in the TG(mREN2)27 rat, directly interferes with insulin signaling 
in skeletal muscle and, consequently, contributes to insulin resistance [31,79]. Similar 
results were obtained with AngII infusion studies [26,32]. As such, in different rodent 
models and cell lines, acute infusion with AngII induced tyrosine phosphorylation of 
IRS-1 and -2 and inhibited basal and insulin stimulated PI3K [26,32,80]. In contrast, 
chronic infusion of AngII enhanced insulin-induced tyrosine phosphorylation of the 
insulin receptor and IRS-1 and -2 and activated the PI3K/Akt pathway [81]. In the latter 
study, however, AngII induced insulin resistance via impaired GLUT4 translocation. 
The relation between disproportionate RAS activation and skeletal muscle insulin 
resistance was established in multiple studies investigating the effect of RAS 
blockade with an ACEi or ARB on insulin signaling. However, conflicting results have 
been reported whether RAS blockade improves insulin sensitivity via increased 
insulin-induced phosphorylation of IRS-1 and PI3K activity [17,32,71,82] or whether 
the effect is due to reduced oxidative stress, which improves GLUT4 translocation 
and insulin sensitivity via effects downstream of PI3K [81]. The relation between 
AngII-induced oxidative stress and insulin resistance in skeletal muscle has been 
confirmed by several studies [79,82,83]. AngII increased ROS generation via NADPH 
oxidase activity in skeletal muscle. Interestingly, this not solely impaired GLUT4 
translocation to the plasma membrane [83], but also impaired insulin-induced IRS-
1 tyrosine phosphorylation and Akt activation. Based on these data, it is likely that 
RAS components affect skeletal muscle insulin signaling at multiple levels with an 
eminent role for AngII-induced oxidative stress and impaired GLUT4 translocation. 
Currently, there is no human data available regarding the direct effects of AngII and 
RAS blockade on skeletal muscle insulin signaling. Consequently, the hypothesis that 
RAS blockade-induced improvement in insulin sensitivity is due to improvements in 
insulin signaling in skeletal muscle remains speculative and should be investigated 
in future studies.
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Recently, Mitsuishi et al. [84] assessed the effect of AngII and RAS blockade on skeletal 
muscle mitochondrial function. In this study, AngII reduced mitochondrial content 
in both cultured myotubular cells and skeletal muscle of mice. Furthermore, AngII-
infusion decreased fat oxidation in mice, which was associated with an increase in 
intramuscular triglyceride content and impaired glucose tolerance [84]. These recent 
findings should be confirmed in future studies. 
The renin-angiotensin system and adipose tissue 
One of the physiological functions of adipose tissue is to buffer the daily influx of 
dietary fat entering the circulation by suppressing the release of non-esterified fatty 
acids (NEFA) into the circulation and increasing the clearance of triacylglycerol. 
However, in obese insulin resistant individuals the capacity of the adipose tissue 
to take up and store dietary lipids is insufficient, leading to lipid overflow in the 
circulation which may increase fat storage in non-adipose tissues, such as skeletal 
muscle, liver and pancreatic islets [85]. These ectopic lipids have been related to 
hepatic and skeletal muscle insulin resistance [86-88]. Furthermore, the adipose 
tissue of obese individuals is characterized by increased expression and/or 
secretion of adipokines and pro-inflammatory cytokines, including TNF-alpha, IL-
6, MCP-1 and leptin, and decreased expression/secretion of the insulin-sensitizing 
hormone adiponectin [85], which leads to systemic inflammation. These alterations 
contribute to insulin resistance, presumably via both local (autocrine/paracrine) as 
well as systemic (endocrine) effects (as reviewed in ref 85). 
Rodent as well as human adipose tissue expresses many components of the 
RAS [89]. In obese and insulin resistant humans, this local adipose tissue RAS 
is upregulated and may contribute to adipose tissue dysfunction and obesity-
related complications, such as hypertension [28,65,90]. AngII was shown to impair 
adipocyte differentiation, leading to large insulin resistant adipocytes [89]. Together 
with RAS-induced impairments in adipose tissue blood flow and altered adipokines 
and pro-inflammatory cytokine secretion, this may lead to impaired lipid handling 
and contribute to an increased lipid supply to non-adipose tissues [91]. The 
underlying processes that contribute to insulin resistance, including the effect of 
RAS blockade, will be described below. 
Adipocyte growth and differentiation
One of the main features of adipose tissue dysfunction is enlargement of adipocytes. 
Enlarged adipocytes are directly related to insulin resistance and the development 
of T2DM [92-94]. An important feature of adipose tissue RAS could be its role in 
adipocyte differentiation. Data from rodents outline an inhibitory effect of AngII in 
pre-adipocyte differentiation, which results in enlarged adipocytes [95,96]. In line, 
RAS blockade promoted the recruitment and differentiation of (pre)adipocytes, 
resulting in an increased number of small insulin-sensitive adipocytes in different 
rodent populations [16,96,97], and improved insulin sensitivity [16]. In vitro studies 
in human adipocyte cell lines demonstrated similar inhibitory effects of AngII 
[98,99], whereas others found a stimulatory effect of AngII on the proliferation of 
human visceral mature adipocytes as well as in vitro-differentiated preadipocytes 
[100]. These discrepant findings might be due to the fact that human mesenchymal 
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stem cells and adipocytes from rodents express both AT1R as well as AT2R, 
whereas human adipocytes predominantly express AT1R [101]. Activation of the 
AT2R may counteract the differentiating effect of AngII which is mainly mediated 
by the AT1R [101]. Furthermore, in differentiated murine 3T3-L1 pre-adipocytes and 
human adipocytes, AngII stimulation resulted in hypertrophic cells with elevated 
triglyceride content and increased expression of the lipogenic enzymes glycerol-3-
phosphate dehydrogenase and fatty acid synthase [102]. ARB treatment attenuated 
these lipogenic effects of AngII [102]. In vivo, long-term treatment with the ARB 
valsartan in individuals with impaired glucose metabolism significantly reduced 
adipocyte size, which may contribute to increased insulin sensitivity [103]. 
One of the processes that could underlie the observed effects of RAS blockade 
on adipocytes size is the activation of peroxisome proliferator-activated receptor 
(PPAR)-γ [104]. PPAR-γ plays a role in regulating glucose and lipid metabolism and 
PPAR-γ agonists improve insulin sensitivity [105]. Although ACEi have been shown 
to have PPAR-γ-agonistic effects, more pronounced effects have been reported 
for ARB [106,107]. However, ARB-induced PPAR-γ activation might differ among 
the various compounds [88]. As such, consistent data exist regarding the PPAR-γ-
agonistic effect of telmisartan [104,107], while this is less conclusive with respect to 
valsartan [107,108] and olmesartan [88]. 
Adipose tissue blood flow and lipolysis 
The positive effect of ARB treatment on adipose tissue lipid handling may include 
an increase of adipose tissue blood flow. Normal adipose tissue blood flow is a 
prerequisite for normal adipose tissue function. Interestingly, an impaired adipose 
tissue blood flow is associated with obesity [109-111] and insulin resistance [111]. 
Impaired adipose tissue blood flow reduces triglyceride clearance and may 
contribute to increased circulating triglycerides, which may lead to ectopic fat 
deposition [85]. Furthermore, it may contribute to increased re-esterification of 
NEFA in adipose tissue [112]. Previously, it was shown that acute infusion with 
AngII dose-dependently reduced local blood flow in both normal weight and obese 
male subjects [68,113,114], whereas local administration of an ARB into abdominal 
subcutaneous adipose tissue restored adipose tissue blood flow [113]. In addition, 
AngII has been shown to exert modest inhibitory effects on adipose tissue lipolysis 
[68,114]. Together this might contribute to enlarged adipocytes and aggravate 
insulin resistance. To date, no studies have been performed investigating the effect 
of prolonged RAS blockade on adipose tissue blood flow. Preliminary data from 
our group indicate an improvement in adipose tissue blood flow after 26-weeks 
treatment with the ARB valsartan in individuals with impaired glucose metabolism 
[103].
Circulating adipokines and pro-inflammatory cytokines 
Adipose tissue is not only involved in energy storage but has emerged as a highly 
active endocrine tissue secreting a variety of proteins, including TNF-alpha, IL-6, 
MCP-1, leptin, resistin and adiponectin [115]. Impaired adipose tissue function 
leads to alterations in adipokine secretion, with increased expression of pro-
inflammatory cytokines and decreased adiponectin. As described previously, AngII 
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may impair adipose tissue function, via impaired adipocyte differentiation and the 
reduction of adipose tissue blood flow. Consequently, an upregulation of RAS has 
frequently been related to altered expression of circulating adipokines and pro-
inflammatory cytokines [102,116,117]. 
The effect of RAS blockade is mainly derived from rodent data. In rodents the 
detrimental effects induced by AngII were counteracted by ARB treatment, resulting 
in suppressed AngII-induced oxidative stress, plasminogen activator inhibitor 
(PAI)-1, TNF-alpha and MCP-1 levels and increased adiponectin levels [96,118,119]. 
Similarly, in western diet-fed mice, valsartan improved the inflammatory profile of 
adipose tissue and improved insulin sensitivity [15]. The underlying mechanisms 
may include a reduction in adipocyte size via increased adipocyte differentiation 
[16,119,120] and reduced oxidative stress [118]. Furthermore, PPAR-γ-agonists, such 
as thiazolidinediones, have been shown to improve adipokine dysregulation [121]. 
Since several ARBs have PPAR-γ agonistic effects, it has been suggested that ARB 
treatment may improve adipokine secretion directly via PPAR-γ activation, although 
not all studies found altered PPAR-γ expression [121]. 
In humans, consistent findings have been reported regarding the positive effect 
of RAS blockade on adiponectin in insulin resistant individuals with or without 
hypertension [122-126]. However, limited data are available with respect to the 
effect of RAS blockade on other adipokines. Low-dose valsartan for 3 months 
reduced serum TNF-alpha and IL-6, without changes in CRP in patients with 
essential hypertension [127]. In addition to the extensive data in rodents, future 
studies should clarify the role of RAS blockade on adipokines and pro-inflammatory 
cytokines in humans. 
In summary, AngII may play an important role in adipose tissue dysfunction, which 
is reflected by enlargement of adipocyte size. This results in altered adipokine and 
pro-inflammatory cytokine secretion, lipid overflow, and excessive fat storage 
in non-adipose tissue, which together may contribute to insulin resistance. 
Consequently, pharmacological treatment with an ARB or ACEi may improve 
adipose tissue function, thereby contributing to improvements in insulin sensitivity 
after RAS blockade.
 
Conclusion 
Blockade of the RAS is associated with delayed onset of T2DM and the underlying 
mechanisms include both improvements in beta-cell function as well as insulin 
sensitivity. The underlying mechanisms of improved beta-cell function and insulin 
sensitivity after RAS blockade are multifactorial and may include alterations in 
adipose tissue function, such as reduction in adipocyte size, improvements in the 
proinflammatory phenotype of adipocytes and increased adipose tissue blood 
flow, which in turn may contribute to reduced ectopic fat deposition and improved 
insulin sensitivity. Furthermore, RAS blockade may directly affect skeletal muscle 
insulin signaling and may possibly reduce ectopic fat accumulation through effects 
on mitochondrial function and fat oxidation. Although in this review the effects of 
RAS blockade on the pancreas, skeletal muscle and adipose tissue are described 
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separately, they are interrelated. As such, adipose tissue dysfunction might impair 
lipid storage capacity of adipose tissue, which may lead to accumulation of lipids in 
skeletal muscle and the pancreas. As stated, these ectopic lipids may interfere with 
normal pancreatic function and insulin signaling in skeletal muscle. Consequently, 
the effects of RAS blockade on insulin secretion and sensitivity are the result of 
RAS blockade-induced effects on multiple tissues. We conclude that in addition to 
life-style intervention and classical anti-diabetic pharmacological therapies, drugs 
that inhibit RAS activity may be considered as a valuable approach in patients with 
or without hypertension who are at high risk to develop T2DM. 
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ABSTRACT
Background
Recently, the NAVIGATOR trial demonstrated that treatment with the angiotensin-
receptor blocker valsartan (VAL) for 5 years resulted in a relative reduction of 14% in 
the incidence of type 2 diabetes mellitus (T2DM) in subjects with impaired glucose 
metabolism (IGM). We investigated whether improvements in beta-cell function 
and/or insulin sensitivity underlie these preventive effects of the angiotensin-
receptor blocker VAL in the onset of T2DM.
Methods
In this randomized controlled double blind two-center study the effects of 26-wks 
VAL (320mg daily, n=40) or placebo (PLB, n=39) on beta-cell function and insulin 
sensitivity were assessed in subjects with impaired fasting glucose (IFG) and/or 
impaired glucose tolerance (IGT), using a combined hyperinsulinemic-euglycemic 
and hyperglycemic clamp with subsequent arginine-stimulation and a 2h 75-g oral 
glucose tolerance test (OGTT). Treatment effects were analyzed using ANCOVA, 
adjusting for center, glucometabolic status and gender. 
Results
VAL increased 1st-phase (P=0.028) and 2nd-phase (P=0.002) glucose-stimulated 
insulin secretion compared to PLB, whereas the enhanced arginine-stimulated 
insulin secretion was comparable between groups (P=0.25). In addition, VAL 
increased the OGTT-derived insulinogenic index (representing 1st-phase insulin 
secretion after an oral glucose load, P=0.027). Clamp-derived insulin sensitivity 
was significantly increased with VAL compared to PLB (P=0.049). VAL treatment 
significantly decreased systolic and diastolic blood pressure compared to PLB 
(P<0.001). BMI remained unchanged in both treatment groups (P=0.89). 
Conclusion
Twenty-six-week VAL treatment increased glucose-stimulated insulin release and 
insulin sensitivity in normotensive subjects with IGM. These findings may partly 
explain the beneficial effects of VAL in the reduced incidence of T2DM. 
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Introduction 
The association between insulin resistance, type 2 diabetes and inappropriate 
activation of the renin-angiotensin system (RAS) has been described extensively 
[1,2]. These relations are not solely attributed to systemic RAS components, which 
are mainly derived from the kidney, liver and lung. Additional activation of local 
RAS in adipocytes and the pancreas may also contribute to impaired insulin 
sensitivity and beta-cell function [3,4]. Recent trials have suggested that RAS 
inhibition with angiotensin II receptor blockers (ARB) or angiotensin-converting 
enzyme inhibitors (ACEi) may reduce the incidence of new-onset type 2 diabetes 
[5,6]. However, these studies were mainly performed in hypertensive patients 
and the onset of type 2 diabetes was not a pre-specified endpoint. More recently, 
the large-scaled prospective trial ‘Nateglinide and Valsartan in Impaired Glucose 
Tolerance Outcomes Research’ (NAVIGATOR), addressed the potential of the ARB 
valsartan (VAL) to protect individuals with impaired fasting glucose (IFG) and/
or impaired glucose tolerance (IGT) against type 2 diabetes and CVD [7]. After a 
treatment period of 5 years, VAL decreased the onset of type 2 diabetes by 14%. 
However, the underlying mechanisms are incompletely understood.
One of the underlying mechanisms may involve a positive effect of RAS blockers on 
insulin sensitivity [8]. In part, these effects may be due to hemodynamic changes, 
increasing skeletal muscle blood flow, with augmented glucose and insulin delivery 
to insulin sensitive tissues [4]. In addition, RAS blockade may exert direct effects 
on skeletal muscle and adipose tissue, such as increased adipocyte differentiation 
[9], which may increase insulin-induced glucose uptake in skeletal muscle [3,4]. 
Furthermore, treatment with an ARB or ACEi may directly affect beta-cell function. 
In vitro, blocking the RAS with an ACEi or ARB prevented the deleterious effects of 
hyperglycemia on beta-cell function [10,11]. In vivo, however, limited information 
regarding the effect of RAS blockade on beta-cell function is available. Short term 
treatment (6 wks) with VAL had no effect on beta-cell function [12], whereas Suzuki 
et al. demonstrated that 3 months treatment with the ARB candesartan increased 
first-phase insulin secretion, assessed during an oral glucose tolerance test (OGTT) 
[13].
We hypothesized that both improvement of insulin sensitivity and beta-cell function 
may underlie the protective effect of ARB intervention in the development of type 
2 diabetes in subjects with impaired glucose metabolism (IGM). We tested this 
hypothesis by conducting a randomized-controlled trial, in which individuals with 
IGM were randomly assigned to receive either VAL (320mg once daily) or placebo 
(PLB) for 26 weeks. Insulin sensitivity and various aspects of beta-cell function 
were assessed using both the gold-standard hyperinsulinemic-euglycemic and 
hyperglycemic clamp as well as an OGTT.
Research design and methods 
Study Design
In this randomized, controlled, double-blind study (VU University Medical Center, 
Maastricht University Medical Center, the Netherlands), patients with IFG and/or 
IGT were randomized to VAL (n=40) or PLB (n=39). Patients received 160 mg VAL 
The PRESERVE study
6
Opzet Proefschrift-def 25052011.indd   101 25-05-11   16:27
102
or PLB once daily (QD) for two weeks. Thereafter, the dosage was doubled to 320 
mg QD VAL or PLB for the subsequent 24 wks. Before and after 26 wks treatment, 
we performed a combined hyperinsulinemic-euglycemic and hyperglycemic clamp 
with arginine-stimulation, and a 2h 75-gram OGTT.
 
Primary endpoint
The effect of VAL vs. PLB on clamp-measured beta-cell function. Secondary 
endpoint: The effect of VAL vs. PLB on clamp-measured insulin sensitivity, blood 
pressure, fasting plasma glucose (FPG), HbA1c, fasting plasma insulin (FPI), body 
weight, waist, safety and tolerability. 
Participants
Participants were recruited by advertisements in newspapers. After obtaining 
written informed consent, 259 subjects underwent a screenings OGTT. Subjects 
with IFG (FPG ≥6.1 and <7.0 mmol/L or FPG ≥5.6 and <7.0 mmol/L and family history 
of type 2 diabetes), and/or IGT (2h plasma glucose level ≥7.8-11.1 mmol/L) were 
eligible. Individuals were only allowed to use lipid-lowering medication (statins). 
Subjects with a blood pressure >140/90 mmHg were treated with amlodipine 
5  mg. If blood pressure persisted >140/90 mmHg, amlodipine was increased to 
10 mg, followed by hydrochlorothiazide 12.5 mg and/or carvedilol 25 mg. Subjects 
with blood pressure <140/90 mmHg were included in the study. 43 subjects with 
IFG (51% males), 11 subjects with IGT (46% males) and 25 subjects with IFG/IGT 
(56% males) were enrolled. Exclusion criteria were excess alcohol intake, hepatitis 
and/or pancreatitis, abnormal liver and renal function tests and recent changes in 
weight (≥5%). The study was conducted according to the Declaration of Helsinki 
and approved by the local ethics committee.
Clamp
A hyperinsulinemic-euglycemic and hyperglycemic clamp with arginine-
stimulation was performed to assess insulin sensitivity and secretion. During the 
hyperinsulinemic-euglycemic clamp the insulin infusion rate was maintained at 
40 mU·min-1·m2 body surface area. After an hour resting period, the hyperglycemic 
clamp was started by giving a glucose bolus, increasing blood glucose concentrations 
to 15.0 mmol/L. Steady-state blood glucose concentration at 15.0  mmol/L was 
sustained with variable 20% glucose infusion for 80 min. Thereafter, 5.0 gram 
arginine was administered to measure maximum insulin secretory capacity at 
steady-state blood glucose concentration of 15.0 mmol/L.
OGTT and blood pressure
A 75-g 2h OGTT was performed. Blood samples were obtained at 7 time-points 
to determine glucose and insulin. Blood pressure was measured using Omron 
705 CP (Omron Corporation, Shiokoji Horikawa, Shimogyo-ku, Japan) on the non-
dominant arm, after 15 minutes of rest. 
Biochemical analyses
Glucose concentrations were determined using a hexokinase method (Gluco-
quant, Roche Diagnostics, Mannheim, Germany). HbA1c was measured by cation 
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exchange chromatography (Menarini Diagnostics, Florence, Italy; reference values: 
4.3-6.1%). Serum insulin concentrations were quantified using immunometric 
assays (Siemens, USA). The intra-assay precision for insulin ranged from 3-4% over 
a mean range from 0.02 to 1.5 nmol/L.
Calculations
Hyperinsulinemic-euglycemic clamp
Insulin sensitivity was defined as the glucose infusion rate (M-value, mg∙min-1∙kg-1), 
during the last 30 minutes of the hyperinsulinemic-euglycemic clamp, with steady 
state blood glucose concentrations of 5.0 mmol/L. The M-value was used, since 
correction for steady-state insulin concentrations (M/I) did not alter the results. 
Hyperglycemic clamp
First-phase insulin secretion was calculated as the insulin area under the curve 
(AUC, pmol∙min-1∙L-1) during the first ten minutes after the glucose bolus, increasing 
glucose levels to 15.0 mmol/L. Second-phase insulin secretion was calculated as 
the insulin AUC during 70 minutes following first-phase insulin secretion. Arginine 
stimulated insulin secretion (AIRarg) was calculated as the insulin AUC during the 
first ten minutes after the arginine bolus administered at t=80 min during the 
hyperglycemic clamp. The disposition-index (mg∙L)/(nmol∙kg), correcting insulin 
secretion for insulin sensitivity, was calculated by multiplying first- and second-
phase glucose-stimulated insulin secretion with M-value.
 
OGTT
First-phase glucose-stimulated insulin secretion (the insulinogenic index) was 
calculated as the ratio of the increment of insulin 30 min after the oral glucose load, 
to the increment of blood glucose concentration over the first 30 min (I30-I0)/(G30-G0). 
Insulin sensitivity was calculated using the insulin sensitivity index composite 
(ISIcomp: 10.000/√G0∙I0∙Gmean∙Imean).
The mean arterial pressure (MAP) was calculated as: diastolic blood pressure + 
(1/3∙(systolic blood pressure-diastolic blood pressure)). 
Statistical analysis
The primary end-point was change in first-phase glucose-stimulated insulin 
secretion after 26-wks treatment with VAL or PLB, which was calculated as the AUC 
of insulin and/or C-peptide over the first 10 min of the hyperglycemic clamp. We 
assumed a decline in AUC first-phase insulin secretion of 2.5% in subjects with IFG/
IGT [14] and an improvement of beta-cell function by VAL of 10% (standard deviation 
50%). A sample size of 68 subjects would provide 80% power to detect 10% increase 
in VAL compared to PLB, taking into account correction for confounders. Assuming 
a drop-out rate of 20%, 80 subjects needed to be included.
Treatment effects were assessed by analysis of covariance (ANCOVA) with 
adjustment for center, gender and glucometabolic status (i.e. IFG and/or IGT) 
and baseline measurement. Univariate correlations (Spearman’s rho) were used 
to examine associations with changes in insulin sensitivity and insulin secretion. 
The PRESERVE study
6
Opzet Proefschrift-def 25052011.indd   103 25-05-11   16:27
104
All statistical analyses were performed using SPSS for windows version 15.0 
(SPSS, Chicago, IL, USA). A P-value<0.05 was considered statistically signifi cant. 
Data are expressed as mean ± standard error of the mean (SEM) or, in case of 
skewed distribution, as median (interquartile range) for numerical variables and as 
proportions for categorical variables. 
Results
Figure 1. Inclusion fl ow chart and baseline characteristics of the study population. Data represent mean ± SE
Subject characteristics
Baseline characteristics of the study population randomized to VAL or PLB are 
listed in Figure 1. VAL included 52% IFG and 48% IFG/IGT and PLB included 56% IFG 
and 44% IFG/IGT. The study medication was well tolerated, there were no serious 
adverse events. All individuals randomized completed the study. 15% of subjects 
randomized to VAL used anti-hypertensive agents compared to 28% in the PLB 
group (P=0.15). At 26 weeks, VAL relative to PLB, resulted in a signifi cant reduction in 
systolic and diastolic blood pressure (Table 1) and MAP (-8.4±1.6 vs. -1.7±1.0 mmHg, 
P<0.001, respectively). Furthermore, 2h post-load glucose tended to increase after 
PLB treatment compared to VAL treatment (P=0.09). 26-wks treatment had no effect 
on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism (Table 1). 
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VAL PLB P-value 
BMI, m/kg2
Baseline 29.8 ± 0.6 29.5 ± 0.8
Post-treatment 29.9 ± 0.7 29.7 ± 0.8
Change 0.16 ± 0.15 0.15 ± 0.12 0.89
Waist, cm
Baseline 101.8 ± 1.7 102.4 ± 2.0
Post-treatment 102.3 ± 1.9 102.8 ± 2.0
Change 0.7 ± 0.7 0.2 ± 0.5 0.56
Systolic blood pressure, mmHg
Baseline 131 ± 1.6 130 ± 1.8
Post-treatment 117 ± 1.9 127 ± 2.0
Change -12.91 ± 2.1 -1.38 ± 1.2 <0.001
Diastolic blood pressure, mmHg
Baseline 83 ± 1.2 83 ± 0.9
Post-treatment 75 ± 1.3 81 ± 1.2
Change -7.24 ± 1.4 -0.69 ± 1.1 <0.001
Fasting plasma glucose, mmol/L
Baseline 6.4 ± 0.1 6.3 ± 0.1
Post-treatment 6.3 ± 0.1 6.3 ± 0.1
Change -0.2 ± 0.1 0 ± 0.1 0.56
2h post load glucose, mmol/L
Baseline 8.4 ± 0.4 8.1 ± 0.4
Post-treatment 8.5 ± 0.5 8.9 ± 0.4
Change 0.1 ± 0.4 0.8 ± 0.2 0.09
HbA1c, %
Baseline 6.0 ± 0.1 5.9 ± 0.1
Post-treatment 5.9 ± 0.1 5.9 ± 0.1
Change -0.05 ± 0.02 0.05 ± 0.01 0.32
Fasting plasma insulin, pmol/L
Baseline 90.4 ± 8.0 87.4 ± 8.3
Post-treatment 90.2 ± 7.7 91.0 ± 9.0
Change -0.5 ± 5.6 3.6 ± 4.3 0.83
Total fasting Cholesterol, mmol/L
Baseline 5.4 ± 0.14 5.3 ± 0.17
Post-treatment 5.4 ± 0.12 5.2 ± 0.17
Change -0.01 ± 0.1 -0.11 ± 0.12 0.33
HDL-cholesterol, mmol/L
Baseline 1.26 ± 0.06 1.26 ± 0.06
Post-treatment 1.23 ± 0.06 1.26 ± 0.06
Change -0.03 ± 0.03 0.01 ± 0.02 0.31
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VAL PLB P-value
LDL-cholesterol, mmol/L
Baseline 3.49 ± 0.12 3.37 ± 0.13
Post-treatment 3.44 ± 0.13 3.26 ± 0.11
Change -0.04 ± 0.08 -0.11 ± 0.08 0.31
Triglycerides, mmol/L
Baseline 1.46 ± 0.12 1.43 ± 0.11
Post-treatment 1.61 ± 0.11 1.58 ± 0.15
Change 0.10 ± 0.09 0.15 ± 0.08 0.70
Table 1. Valsartan induced changes in glucometabolic variables. Data represent mean ± SE; abbreviations: VAL = 
valsartan; PLB = placebo; n=40 in the VAL-group and n=39 in the PLB-group.
Beta-cell function
At baseline there were no differences in insulin secretion between the two 
treatment groups (first-phase: 2.4±0.3 vs. 2.6±0.4 nmol∙min/L, P=0.66; second-
phase 21.7±1.8 vs. 27.2±2.9 nmol∙min/L, P=0.13; Arginine stimulated 20.0±1.6 vs. 
24.7±2.1 nmol∙min/L, P=0.10; VAL vs. PLB, respectively). At 26 weeks, VAL versus 
PLB increased first- and second-phase glucose-stimulated insulin secretion 
during the hyperglycemic clamp, whereas arginine-stimulated insulin secretion 
was comparable between groups (Figure 2). The disposition-index tended to 
be increased after VAL treatment compared to PLB, although this did not reach 
statistical significance (5±14 vs. -30±18 (nmol·min-1·L-1)·(mg·kg-1·min-1), P=0.12, 
respectively). In accordance with clamp-measured beta-cell function, VAL treatment 
significantly increased the insulinogenic index, reflecting an increased first-phase 
insulin secretion during the OGTT (Figure 2). 
Insulin sensitivity 
Twenty-six week VAL treatment significantly increased clamp-derived insulin 
sensitivity compared to PLB (Figure 3). There were no between group differences 
in insulin plasma levels during the hyperinsulinemic-euglycemic clamp. Correcting 
the M-value for prevailing insulin levels did not alter the results. Interestingly, the 
difference in OGTT-derived insulin sensitivity did not reach statistical significance 
(Figure 3). 
Determinants of insulin sensitivity and beta-cell function
The change in clamp-derived insulin sensitivity was inversely correlated with the 
change in MAP (r=-0.30, P=0.02). However, no significant correlations were found 
between MAP and beta-cell function parameters (1st-phase insulin secretion: 
r=-0.028, P=0.82; 2nd-phase: r=-0.006, P=0.96; IGIOGTT: r=-0.08, P=0.51). No other 
determinants were detected that could explain the change in insulin sensitivity and 
beta-cell function.
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Figure 2. Effect of 26-week valsartan on clamp- and OGTT-derived measures of beta-cell function. Changes in 
AUC first- (A) and second-phase (B) glucose-stimulated insulin secretion and combined hyperglycemia and 
arginine-stimulated insulin secretion (C) and insulinogenic index (D) at 26 weeks of VAL (grey bars) or PLB (white 
bars); data represent mean±SE or in case of non-normally distributed data median (interquartile range).
Figure 3. Effect of 26-week valsartan on clamp- and OGTT-derived insulin sensitivity. Changes in clamp-derived 
insulin sensitivity (A) and OGTT-derived insulin sensitivity (B) at 26 weeks of VAL (grey bars) or PLB (white bars); 
data represent mean±SE.
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Discussion
The present study demonstrated that 26 week VAL treatment improved various aspects 
of beta-cell function and insulin sensitivity, compared to PLB in individuals with IGM. 
Importantly, all subjects had blood pressure values within the normal range at baseline, 
with or without concomitant antihypertensive therapy.
Recently, the DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone 
Medication) trial [15] and the NAVIGATOR trial specifically addressed the effect of 
prolonged ACEi and ARB treatment, respectively, on incident type 2 diabetes in large 
populations of individuals with IGM. In the DREAM trial, ramipril (15 mg QD), given 
for 3 years, non-significantly reduced the incidence of type 2 diabetes by 9%. During 
this relatively short intervention period, individuals treated with ramipril were more 
likely to revert from IGM to normoglycemia and their post-load glucose levels were 
significantly reduced compared to PLB [15]. In the NAVIGATOR trial, VAL (160 mg QD), 
given for 5 years, not only reduced fasting and post-load glucose after an OGTT, but 
also reduced the incidence of type 2 diabetes by 14% (11). However, in these trials no 
underlying mechanisms were addressed. Our data, obtained in a comparable high-
risk population, suggest that improvement in beta-cell function as well as in insulin 
sensitivity may contribute to the effect of ARB to reduce the incidence of type 2 diabetes.
Previously, short-term (6 wks) low-dose of VAL (80mg QD) did not effect clamp-measured 
beta-cell function in subjects with IGT [12]. In contrast, others found increased OGTT-
derived first-phase insulin secretion after 3 months candesartan treatment (8mg QD) in 
subjects with IGT and hypertension [13]. Our study is the first to simultaneously measure 
the effects of 26 wks high-dose VAL treatment on multiple aspects of beta-cell function 
using the hyperglycemic clamp method. We found an increase in clamp-measured 
glucose-stimulated insulin secretion, with no alterations in arginine-stimulated insulin 
secretion. Furthermore, similar to Suzuki et al., the insulinogenic index, reflecting 
first-phase insulin secretion during an OGTT, increased with VAL compared to PLB. 
The discrepant findings between the current study and the study of Bokhari et al. who 
did not find an effect on clamp-measured beta-cell function after ARB treatment, may 
be explained by differences in exposure-time and the used dosage.
In the current study and the study of Suzuki, treatment-related alterations in clamp- 
and OGTT-derived beta-cell function were unrelated to changes in blood pressure, 
suggesting that VAL may directly affect pancreatic islets, thereby increasing insulin 
secretion. Molecular mechanisms explaining this observation have been addressed 
in vitro and in vivo in rodent studies [10,11]. In the pancreas a local RAS is present, 
with the expression and localization of angiotensinogen and AT1 receptors particularly 
localized in the islets and endothelial cells of the pancreatic vasculature [16]. A relation 
between RAS activation and hyperglycemia was assessed in vitro, where exposure 
to high glucose concentrations upregulated RAS components in rodent and human 
pancreatic beta cells [10]. Glucose-induced RAS activation resulted in increased ROS 
production, tissue inflammation and increased cell proliferation and apoptosis [11]. 
Furthermore, RAS blockade prevented these deleterious effects of hyperglycemia on 
beta-cell function [10]. 
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In addition to improvements in beta-cell function, we found that VAL relative to PLB 
increased insulin sensitivity, assessed with the hyperinsulinemic-euglycemic clamp. 
However, the observed increase of OGTT-derived insulin sensitivity (ISIcomp) following 
VAL treatment did not reach statistical significance. After an OGTT, there is a great 
intra- and inter-subject variability in glucose uptake and hepatic glucose production. 
Therefore, although OGTT-derived insulin sensitivity may take into account more 
physiological contributing mechanisms, the variability by far exceeds that of clamp-
measured insulin sensitivity [17].
Clamp-measured insulin sensitivity provides an accurate estimate of whole-body 
insulin sensitivity, which is largely determined by skeletal muscle as the used insulin 
levels almost fully suppress endogenous glucose production [18]. Several mechanisms 
may underlie the VAL-induced improvement in peripheral insulin sensitivity. First, 
AngII decreases skeletal muscle blood flow in humans [19]. Accordingly, RAS blockade 
resulted in increased forearm blood flow [20], thereby increasing glucose and insulin 
delivery to skeletal muscle, which may lead to increased glucose utilization. Second, 
in rodents, AngII directly inhibited insulin signaling in skeletal muscle [2], which was 
counteracted by ARB treatment [2,3]. Finally, AngII may increase the number of large 
insulin resistant adipocytes via inhibition of adipocyte differentiation. RAS blockade 
reduced adipocyte size and improved adipose tissue function in human adipocytes 
[9] and in rodents [21]. The underlying mechanisms of improved insulin sensitivity 
need to be investigated in future studies in humans. 
The effect of ARB treatment on insulin sensitivity might differ among the various 
compounds. Hsueh et al. [22] recently showed that telmisartan (160 mg QD, 16 weeks 
treatment) did not affect insulin sensitivity in obese hypertensive normoglycemic 
individuals. Ideally, a head-to-head comparison of different ARB in a randomized 
controlled trial is needed to address the issue whether improvement in insulin 
sensitivity is a class effect of ARB or is confined to specific agents. Furthermore, 
conflicting results have been published regarding the protective effect of ARB in 
addition to blood pressure medication known to induce type 2 diabetes [23,24]. 
Therefore, the glucometabolic benefits of ARB might depend on the agent that is 
used, the study population (a priori risk), concomitant medication and the duration 
of exposure. 
Despite changes in insulin secretion and action, there were no significant changes 
in FPG, FPI and HbA1c. A trend towards improvement in 2-h post-load glucose was 
observed in the VAL group. This lack of changes in clinical variables of glucose 
metabolism is in line with previous studies [8] and is likely to be due to the 
treatment duration of these studies, which all last less than 6 months. Although 
pathophysiological differences have been described in the underlying defects of 
IFG and/or IGT, in general, subjects with IFG and/or IGT are already characterized by 
impaired insulin sensitivity and beta-cell function [25]. This study was not powered 
to measure the effect of VAL in IFG and IFG/IGT individuals separately. Furthermore, 
we were not able to detect a delay in the onset of type 2 diabetes as seen in large 
clinical studies. This might be due to the treatment time and limited power, although 
a high dose of VAL was used. 
The PRESERVE study
6
Opzet Proefschrift-def 25052011.indd   109 25-05-11   16:27
110
In conclusion, the present study demonstrates that 26-wks treatment with VAL 
significantly improved glucose-stimulated insulin release and insulin sensitivity in 
subjects with IGM. These findings may partly explain the beneficial role of VAL in 
lowering the risk of incident type 2 diabetes in comparable, high-risk populations. 
However, the mechanisms underlying the VAL-induced improvements in beta-
cell function and insulin sensitivity remain to be established and warrant further 
investigation. 
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ABSTRACT
Background
Individuals with impaired glucose metabolism (IGM) are at high risk to develop 
type 2 diabetes (T2DM). The renin–angiotensin system (RAS) is activated in insulin 
resistant states and its inhibition resulted in delayed onset of T2DM. The underlying 
mechanisms may include improvement of microvascular structure and function, 
which may increase glucose and insulin delivery to insulin-sensitive tissues. We 
hypothesized that functional and structural capillary density is impaired in insulin 
resistant subjects with IGM and that treatment with the angiotensin-receptor 
blocker valsartan (VAL) will improve insulin sensitivity and microvascular function. 
Methods
In this randomized-controlled trial, individuals with IGM (n=48) underwent a 
hyperinsulinemic-euglycemic clamp to assess insulin sensitivity (M-value) and 
capillaroscopy to examine baseline skin capillary density (BCD), capillary density 
after arterial occlusion (PRH) and capillary density during venous occlusion (VEN) 
before and after 26-wks VAL or placebo (PLB). Sixteen BMI-matched normoglycemic 
individuals (NGM) served as controls. 
Results
IGM were more insulin resistant (P<0.001) and had impaired microvascular 
function compared to NGM (all P<0.01). Univariate associations were found for 
microvascular function (BCD, PRH, VEN) and M-value (all P<0.005). The relations 
were independent of age, gender and BMI. VAL improved insulin sensitivity 
(P=0.034) and lowered blood pressure as compared to PLB, whereas microvascular 
function remained unchanged. 
Conclusion
In insulin resistant individuals with IGM impaired functional and structural capillary 
density was inversely associated with insulin sensitivity. VAL improved insulin 
sensitivity without affecting functional and structural capillary density, indicating 
that other mechanisms may be stronger determinants in the VAL-mediated insulin 
sensitizing effect.
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Introduction
Individuals with impaired glucose metabolism (IGM) are at increased risk to 
develop type 2 diabetes mellitus (T2DM) and cardiovascular disease [1]. This has 
prompted a large number of clinical trials investigating interventions that might 
prevent or delay the onset of T2DM and consequently, reduce the associated 
morbidity and mortality from cardiovascular causes [2]. Since insulin resistant 
states are characterized by an upregulation of the renin-angiotensin system (RAS) 
[3], it has been suggested that pharmacological interventions blocking the RAS may 
not only reduce cardiovascular disease risk, but may also have beneficial effects 
on the onset of T2DM. Indeed, several clinical trials suggested that RAS blockade 
using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor 
blockers (ARB) reduced the incidence of T2DM in hypertensive patients [4-6]. 
In the NAVIGATOR trial (Nateglinide and Valsartan in Impaired Glucose Tolerance 
Outcomes Research), RAS blockade with the ARB valsartan for 5 years resulted in 
a 14% reduction in the onset of T2DM in individuals with IGM [6]. The mechanisms 
by which ARB lower T2DM risk, have partly been attributed to improvements in 
peripheral insulin sensitivity [7-9]. One of the proposed responsible mechanisms 
includes ARB-induced hemodynamic changes, resulting in increased blood flow 
with increased glucose and insulin delivery to insulin-sensitive tissues [10]. 
Recently, it has become clear that vascular tissue, particularly the endothelial cell, 
is an important physiological target for insulin and a significant regulator of overall 
insulin-stimulated glucose uptake [11]. Insulin promotes its own access to muscle 
interstitium by increasing blood flow and by recruiting capillaries to expand the 
endothelial transporting surface available for nutrient exchange. Therefore, capillary 
rarefaction, i.e. decreased capillary density and impaired recruitment, may reduce 
glucose uptake and contribute to insulin resistance [12,13]. Indeed, decreased 
capillary density and recruitment has been established in chronic conditions such 
as hypertension [14] and obesity [15], and related directly to impaired insulin-
stimulated glucose uptake in these specific populations [14,16]. Whereas several 
studies demonstrated impaired microvascular function in subjects with IGM [17,18], 
it is presently unknown whether this relationship is independent of obesity.
In the present study, we assessed functional and structural capillary density 
in insulin-resistant individuals with IGM and BMI-matched insulin-sensitive 
normoglycemic controls. We tested the hypothesis that treatment with the ARB 
valsartan (VAL) for 26 weeks improved insulin sensitivity as well as capillary 
density. To this purpose, insulin sensitivity was assessed with the gold-standard 
hyperinsulinemic-euglycemic clamp technique and capillary density was assessed 
with nailfold capillaroscopy. Since circulating cytokines are considered to influence 
both insulin sensitivity and microvascular function [19], and RAS inhibition has 
anti-inflammatory effects [20], we additionally examined associations between the 
pro-inflammatory markers leptin, monocyte chemoattractant protein-1 (MCP-1), 
tumor necrosis factor (TNF)-alpha and High-sensitive C-reactive protein (HsCRP), 
but also adiponectin, in relation to microvascular function. Finally, we assessed the 
relation between glucometabolic variables, insulin sensitivity and microvascular 
function. 
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Research design and methods
This study was conducted within the framework of the PRESERVE study (PancREatic 
beta-cell dySfunction rEstoRed by Valsartan Effects), which is a randomized 
placebo-controlled trial, carried out at two centers in the Netherlands (Amsterdam 
and Maastricht). The current sub-study was performed only at the VU University 
Medical Center. The local ethics committee approved the study protocol and all 
individuals gave their written informed consent before participating in the study. 
The study conformed to the principles outlined in the Declaration of Helsinki.
Participants
Individuals with IGM, i.e. impaired fasting glucose (IFG, fasting plasma glucose 
(FPG) ≥6.1 and <7.0 mmol/L or FPG ≥5.6 and <7.0 mmol/L and a family history of 
T2DM), and/or impaired glucose tolerance (IGT, 2h plasma glucose level (2h-PG 
load) ≥7.8-11.1 mmol/L) were eligible. Caucasian individuals were recruited by 
advertisements in local newspapers. After obtaining written informed consent, 
124 individuals underwent a 2h 75-gram OGTT during a screenings visit, of which 
48 individuals (56% males) were eligible to participate in the study. 16 age- and 
BMI-matched drug-naïve individuals with normal glucose metabolism (NGM, 
63% males) served as controls. Individuals with IGM were allowed to use lipid 
lowering medication (statins). Individuals with a blood pressure >140/90 mmHg 
were treated with amlodipine 5 mg. If blood pressure persisted >140/90 mmHg, the 
amlodipine dosage was increased to 10 mg. If this did not lower blood pressure, 
hydrochlorothiazide 12.5 mg and/or carvedilol 25 mg was given. Only individuals 
with a blood pressure <140/90 mmHg were included in the study. Exclusion criteria 
were excess alcohol intake (>20 units/week), history of diabetes, hepatitis and/
or pancreatitis, abnormal liver and renal function tests (>2 times upper limits of 
normal) and recent (<3 months) changes in weight (≥5%). 
Study design and methods
All 48 eligible individuals underwent a hyperinsulinemic-euglycemic clamp and 
nailfold capillaroscopy. Of these 48 individuals, 41 (isolated IFG, n=24, 52% males; 
isolated IGT, n=2, 67% males; combined IFG/IGT, n=15, 63% males) were willing 
to participate in the randomized controlled double-blind study, receiving VAL 
(n=21) or placebo (PLB, n=20). Four-block randomization was carried out by the 
department of experimental pharmacology from the VU University Medical Center. 
Initially, patients received 160 mg VAL or PLB once daily (QD) for two weeks. 
Thereafter, the dosage was doubled to 320 mg QD VAL or PLB for the subsequent 
24 wks. After 26  wks treatment, the hyperinsulinemic-euglycemic clamp and 
nailfold capillaroscopy were repeated. All measurements were performed after an 
overnight fast. 
Microcirculation
Microvascular measurements were performed in the morning after 30 minutes of 
acclimatisation in a quiet, temperature-controlled room, with the individuals in the 
sitting position and the investigated, non-dominant hand at heart level. Perfused 
nailfold capillaries in the dorsal skin of the third finger were visualised by a capillary 
microscope [12]. Capillaries were made visible in a standardized manner, making 
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it possible to find the exact same position after the intervention. Capillaries were 
visualised approximately 1.5 mm proximal to the terminal row of capillaries in the 
middle of the nailfold of the third finger of the non-dominant hand. Two separate 
visual fields of 1 mm2 were recorded before and after four minutes of arterial 
occlusion with a digital cuff, and the images were stored on videotape. Additionally, 
after 5 minutes of rest, venous occlusion, with the digital cuff inflated to 60 mmHg 
for 1 minute, was assessed. The number of capillaries at baseline (BCD), directly 
after arterial occlusion (peak reactive hyperemia, PRH) and during venous occlusion 
(VEN) were counted off-line by a single experienced investigator (NJZ). BCD was 
defined as the number of erythrocyte-perfused capillaries per square millimeter of 
nailfold skin during 15 seconds, only counting continuously perfused capillaries. 
PRH was counted during the first 30 seconds after release of the cuff, and was 
used to assess functional recruitment of capillaries. During venous occlusion all 
perfused capillaries were counted, reflecting the maximal number of non-perfused 
capillaries. Intra-subject coefficient of variation (CV) was 6.2±4.3% (measured on 
two occasions in 8 individuals). 
Hyperinsulinemic-euglycemic clamp 
A hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity 
at week 0 and week 26 [21]. During the hyperinsulinemic-euglycemic clamp the 
insulin infusion rate was maintained at 40 mU·min-1·m2 body surface area. Insulin 
sensitivity was defined as the glucose infusion rate (M-value, mg·kg-1·min-1), during 
the last 30 minutes of the hyperinsulinemic-euglycemic clamp, with blood glucose 
levels at a steady state of 5.0 mmol/L. Calculating the M-value corrected for insulin 
levels (M/I) did not alter the results, therefore the M-value was used.
Biochemical analyses
Plasma glucose concentrations were determined using a hexokinase method 
(Gluco-quant, Roche Diagnostics, Mannheim, Germany). HbA1c was measured by 
cation exchange chromatography (Menarini Diagnostics, Florence, Italy; reference 
values: 4.3-6.1%). Insulin and C-peptide concentrations were quantified using an 
immunometric assay (Siemens, USA). The intra-assay precision ranged from 3-4% 
over a mean range from 20 to 1500 pmol/L for insulin and from 4-5% over a mean 
range from 0.13 to >0.5 nmol/L for C-peptide. Serum MCP-1, TNF-alpha and leptin 
concentrations were measured using the Bioplex Protein Array System (Bio-Rad 
Laboratories, Hercules, CA) by fluorescent conjugated monoclonal antibodies in 
duplicate against a standard curve, according to the manufacturer’s instructions. 
A commercially available ELISA kit was used to measure serum adiponectin 
concentration (Quantikine, R&D Systems, Abingdon, UK). 
Statistical analysis
Data are expressed as mean±standard error of the mean (SEM) or, in case of 
skewed distribution, as median (interquartile range, IQR) for numerical variables 
and as proportions for categorical variables. Differences between IGM and NGM 
were tested by analysis of variances (ANOVA). Differences in non-normally 
distributed variables were tested with the Kruskal-Wallis test. Additionally, analysis 
of covariance was applied to test for differences in microvascular variables between 
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IGM and NGM with gender and BMI as covariates. Pearson correlations were used to 
evaluate the relation between microvascular function and relevant anthropometric- 
and metabolic determinants, adipokines and pro-inflammatory cytokines (i.e. BMI, 
waist, systolic- and diastolic blood pressure, heart rate, FPG, 2h-PG load, HbA1c, 
insulin sensitivity and circulating adiponectin, HsCRP, leptin, TNF-alpha and MCP-1). 
Multivariable regression analyses were used to assess independent determinants 
of microvascular function. Statistical analyses were performed using SPSS for 
windows version 15.0 (SPSS, Chicago, IL, USA).  Treatment effects were assessed 
by analysis of covariance (ANCOVA) with adjustment for gender, glucometabolic 
status (i.e. IFG and/or IGT) and baseline measurement. All statistical analyses 
were performed using SPSS for windows version 15.0 (SPSS, Chicago, IL, USA). 
A P-value <0.05 was considered statistically significant. We assumed a decline in 
capillary density of 15% in subjects with IGM and an improvement by VAL of 10% 
(standard deviation 50%). A sample size of 20 subjects per group would provide 
80% power to detect a 10% increase in VAL compared to PLB, taking into account 
correction for confounders. 
Results
NGM (n=16) IGM (n=48) P-value
Gender, % males 63 56 0.45
Age, years 54.4 ± 1.8 56.7 ± 1 0.29
Weight, kg 86.8 ± 3.1 88.3 ± 2.1 0.72
BMI, kg/m2 27.5 ± 0.7 28.8 ± 0.5 0.21
Waist, cm 98.2 ± 2.5 101.8 ± 1.6 0.26
Systolic blood pressure, mmHg 122 ± 1.7 130.4 ± 1.5 <0.01
Diastolic blood pressure, mmHg 78.4 ± 1.6 83.7 ± 0.9 <0.01
Heart rate, bpm 54.9 ± 2.1 63.1 ± 1.7 <0.01
Total cholesterol, mmol/L 5.34 ± 0.2 5.25 ± 0.14 0.75
HDL, mmol/L 1.54 ± 0.10 1.37 ± 0.06 0.16
LDL, mmol/L 3.28 ± 0.23 3.20 ± 0.11 0.76
TG, mmol/L 1.21 ± 0.12 1.55 ± 0.11 0.10
NEFA fasting, mmol/L 0.5 (0.3-0.5) 0.6 (0.5-0.7) 0.06
NEFA hyperinsulinemia, mmol/L 0.03 (0.02-0.04) 0.06 (0.03-0.08) 0.03
FPG, mmol/L 5.5 (5.3-5.6) 6.3 (5.9-6.9) <0.001
2h-PG load, mmol/L 5.8 (5.0-6.4) 8.5 (7.1-10.3) <0.001
HbA1c, % 5.5 (5.2-5.6) 5.8 (5.0-6.6) <0.001
Antihypertensive treatment, % 0 23 0.03
Calcium channel blocker, % 0 19 0.06
Thiazide diuretics, % 0 4 0.56
Beta-blockers, % 0 15 0.12
Table 1. Characteristics of the study population. Values are means (±standard error of the mean) or medians 
(interquartile range). NGM, normal glucose metabolism; IGM, impaired glucose metabolism; HDL-C, HDL-
cholesterol; LDL-C, LDL-cholesterol; TG, triglycerides; NEFA, non-esterified fatty acid; FPG, fasting plasma glucose; 
2h-PG, 2h post-load glucose level; HbA1c, glycated haemoglobin
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Participants’ characteristics
IGM and NGM were matched for age and BMI. Furthermore, there were no 
differences in waist and lipid profile (Table 1). Individuals with IGM had higher 
HbA1c, FPG and 2h-PG load after an OGTT, compared to NGM (Table 1). Although 
within the normal range, individuals with IGM had higher systolic and diastolic 
blood pressure compared to NGM. 23% of IGM were treated with blood 
pressure lowering medication to achieve blood pressure <140/90 mmHg prior to 
randomization (Table 1).
Circulating adipokines and pro-inflammatory cytokines
Plasma adiponectin was significantly lower (IGM: 3.6 (2.0-6.2) ng/ml vs. NGM: 6.6 
(3.5-8.7) ng/ml, P<0.03), whereas plasma leptin levels were significantly higher in 
IGM compared to NGM (IGM: 22 (12-38) ng/ml vs. NGM: 10 (6-15) ng/ml, P=0.01). 
No between-group differences were observed for plasma HsCRP (IGM: 2.66 ± 0.54 
mg/L vs. NGM: 2.42 ± 0.81 mg/L, P=0.81), TNF-alpha (IGM: 7.0 (5.0-8.9) pg/ml vs. 
NGM: 6.6 (5.5-8.2) pg/ml, P=0.99) and MCP-1 (IGM: 288 (209-400) pg/ml vs. NGM: 
315 (268-387) pg/ml, P=0.47). 
Insulin sensitivity
M-value was significantly decreased in individuals with IGM versus NGM (IGM 
4.6±0.3 mg∙min-1∙kg-1 vs. NGM 9.2±0.8 mg∙min-1∙kg-1, P<0.001), indicating impaired 
insulin sensitivity. 
BCD PRH VEN
r r r
BMI, kg/m2 -0.26* -0.35** -0.37**
Waist, cm NS -0.32* NS
SBP, mmHg -0.27* NS NS
DBP, mmHg -0.26* NS NS
Heart rate, bpm -0.31* NS NS
FPG, mmol/L -0.38** NS NS
2h-PG, mmol/L -0.41** NS -0.29*
HbA1c, % -0.38** NS NS
Adiponectin, ng/ml 0.34* 0.31* 0.27*
HsCRP, mg/L NS NS NS
Leptin, ng/ml -0.27* NS NS
TNF-alpha, pg/ml NS NS NS
MCP-1, pg/ml NS NS NS
Table 2. Univariate Associations between microvascular function, anthropometric, glucometabolic and 
inflammatory variables. NS, not significant; r, Pearson correlation coefficient; * P<0.05; ** P<0.01; BCD, baseline 
capillary density; PRH, peak reactive hyperemia; VEN, capillary density during venous occlusion; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 2h-PG, 2h post-
load glucose level; M-value, metabolized glucose; HsCRP, High-sensitive C-reactive protein; TNF-alpha, tumor 
necrosis factor-alpha; MCP-1, monocyte chemotactic protein-1.
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Microvascular structure and function 
At baseline, BCD was diminished by 30% in individuals with IGM versus NGM 
(P<0.001). Similar results were found for PRH (21% decrease in IGM compared to 
NGM, P<0.001) and VEN (20% decrease in IGM compared to NGM, P<0.001) (Figure 
1). Correction for gender and BMI did not alter the results (BCD, PRH and VEN: P<0.001 
IGM vs. NGM). At baseline there were no significant differences in microvascular 
variables between individuals with or without blood pressure lowering medication 
prior to randomization (BCD: P=0.59; PRH: P=0.69; VEN: P=0.31).
Figure 1. Differences in microvascular function between NGM and IGM. Differences in baseline capillary density 
(A), peak reactive hyperemia (B) and density during venous occlusion (C) between NGM (white bars) and 
IGM (grey bars). Abbreviations: NGM: normal glucose metabolism; IGM: impaired glucose metabolism. Data 
represent mean±SEM.
Associations between microvascular function, anthropometric- and metabolic 
variables, adipokines and pro-inflammatory cytokines
Univariate correlations are listed in Table 2. BCD was negatively associated with 
BMI, systolic and diastolic blood pressure, heart rate, FPG, 2h-PG, HbA1c and leptin. 
Additionally, microvascular function correlated positively with adiponectin, but 
no associations were found between microvascular function and inflammatory 
markers. Furthermore, microvascular function variables were positively associated 
with insulin sensitivity (Figure 2). In multivariate regression analyses the relations 
between microvascular function (BCD, PRH as well as VEN) and insulin sensitivity 
appeared to be independent of age, gender and BMI (data not shown).
 
Figure 2. Dot plots showing the relationship between insulin sensitivity (M-value) and baseline capillary density 
(A), peak reactive hyperemia (B) and density during venous occlusion (C). r, Pearson correlation coefficient.
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The effect of 26 weeks valsartan treatment
The study medication was well tolerated and no serious adverse events occurred. 
VAL vs. PLB significantly decreased systolic and diastolic blood pressure (Table 3). 
FPG and HbA1c trended to be lower after VAL treatment compared to PLB (Table 
3). Furthermore, VAL significantly increased insulin sensitivity compared to PLB 
(P=0.034, Figure 3). However, treatment with VAL did not affect microvascular 
function (Figure 3) or BMI, heart rate, 2h-PG and inflammatory markers (Table 3). 
14% of individuals randomized to VAL were treated with blood pressure lowering 
medication prior to randomization, compared to 40% in the PLB group (P=0.06). 
Excluding or correction for individuals with blood pressure medication prior to 
randomization did not alter the results. 
Figure 3. Changes in clamp-derived insulin sensitivity (M-value, A), baseline capillary density (B), peak reactive 
hyperemia (C) and capillary density during venous occlusion (D) at 26 weeks of VAL (grey bars) or PLB (white 
bars); Abbreviations: VAL, valsartan; PLB, placebo. Data represent mean±SEM.
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Valsartan (n=21) Placebo (n=20) P-value 
BMI, kg/m-2
Baseline 29.0 ± 0.7 28.2 ± 1.0
Post-treatment 29.1 ± 0.7 28.5 ± 1.0
Change 0.2 ± 0.2 0.3 ± 0.2 0.60
SBP, mmHg
Baseline 131.8 ± 1.8 128.6 ± 2.5
Post-treatment 122.2 ± 2.5 129.9 ± 2.7
Change -10.42 ± 2.8 1.28 ± 1.64 <0.01
DBP, mmHg
Baseline 84.3 ± 1.4 82.9 ± 1.1
Post-treatment 78.4 ± 1.9 83.3 ± 1.5
Change -6 ± 2 0.5 ± 1.5 0.02
Heart rate, bpm
Baseline 64.7 ± 2.3 62.4 ± 2.9
Post-treatment 62.2 ± 2.3 61.4 ± 2.0
Change -2.6 ± 2.29 1.06 ± 1.69 0.58
FPG, mmol/L
Baseline 6.4 (5.9-7.0) 6.4 (5.9-7.1)
Post-treatment 5.8 (6.1-6.9) 5.8 (6.6-7.0)
Change -0.5 (-0.2-0.1) -0.3 (-0.1-0.7) 0.07
2h-PG, mmol/L
Baseline 8.6 (7.3-10.9) 8.4 (6.8-9.8)
Post-treatment 6.6 (8.7-11.6) 7.5 (8.9-10.5)
Change -2.4 (0.4-1.5) -0.38 (0.8-1.8) 0.23
HbA1c, %
Baseline 5.9 (5.6-6.1) 5.7 (5.6-6.1)
Post-treatment 5.7 (5.8-6.1) 5.7 (5.9-6.2)
Change -0.1 (0.0-0.1) -0.07 (0.1-0.2) 0.06
Adiponectin, ng/ml
Baseline 3342 (1789-6098) 3821 (2430-7579)
Post-treatment 3451 (2137-5950) 3720 (2280-7064)
Change 543 (-20-1279) 459 (-464-1175) 0.30
HsCRP, mg/L
Baseline 2.8 ± 1.1 2.8 ± 0.6
Post-treatment 2.9 ± 0.6 2.9 ± 0.7
Change -0.64 ± 1.33 0.18 ± 0.37 0.26
Leptin, ug/ml
Baseline 24.3 (13.6-45.9) 15.9 (10.8-27.0)
Post-treatment 20.8 (13.7-54.5) 21.2 (15.5-38.3)
Change 1.4 (-3.5-4.0) 4.0 (-0.09-10.4) 0.24
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TNF-alpha, pg/ml
Baseline 7 (4.9-8.6) 5.7 (5-9.3)
Post-treatment 6.5 (4.8-8.3) 6.7 (5.7-9.3)
Change -0.1 (-0.7-0.3) 0.3 (-0.5-1.1) 0.34
MCP-1, pg/ml
Baseline 311 (214-415) 267 (204-385)
Post-treatment 314 (237-419) 259 (192-381)
Change 27 (-69-65) -1 (-40-23) 0.16
Table 3. Valsartan induced changes in patient characteristics, glucometabolic variables and inflammatory 
markers. Values are means (±standard error of the mean) or medians (interquartile range). P-values  represent 
between-group differences. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
FPG, fasting plasma glucose; 2h-PG, 2h post-load glucose level; HbA1c, glycated haemoglobin; HsCRP, High-
sensitive C-reactive protein; TNF-alpha, tumor necrosis factor-alpha; MCP-1, monocyte chemotactic protein-1.
Discussion
The present study is the first demonstrating that insulin resistant individuals 
with IGM have marked impairments in functional and structural capillary density 
compared to BMI-matched insulin-sensitive normoglycemic controls. Structural 
and functional capillary density was related to insulin sensitivity, independent of 
age, gender and BMI. Treatment with VAL for 26-wks significantly improved insulin 
sensitivity but this beneficial effect could not be explained by improvements in 
capillary density or changes in circulating adipokines or pro-inflammatory cytokines. 
Morphologically, the microcirculation is widely taken to encompass vessels <150 
µm in diameter, i.e. arterioles, capillaries and venules [22]. A primary function of 
the microcirculation is to optimise nutrient and oxygen supply within the tissue 
in response to variations in demand [23]. Consequently, changes at the level of 
the microvascular network, i.e. capillary rarefaction, involving a reduction in the 
number of arterioles or capillaries within vascular beds, may lead to inadequate 
perfusion and reduced nutrient, hormone and oxygen delivery to tissues. Since 
capillary recruitment is an important mechanism by which insulin promotes uptake 
of glucose from the blood [11], capillary rarefaction and impaired recruitment may 
be involved in reduced glucose uptake and consequently contribute to insulin 
resistance. This was confirmed in obesity and hypertension, where capillary 
rarefaction, a well-established abnormality in these chronic conditions, was related 
to impaired insulin-mediated glucose uptake [14,16]. However, to date, it has 
been unclear whether insulin-resistant individuals with IGM are characterized by 
capillary rarefaction independent of obesity and, when the capillary rarefaction is 
present, whether this is associated with impaired insulin sensitivity. In the current 
study, we demonstrated that both structural and functional capillary rarefaction is 
present in individuals with IGM independent of BMI. The impairments in functional 
and structural capillary rarefaction were related to impaired insulin sensitivity. 
Furthermore, diminished BCD was associated with a more severe cardiometabolic 
risk profile, i.e. higher blood pressure, FPG, 2h-PG and leptin. This might imply 
that an intact microcirculation is required to protect obese individuals from 
cardiometabolic disorders.
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RAS blockade has been shown to improve insulin sensitivity in individuals with 
hypertension or glucometabolic disorders [7-9]. In line with these data, we found 
improved insulin sensitivity after 26-wks VAL treatment compared to PLB. Several 
underlying mechanisms have been proposed, including improved insulin signaling 
in skeletal muscle [24], improved adipose tissue function [25] and increased insulin 
delivery to skeletal muscle cells via direct effects on the microvasculature. The present 
study was designed to test the latter hypothesis and examined the effects of prolonged 
ARB-treatment on capillary density and capillary recruitment. In humans, it has been 
shown that AngII decreases skeletal muscle blood flow [10]. More recently, AngII was 
shown to impair skeletal muscle blood flow and glucose uptake via the angiotensin 
receptors in skeletal muscle microcirculation in rodents [26]. Furthermore, although 
assessed with different techniques (i.e. contrast-enhanced ultrasound, intravital 
capillaroscopy and immunohistochemistry to assess capillary density), ARB treatment 
prevented or reduced capillary rarefaction in spontaneously hypertensive rats and 
Sprague-Dawley rats [26-28]. In contrast to animal data, very limited data is available 
regarding the effects of RAS blockade on microvascular function in humans. Although 
a recent cross-sectional study reported a higher capillary density in hypertensive 
patients treated with an ACEi-based regimen compared to those not receiving RAS-
blocking agents [29], no randomized-controlled study has been performed to assess 
the effects of ARB treatment on capillary density. In the current study, treatment with 
VAL for 26-weeks did not affect structural and functional capillary density, which 
was assessed with nailfold capillaroscopy. There may be several reasons to explain 
this finding. First, the positive effect of RAS blockade on microvessel structure and 
function might be more pronounced after treatment with an ACEi compared to an ARB 
[30]. Ideally, a head-to-head comparison of ACEi and ARB in a randomized controlled 
trial is needed to address the issue whether alterations in microvascular function are 
confined specifically to ACEi or ARB. Second, it is possible that only prolonged blood 
pressure control with an ARB may have beneficial effects on microvascular function 
and structure. Consequently, our treatment duration might have been too short to 
detect improvements in microvascular function and structure. Finally, we cannot 
exclude the possibility that ARB-treatment improves insulin signaling in the vessel 
wall [31] with subsequent improvement of insulin-induced capillary recruitment. 
Nevertheless, the latter is strongly related to the number of capillaries recruited 
during post-occlusive peak reactive hyperemia without insulin infusion as measured 
in the present study [32].
Insulin resistant states and obesity are characterized by changes in circulating 
adipokines and pro-inflammatory cytokines [33,34]. This pro-inflammatory profile 
impairs both insulin signaling [33,34] as well as endothelial function [34,35]. 
Involvement of the RAS in this pro-inflammatory profile has been described 
previously. In rodents, RAS activation was associated with increased inflammation 
and oxidative stress [35], whereas RAS blockade counteracted these pro-inflammatory 
effects [20,36] and improved insulin sensitivity [35]. Furthermore, blockade of RAS 
increased adiponectin in parallel with improvements in insulin sensitivity [25,37] 
and reduction in inflammatory markers [37]. In the present study, VAL did not affect 
circulating inflammatory markers. This might be due to the fact that at baseline only 
leptin and adiponectin showed minor differences between IGM and NGM. 
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Several limitations of our study should be mentioned. First, although muscle tissue 
is the main peripheral site of insulin-mediated glucose uptake, microvascular 
measurements were performed in skin and not muscle. However, the cutaneous 
microcirculation is considered a representative vascular bed to examine the 
mechanisms of generalized microvascular dysfunction [38]. The human skin is the 
only site available in humans to directly and non-invasively assess capillary density 
and recruitment of capillaries. Moreover, comparable insulin-mediated metabolic and 
microvascular effects were demonstrated in skin and muscle [32]. Second, individuals 
with blood pressure >140/90 mmHg were treated with low-dose blood pressure 
lowering drugs prior to inclusion (VAL n=3 and PLB n=8). These drugs might have 
disturbed the effect of VAL on microvascular function. However, excluding blood 
pressure treated individuals from the analyses did not alter the results.
In conclusion, the present study demonstrates that individuals with IGM are 
characterized by both insulin resistance and impaired structural and functional 
capillary density, which are interrelated, compared to age- and BMI-matched insulin 
sensitive individuals. 26-wks treatment with VAL significantly improved insulin 
sensitivity but did neither improve functional and structural capillary density nor 
circulating adipokines and pro-inflammatory cytokines. The mechanisms underlying 
the VAL-induced improvement in insulin sensitivity remain to be established in 
future studies. 
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ABSTRACT
Background
Blockade of the renin-angiotensin system (RAS) delays the onset of type 2 diabetes 
mellitus. Recent animal studies indicate that RAS blockade improves adipose 
tissue (AT) function, which may contribute to improved insulin sensitivity. We 
hypothesized that long-term RAS blockade improves AT function in humans with 
impaired glucose metabolism (IGM).
Methods
Subjects with IGM (n=38) participated in this randomized, placebo-controlled, 
double-blind study. Before and after 26-weeks treatment with the angiotensin-
receptor blocker valsartan (VAL, 320 mg/d) or placebo (PLB), an abdominal 
subcutaneous AT biopsy was collected for measurement of adipocyte size and AT 
gene/protein expression of capillarisation, adipogenesis, lipolytic and inflammatory 
cell markers. Furthermore, fasting and postprandial (high-fat mixed-meal) AT blood 
flow (ATBF) was measured (133Xe wash-out), systemic inflammation was examined 
and a hyperinsulinemic-euglycemic clamp was performed.
Results
VAL treatment markedly reduced abdominal subcutaneous adipocyte size (P<0.001), 
with a shift from large to small adipocytes. VAL increased fasting (P=0.043) and 
postprandial ATBF (P=0.049), and decreased AT gene expression of capillarisation 
markers compared to PLB. The decrease in adipocyte size was associated with 
reduced AT gene/protein expression of adipogenesis, lipolytic, chemoattraction, 
macrophage infiltration and inflammatory markers, and improved insulin 
sensitivity. VAL did not affect plasma MCP-1, TNF-alpha, adiponectin and leptin 
concentrations.
Conclusion
26-weeks VAL treatment reduced abdominal subcutaneous adipocyte size and 
increased ATBF in IGM subjects. The decrease in adipocyte size was associated with 
reduced AT gene expression of inflammatory cell markers and improved insulin 
sensitivity.
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Introduction 
Multiple lines of evidence suggest that the renin-angiotensin system (RAS) is 
involved in the development of type 2 diabetes [1-4]. A meta-analysis of comparative 
outcome trials has demonstrated that blockade of the RAS, using either angiotensin-
converting enzyme inhibitors (ACEi) or angiotensin (Ang) II type 1 (AT1) receptor 
blockers (ARBs), reduced the incidence of new-onset type 2 diabetes by 22% in 
subjects at high risk of developing this disease [5]. More recently, the prospective 
NAVIGATOR trial, which was the first randomized clinical trial with the onset of type 
2 diabetes as primary outcome, has shown that treatment with the ARB valsartan 
(VAL; median follow-up 5.0 years), in addition to lifestyle modification, led to a 
relative risk reduction of 14% in the incidence of type 2 diabetes in subjects with 
impaired glucose tolerance (IGT) [6]. Thus, these findings corroborate the assertion 
that RAS blockade is protective against the development of overt type 2 diabetes 
in humans.
The beneficial effects of RAS blockade in the prevention of type 2 diabetes in animal 
models and humans have mainly been explained by hemodynamic and metabolic 
effects that may improve insulin sensitivity and insulin secretion [1-3,7]. However, 
studies that have investigated the effect of short-term (10 days - 12 weeks) RAS 
blockade on insulin sensitivity in high-risk subjects report conflicting results [8], 
and the underlying mechanisms are not yet fully understood.
Converging evidences suggest that several aspects of adipose tissue (AT) 
dysfunction, including AT macrophage infiltration, inflammation and an impaired 
AT blood flow (ATBF), may contribute to the development of type 2 diabetes, fatty 
liver and cardiovascular disease [9-13]. In rodents, RAS blockade exerts beneficial 
effects on adipose tissue function. In fact, it has been shown in several mouse and 
rat models that RAS blockade decreased adipocyte size and AT gene expression 
of chemoattraction, macrophage infiltration, inflammatory and oxidative stress 
markers, and improved glucose homeostasis [14-19]. However, in humans, it is 
presently unknown whether RAS blockade evokes beneficial effects on adipose 
tissue function, which in turn may contribute to improved insulin sensitivity.
Therefore, the primary aim of the present study was to investigate whether long-
term RAS blockade improves AT function in subjects with IGM. We have recently 
conducted a randomized placebo-controlled trial and demonstrated that 26-weeks 
VAL treatment improved both insulin sensitivity and glucose-stimulated insulin 
secretion in subjects with impaired glucose metabolism (IGM) [20]. To elucidate 
the underlying mechanisms for improved insulin sensitivity, in the present sub-
study several factors associated with adipose tissue function, including adipocyte 
size, ATBF, AT gene/protein expression of chemoattraction, macrophage infiltration, 
inflammatory markers and lipolytic enzymes, systemic inflammation and insulin 
sensitivity (hyperinsulinemic-euglycemic clamp) were assessed at baseline and 
after 26-weeks treatment.
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Research Design and Methods
The present study was conducted within the framework of the PRESERVE study 
(PancREatic beta-cell dySfunction rEstoRed by Valsartan Effects), which is a 
placebo-controlled double-blind randomized trial carried out in two different 
centers in the Netherlands (Maastricht and Amsterdam) [20]. The present sub-
study was performed at Maastricht University Medical Center. The Medical-Ethical 
Committee of Maastricht University Medical Center approved the study protocol, 
and all subjects gave their written informed consent before participating in the 
study, which conformed to the principles outlined in the Declaration of Helsinki.
Subjects
38 subjects with impaired fasting glucose (IFG; fasting plasma glucose (FPG) ≥6.1 
and <7.0 mmol/L or FPG ≥5.6 and <7.0 mmol/L and a family history of type 2 diabetes 
(first degree relative)), and/or IGT (2h plasma glucose concentration ≥7.8-11.1 
mmol/L) participated in this study (isolated IFG, n=19; isolated IGT, n=9; combined 
IFG/IGT, n=10). Subjects had to be weight-stable for at least 3 months prior to 
participation. Exclusion criteria were diabetes mellitus, cardiovascular disease, 
cancer, lung disease, liver or kidney malfunction, intentions to lose weight or follow 
a hypocaloric diet and alcohol or drug abuse. Subjects were only allowed to use 
(lipid lowering) statins. Subjects with a blood pressure >140/90 mmHg at screening 
were treated with 5 mg amlodipine. If blood pressure >140/90 mmHg persisted, 
the amlodipine dosage was increased to 10 mg, followed by hydrochlorothiazide 
12.5 mg and/or carvedilol 25 mg if needed. Only individuals with a blood pressure 
<140/90 mmHg entered the study.
Protocol
Subjects were randomized to VAL (n=19) or PLB (n=19) treatment. Subjects were 
treated with 160 mg VAL or PLB once daily (QD) for the first two weeks and, 
thereafter, the dosage was doubled to 320 mg QD for the subsequent 24 weeks. At 
baseline and after 26-weeks treatment, a frequently sampled 75g 2h oral glucose 
tolerance test (OGTT), hyperinsulinemic-euglycemic clamp, and postprandial study 
(measurement of fasting and postprandial ATBF) were performed, and an adipose 
tissue biopsy was collected, as described below. Subjects were asked to refrain 
from drinking alcohol and to perform no strenuous exercise for a period of 48h 
before the study days, and not to change their dietary and physical activity habits 
throughout the study. All procedures were randomized and completed within 5 
weeks after inclusion, with at least 1 week between measurements.
Adipose tissue biopsy
An abdominal subcutaneous adipose tissue biopsy (~1g) was collected 6-8 
cm lateral from the umbilicus under local anesthesia (2% lidocaine) by needle 
biopsy after an overnight fast. Adipose tissue was washed with sterile saline and 
processed within 5min. A small part of the adipose tissue was fixed overnight in 
4% paraformaldehyde and embedded in paraffin, whereas the other part was snap 
frozen in liquid nitrogen and stored at -80°C until analysis.
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Adipocyte size
Histological sections (8 mm) were cut from paraffin embedded tissue, mounted on 
microscope glass slides and dried overnight in an incubator at 37°C. The sections were 
stained with hematoxylin and eosin (HE). Digital images were captured using a Leica 
DFC320 digital camera (Leica, Rijswijk, the Netherlands) at 20x magnification (Leica DM3000 
microscope, Leica, Rijswijk, the Netherlands). Computerized morphometric analysis 
(Leica QWin V3, Cambridge, United Kingdom) of individual adipocytes was performed 
in a blinded fashion. Approximately 400 adipocytes from each sample were measured.
Quantitative RT-PCR
Total RNA was extracted from adipose tissue (~500mg) using Trizol chloroform extraction 
(Invitrogen, Cergy Pontoise, France). SYBR-Green based real-time PCRs were performed 
as one-step reactions on the StepOne real-time PCR system (Applied Biosystems, Foster 
City, CA). Results were normalized to a house-keeping gene (18S ribosomal RNA).
Western blot analysis
Approximately 200 mg adipose tissue was ground to a fine powder under liquid nitrogen 
and homogenized in 200 µl of ice-cold buffer [21]. The homogenate was vortexed for 5 min 
and centrifuged at 20,000 x g for 30 min at 4°C. The supernatant was carefully collected, 
and aliquots were stored at -80°C. The protein concentration was determined by the 
Bradford-based protein assay (catalog no. 500-0006; Bio-Rad). Next, protein expression 
of ATGL and HSL was measured, as described previously [21]. CGI-58 was detected 
using a rabbit polyclonal antibody raised against human CGI-58 (Novus Biologicals, 
NB110-41576). The G0S2 antibody was a kind gift from Dr. Sander Kersten (Wageningen 
University, The Netherlands) [22].
Fasting and postprandial ATBF
ATBF was continuously measured at baseline and for 4h after consumption of a standardized 
high-fat mixed meal (consumption within 5 min), containing 2.6 MJ, consisting of 
61E% fat (35.5E% saturated fatty acids (FAs), 18.8E% monounsaturated FAs and 1.7E% 
polyunsaturated FAs), 33E% carbohydrate and 6E% protein, as previously described [23]. 
Briefly, 133Xe (~1 MBq) was injected para-umbilically into the adipose tissue, approximately 
10 mm deep, using an insulin-injection syringe with a fine needle (0.36 mm external 
diameter). A CsI crystal detector (Oakfield Instruments, Eynsham, UK) was placed over 
the exact site of injection and taped firmly in place to monitor the mono-exponential 
decay of radioactivity in the adipose tissue. This γ-counter probe collected continuous 
20s readings.
Hyperinsulinemic-euglycemic clamp
A hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity 
[24]. Briefly, a cannula was inserted into a superficial dorsal hand vein for sampling of 
arterialized blood and in an antecubital vein of the contralateral forearm for insulin and 
glucose infusion. Blood glucose concentration was measured every 5 min (EML 105, 
Radiometer, Copenhagen, Denmark) and euglycemia was maintained at 5.0 mmol/L 
(variable 20% glucose infusion). The mean glucose infusion rate during steady-state (last 
30min) was used to assess insulin sensitivity. The M-value was used, since adjustments 
for steady state insulin concentration (M/I) did not alter the results.
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Biochemical analyses
Blood samples were collected into ice-chilled EDTA-tubes and centrifuged at 1000g, 4°C 
for 10 min. Plasma was immediately frozen in liquid nitrogen and stored at -80°C until 
analysis. Plasma glucose concentrations were determined using a hexokinase method 
(Gluco-quant, Roche Diagnostics, Mannheim, Germany). Glycated hemoglobin (HbA1c) 
was measured by cation exchange chromatography (Menarini Diagnostics, Florence, 
Italy). Insulin concentrations were quantified using an immunometric assay (Siemens, 
USA). Serum monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor (TNF)-
alpha and leptin concentrations were measured using the Bioplex Protein Array System 
(Bio-Rad Laboratories, Hercules, CA) by fluorescent conjugated monoclonal antibodies 
in duplicate against a standard curve, according to the manufacturer’s instructions. A 
commercially available ELISA kit was used to measure serum adiponectin concentration 
(Quantikine, R&D Systems, Abingdon, UK).
Statistical analyses
Data are presented as mean ± standard error of the mean (SEM). Baseline comparisons 
between treatment groups were analyzed using Student’s unpaired t test. Treatment 
effects were assessed by repeated-measures ANOVA, using time as within-subject factor 
and treatment as between-subject factor, with adjustment for gender and glucometabolic 
status. Since there was no treatment interaction with gender and glucometabolic status 
for the studied parameters, unadjusted values were used. Univariate correlations were 
used to examine associations between parameters. All variables were checked for normal 
distribution, and variables with a skewed distribution were ln-transformed to satisfy 
conditions of normality. Calculations were done using SPSS 15.0 for Windows (Chicago, 
IL, USA). P<0.05 was considered to be statistically significant.
Results
Subject characteristics are summarized in Table 1. Before treatment, age, BMI, body fat 
percentage, waist and hip circumferences, blood pressure, lipid profile, plasma glucose 
and insulin concentrations and insulin sensitivity were comparable between subjects 
randomized to VAL or PLB. The study medication was well-tolerated and no serious 
adverse events were reported.
Blood pressure
At baseline, both systolic and diastolic blood pressure was comparable between treatment 
groups (Table 1). As expected, VAL treatment significantly decreased systolic (VAL:-15.7 
± 3.2 vs. PLB:-4.3 ± 1.7 mmHg, P=0.004) and diastolic (VAL:-8.7 ± 2.1 vs. PLB:-2.0 ± 1.4 
mmHg, P=0.009) blood pressure compared to PLB (Table 1).
Adipocyte size
At baseline, abdominal subcutaneous adipocyte size were comparable between treatment 
groups (PLB: 65.6 ± 1.8 vs. VAL: 70.0 ± 2.1 mm, P=0.121). VAL treatment markedly reduced 
mean adipocyte size compared to PLB (P<0.001, Figure 1A), with a shift towards a higher 
frequency of small adipocytes (Figure 1B). Noteworthy, the reduction in adipocyte size was 
a very consistent finding, since this was observed in all subjects treated with VAL. Body 
weight remained stable during the study, indicating that these effects were independent 
of changes in body weight.
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Placebo (n=19) Valsartan (n=19)
Baseline 26 weeks Baseline 26 weeks P-value*
Sex, male/female 11/8 - 7/12 - -
Age, yr 59.2 ± 1.2 - 59.4 ± 1.5 - N.S.
Weight, kg 90.2 ± 4.0 90.1 ± 3.9 86.2 ± 3.0 86.6 ± 3.3 N.S.
BMI, kg/m2 30.9 ± 1.2 30.9 ± 1.2 30.6 ± 1.0 30.7 ± 1.1 N.S.
Total body fat, % 31.8 ± 1.5 32.3 ± 1.6 34.6 ± 1.9 34.3 ± 1.9 0.073
Trunk fat, % 33.7 ± 1.5 34.3 ± 1.5 35.3 ± 1.9 35.5 ± 1.9 N.S.
Waist, cm 104.7 ± 3.1 105.3 ± 2.9 101.1 ± 2.4 102.8 ± 3.1 N.S.
Hip, cm 103.0 ± 2.0 105.6 ± 2.3 105.5 ± 2.2 106.6 ± 2.5 N.S.
W/H-ratio 1.02 ± 0.02 1.00 ± 0.02 0.96 ± 0.02# 0.96 ± 0.02 N.S.
SBP, mmHg 130.2 ± 3.0 124.5 ± 2.8 127.0 ± 2.1 111.5 ± 2.4 0.004
DBP, mmHg 80.1 ± 2.0 78.6 ± 1.9 79.5 ± 1.6 70.8 ± 1.1 0.009
Fasting PG, mmol/l 6.2 ± 0.1 5.9 ± 0.1 6.4 ± 0.1 6.2 ± 0.2 N.S.
2h PG, mmol/l 7.6 ± 0.6 8.5 ± 0.6 7.5 ± 0.6 7.7 ± 0.6 N.S.
Fasting PI, pmol/l 100.7 ± 10.9 100.3 ± 8.9 103.0 ± 20.6 104.0 ± 14.7 N.S.
HbA1c, % 6.0 ± 0.1 6.0 ± 0.1 6.1 ± 0.1 6.0 ± 0.1 N.S.
M-value, mg·min-1·kg-1 3.2 ± 0.4 3.1 ± 0.3 3.4 ± 0.4 3.6 ± 0.4 N.S.
Fasting TAG, mmol/l 1.39 ± 0.15 1.69 ± 0.23 1.23 ± 0.08 1.48 ± 0.10 N.S.
Fasting FFA, μmol/l 577.9 ± 40.2 567.5 ± 72.3 570.0 ± 43.9 520.6 ± 46.1 N.S.
Table 1. Clinical characteristics before and after 26-weeks treatment with VAL or PLB. BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; PG, plasma glucose; PI, plasma insulin; HbA1c, glycated 
hemoglobin; TAG, triacylglycerol; FFA, free fatty acid; N.S., not significant. *VAL vs. PLB treatment assessed by 
repeated-measures ANOVA. #P<0.05 vs. PLB. Values are means ± SEM.
Abdominal subcutaneous AT gene expression of peroxisome proliferator-activated 
receptor (PPAR)-γ (P=0.061), adipocyte fatty acid binding protein (aP2) (P=0.016) 
and CCAAT/enhancer binding protein (C/EBP)a (P=0.006), which are key regulatory 
factors in adipogenesis and lipogenesis [25,26], were decreased after VAL treatment 
compared with PLB (Table 2). Moreover, the decrease in AT mRNA expression of 
PPAR-γ (r=0.528, P=0.007) and aP2 (r=0.618, P=0.002) was positively associated 
with the reduction in adipocyte size after VAL treatment. Taken together, these data 
indicate that VAL-induced inhibition of adipogenesis and lipogenesis may have 
contributed to the reduction in adipocyte size.
ATBF and AT gene expression of capillarisation markers
Both fasting ATBF (PLB: 1.8 ± 0.1 vs. VAL: 1.7 ± 0.2 ml·100g tissue-1·min-1, P=0.675) 
and the postprandial enhancement of ATBF (iAUCATBF/min) after consumption of 
the high-fat mixed-meal (PLB: 0.37 ± 0.12 vs. VAL: 0.21 ± 0.11 ml·100g tissue-1·min-1, 
P=0.349) were comparable before the start of treatment. VAL treatment increased 
both fasting (P=0.043) and postprandial (P=0.049) ATBF compared to PLB (Figure 
2A and B, respectively), and this effect was more pronounced in women.
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Figure 1. Mean adipocyte diameter and adipocyte size distribution before and after 26-weeks VAL (n=16) or PLB 
(n=15) treatment. VAL treatment significantly reduced (A) adipocyte size compared to PLB, with (B) a shift towards 
a higher proportion of small adipocytes. Values are means ± SEM. *P<0.05, #P<0.01, †P<0.001 VAL vs. PLB.
Abdominal subcutaneous AT mRNA expression of vascular endothelial growth 
factor (VEGF), the master regulator of vasculogenesis, angiogenesis and 
remodelling of blood vessels [27, 28], was decreased after VAL treatment compared 
to PLB (P=0.051) (Table 2). In accordance, VAL treatment significantly reduced AT 
gene expression of the angiogenesis and capillarisation markers CD34 (P=0.037) 
and angiogenin (ANG) (P=0.028) (Table 2). The decrease in AT gene expression of 
CD34 (r=0.396, P=0.050) and ANG (r=0.458, P=0.021) was significantly associated 
with the reduction in adipocyte size.
AT chemoattraction, macrophage infiltration and inflammatory markers
Since adipocyte size is closely associated with AT gene expression of 
chemoattraction, macrophage infiltration and inflammatory markers, we next 
investigated whether VAL could improve the inflammatory state of AT. Indeed, 
VAL treatment decreased abdominal subcutaneous AT gene expression of 
the macrophage infiltration markers CD68 (P=0.014), CD163 (P=0.023), CD206 
(P=0.004) and Krupel-like factor (KLF)4 (P=0.053) (Table 2). Furthermore, VAL 
treatment decreased cathepsin S (CTSS)-1 (P=0.014) and CTSS-2 (P=0.014) AT 
mRNA expression (Table 2), indicating that the inflammatory state of AT was 
reduced [29]. Despite these reductions, the changes in AT expression of monocyte-
chemoattractant protein (MCP)-1 (P=0.202), interleukin (IL)-6 (P=0.426), tumor 
necrosis factor (TNF)-alpha (P=0.464), plasminogen activator inhibitor (PAI)-1 
(P=0.476) and adiponectin (P=0.393) did not change after VAL treatment.
Interestingly, the decrease in adipocyte size after VAL treatment was positively 
associated with the reduction in abdominal subcutaneous AT gene expression 
of leptin (r=0.655, P<0.001), MCP-1 (r=0.435, P=0.034), CD68 (r=0.555, P=0.004), 
CD163 (r=0.676, P<0.001), CD206 (r=0.551, P=0.004), CD11b (r=0.439, P=0.032), 
CD40 (r=0.380, P=0.056), KLF4 (r=0.362, P=0.076), CTSS-1 (r=0.589, P=0.002), 
CTSS-2 (r=0.493, P=0.017) and TNF-alpha (r=0.386, P=0.062), which underlines 
the importance of adipocyte size reduction in the improvement of adipose tissue 
function.
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Placebo (n=13) Valsartan (n=19)
Baseline 26 weeks Baseline 26 weeks P*
Adipogenesis
PPAR-γ mRNA 1.03 ± 0.24 1.28 ± 0.20 1.22 ± 0.14 0.98 ± 0.13 0.061
aP2 mRNA 0.71 ± 0.11 0.73 ± 0.10 0.93 ± 0.15 0.51 ± 0.07 0.016
C/EBP-a mRNA 1.14 ± 0.14 1.51 ± 0.25 1.39 ± 0.17 0.92 ± 0.08 0.006
Capillarisation
VEGF mRNA 0.51 ± 0.08 0.64 ± 0.10 0.67 ± 0.07 0.59 ± 0.09 0.051
CD34 mRNA 0.77 ± 0.12 1.05 ± 0.16 0.91 ± 0.10 0.76 ± 0.09 0.037
ANG mRNA 0.50 ± 0.07 0.57 ± 0.08 0.58 ± 0.05 0.46 ± 0.06 0.028
Inflammation
CD68 mRNA 1.10 ± 0.15 2.06 ± 0.47 1.96 ± 0.35 1.23 ± 0.19 0.014
CD163 mRNA 1.19 ± 0.14 1.36 ± 0.16 1.43 ± 0.18 0.99 ± 0.17 0.023
CD206 mRNA 1.06 ± 0.12 1.59 ± 0.28 1.34 ± 0.16 1.00 ± 0.13 0.004
KLF4 mRNA 1.24 ± 0.19 1.41 ± 0.20 1.51 ± 0.23 1.04 ± 0.11 0.053
CTSS-1 mRNA 0.66 ± 0.08 1.21 ± 0.30 1.20 ± 0.22 0.83 ± 0.14 0.014
CTSS-2 mRNA 0.61 ± 0.10 1.56 ± 0.42 1.50 ± 0.32 0.91 ± 0.20 0.014
Lipolysis
ATGL mRNA 0.74 ± 0.12 0.82 ± 0.17 0.78 ± 0.09 0.50 ± 0.07 0.083
CGI-58 mRNA 0.59 ± 0.15 0.58 ± 0.11 0.61 ± 0.09 0.39 ± 0.05 0.090
HSL mRNA 2.39 ± 0.40 2.62 ± 0.50 2.35 ± 0.28 1.66 ± 0.23 0.710
G0S2 mRNA 0.94 ± 0.16 1.25 ± 0.28 1.05 ± 0.17 0.73 ± 0.10 0.092
Table 2. Abdominal subcutaneous AT gene expression before and after 26-weeks treatment with VAL or PLB. 
PPAR-γ, peroxisome proliferator-activated receptor γ; aP2, adipocyte fatty acid binding protein; C/EBPa, CCAAT/
enhancer binding protein a; VEGF, vascular endothelial growth factor; ANG, angiogenin; KLF4, Krupel-like factor 
4; CTSS, cathepsin S; ATGL, adipose triglyceride lipase; CGI-58, comparative gene indentification 58; G0S2, 
G0/G1 switch gene 2; HSL, hormone-sensitive lipase. *VAL vs. PLB treatment assessed by repeated-measures 
ANOVA. Values are means ± SEM.
Figure 2. Fasting and postprandial ATBF before and after 26-weeks treatment with VAL (n=16) or PLB (n=14). 
VAL treatment significantly increased both (A) fasting ATBF and (B) postprandial ATBF (P=0.049) compared 
to PLB. A mixed-meal (containing 2.6 MJ, consisting of 61E% fat (35.5E% saturated fatty acids (FAs), 18.8E% 
monounsaturated FAs and 1.7E% polyunsaturated FAs), 33E% carbohydrate and 6E% protein) was ingested at t0 
min to stimulate ATBF. Values are means ± SEM. *P<0.05 VAL vs. PLB. ATBF, adipose tissue blood flow.
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Systemic inflammatory markers
Before the start of treatment, fasting plasma MCP-1 (PLB: 190.4 ± 22.7 vs. VAL: 190.1 
± 21.7 pg/ml, P=0.994), TNF-alpha (PLB: 6.6 ± 0.6 vs. VAL: 5.6 ± 0.6 pg/ml, P=0.243), 
adiponectin (PLB: 4.1 ± 0.4 vs. VAL: 4.4 ± 0.4 mg/ml, P=0.595) and leptin (PLB: 26.9 
± 3.9 vs. VAL: 32.4 ± 4.8 ng/ml, P=0.380) concentrations were comparable. VAL 
treatment did not significantly alter plasma concentrations of MCP-1 (P=0.497), 
TNF-alpha (P=0.106), adiponectin (P=0.312) and leptin (P=0.117) (Figure 3A-D).
Figure 3. Circulating inflammatory markers before and after 26-weeks treatment with VAL (n=17) or PLB (n=19). 
VAL treatment did not significantly affect plasma concentrations of (A) MCP-1, (B) TNF-alpha, (C) adiponectin and 
(D) leptin compared to PLB. MCP-1, monocyte chemoattractant protein-1; TNF-alpha, tumor necrosis factor-alpha.
AT expression of lipolytic enzymes and co-factors involved in lipolysis
VAL treatment tended to reduce AT gene expression of the lipolytic enzyme 
adipose triglyceride lipase (ATGL) and its activator protein comparative gene 
indentification 58 (CGI-58) compared to PLB (P=0.083 and P=0.090, respectively) 
(Table 2). Furthermore, there was a tendency for decreased AT gene expression of 
G0/G1 switch gene 2 (G0S2) (P=0.092), which seems to attenuate ATGL action [30] 
and increase adipocyte differentiation [22], whereas gene expression of hormone-
sensitive lipase (HSL) was unaltered (P=0.710) after VAL treatment (Table 2). The 
decrease in adipocyte size after VAL treatment was positively associated with 
the reduction in abdominal subcutaneous AT gene expression of ATGL (r=0.637, 
P=0.001), CGI-58 (r=0.458, P=0.028) and G0S2 (r=0.551, P=0.010). Protein expression 
of ATGL (P=0.335), CGI-58 (P=0.947), HSL (P=0.821) and G0S2 (P=0.299) in abdominal 
subcutaneous AT was not altered after VAL treatment compared to PLB.
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Insulin sensitivity
As mentioned earlier, the present study was conducted within the framework of the 
PRESERVE study (n=79), in which we have recently demonstrated that 26-weeks 
VAL significantly increased insulin sensitivity compared to PLB treatment [20]. 
Although the change in insulin sensitivity (M-value) after 26-weeks VAL treatment 
was of the same order of magnitude (~10%) in the subset of subjects that was 
studied here (n=38) compared to the total study population, the VAL-induced 
increase in insulin sensitivity did not reach statistical significance in the present 
analysis (P=0.248; Table 1). Interestingly, however, the decrease in adipocyte size 
tended to be associated with the increase in insulin sensitivity (r=-0.340, P=0.062).
Discussion
Recent large clinical trials have provided evidence that RAS blockade reduces the 
incidence of new-onset type 2 diabetes [5,6]. We have recently shown that 26-weeks 
RAS blockade using VAL improved insulin sensitivity in subjects with IGM [20]. 
The present study demonstrated that this was accompanied by a decrease in 
abdominal subcutaneous adipocyte size, with a shift towards a higher frequency of 
small adipocytes, and increased ATBF compared to PLB. The decrease in adipocyte 
size was associated with reduced AT gene expression of inflammatory cell markers 
and improved insulin sensitivity.
We have previously demonstrated that local administration of Ang II, the active 
component of the RAS, in abdominal subcutaneous AT decreased ATBF [31,32], 
whereas local infusion of the ARB losartan increased ATBF [32]. Therefore, we 
hypothesized that long-term ARB treatment may increase ATBF. Indeed, VAL 
treatment increased both fasting and postprandial ATBF compared to PLB. 
As anticipated, the magnitude of the effect on ATBF in the present study (~35% 
increase) was lower than that observed during acute local ARB administration into 
abdominal subcutaneous AT (~55%) [32]. The VAL-induced increase in ATBF may 
not be entirely due to reduced Ang II action via the Ang II type 1 receptor but may 
also be mediated in part through increased nitric oxide production due to increased 
stimulation of the Ang II type 2 receptor [33]. We and others have previously 
demonstrated that both fasting ATBF and the postprandial increase in ATBF [32,34] 
are decreased in obese, insulin resistant and type 2 diabetes subjects [23,35-37]. 
An impaired ATBF response to nutrient intake is closely associated with insulin 
resistance [36,37], suggesting that ATBF is of great importance in the regulation of 
metabolism. Indeed, it has been shown that the postprandial increase in ATBF is 
closely associated with increased clearance of triacylglycerol by adipose tissue [38]. 
Thus, an increased ATBF may improve lipid buffering by adipose tissue, especially 
in the postprandial state, which in turn may contribute to less lipid overflow in the 
circulation and reduced ectopic fat storage, thereby increasing insulin sensitivity 
[11]. In the present study, AT gene expression of angiogenesis and capillarisation 
markers was significantly reduced after VAL treatment, which may reflect a lowered 
angiogenic response secondary to the increase in ATBF.
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In the present study, we found that 26-weeks VAL treatment markedly reduced 
adipocyte size and increased the proportion of small adipocytes, which was 
associated with increased insulin sensitivity. Adipocyte hyperthrophy appears to 
be an independent marker of insulin resistance [39]. In fact, enlarged abdominal 
subcutaneous adipocyte size and insulin resistance appear to be independent and 
additive predictors of the development of type 2 diabetes [40]. The reason for this 
may be that hyperthropic adipocytes have a reduced lipid buffering capacity and 
show disturbances in adipokine expression and secretion, with a shift towards a 
more proinflammatory phenotype [11]. Here, we demonstrate that the decrease in 
adipocyte size after VAL treatment was associated with a significant reduction in 
AT gene expression of chemoattraction, macrophage infiltration and inflammatory 
markers, and increased insulin sensitivity.  These findings are fully in agreement 
with previous studies in rodents, showing that ARB treatment reduced adipocyte 
size and AT inflammation, and improved insulin sensitivity and glucose homeostasis 
[14-19]. Importantly, we found that the VAL treatment evoked these beneficial effects 
without affecting total body weight, although there was a tendency for a decrease 
in body fat percentage. The reduction in inflammatory cell markers in abdominal 
subcutaneous AT did not translate into alterations in circulating adipokines, since 
systemic inflammatory markers and adiponectin concentrations were not affected 
by VAL treatment. In line, it has been found that 8-weeks treatment with the ARB 
losartan had no effects on circulating concentrations of leptin, TNF-alpha and 
adiponectin, despite increased insulin sensitivity [41]. However, other studies 
demonstrated that ARB treatment increased circulating adiponectin [42-44] and 
decreased MCP-1 [45] and TNF-alpha concentrations [45,46]. These conlicting 
findings may be explained by differences in study population, since in several of 
these studies patients with essential hypertension and/or increased inflammation 
participated.
Based on rodent and cell studies [16,18,19,47,48], we hypothesized that stimulation 
of adipocyte differentiation may underlie the VAL-induced decrease in adipocyte 
size. We found that AT gene expression of the adipocyte differentiation marker 
PPAR-γ was significantly reduced, rather than increased, after VAL treatment. 
Although this finding was surprising, it may well be that adipocyte size was already 
reduced several weeks before the end of treatment, which may in turn have down-
regulated PPAR-γ expression, since the decrease in adipocyte size was strongly 
associated with reduced PPAR-γ expression after VAL treatment. Unfortunately, we 
did not collect AT biopsies at different time-points during the treatment period to 
confirm this.
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Important processes in the regulation of adipocyte size, in addition to adipocyte 
differentiation, include the storage and release of fatty acids. In accordance with 
previous findings showing increased lipid synthesis and storage in 3T3-L1 and 
human adipocytes during Ang II stimulation [49], the reduced AT gene expression of 
aP2 and C/EBPa, which are key regulatory factors in adipogenesis and lipogenesis 
[25,26], suggest that the VAL-induced decrease in adipocyte size may, at least partly, 
be explained by decreased AT lipogenesis. Furthermore, we assessed whether VAL 
may affect lipolysis, since previous studies from our laboratory have demonstrated 
that Ang II may exert modest inhibitory effects on AT lipolysis in humans [31,50]. 
There was a tendency for reduced AT gene expression of lipolytic enzyme ATGL as 
well as its co-factor CGI-58 after VAL treatment. In addition, we found that AT mRNA 
expression of G0S2, which may inhibit ATGL activity [30], tended to be lower after 
VAL treatment. Although the reductions in AT gene expression of ATGL, CGI-58 and 
G0S2 were positively associated with the decrease in AT size, protein expression of 
these factors in AT was not altered by VAL. Taken together, these data suggest that 
it is unlikely that increased AT lipolysis contributed to a significant extent to the 
reduction in adipocyte size after VAL treatment, although we cannot fully exclude 
that lipolysis was stimulated during the early phase of treatment.
In conclusion, we have demonstrated for the first time that 26-weeks VAL treatment 
reduced abdominal subcutaneous adipocyte size, with a shift towards a higher 
frequency of small adipocytes, and increased ATBF in subjects with IGM. The 
decrease in adipocyte size was associated with reduced AT gene expression of 
inflammatory cell markers and improved insulin sensitivity. The present findings 
suggest that improved AT function may underlie the increased insulin sensitivity 
after long-term RAS blockade, which in turn may contribute to the reduced incidence 
of type 2 diabetes after long-term treatment with ARBs in subjects at high-risk of 
developing this disease. 
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ABSTRACT
Blockade of the renin-angiotensin system may lower the risk of T2DM through 
improved insulin secretion and insulin sensitivity. The underlying mechanisms 
remain unclear but may involve alterations in body composition and fat distribution. 
We evaluated the effect of 26-weeks valsartan (VAL, n=40) or placebo (PLB, n=39) 
treatment on body composition (DEXA-scan) in individuals with impaired glucose 
metabolism. Furthermore, visceral (VAT) and subcutaneous adipose tissue (SAT; 
MRI), liver and pancreatic fat content (1H-MRS) were examined. VAL reduced total 
body fat mass (P=0.03) and leg fat mass (P=0.01). VAL did not alter body weight 
(P=0.92), trunk fat (P=0.74), VAT (P=0.83), SAT (P=0.53), liver (P=0.61) and pancreatic 
fat content (P=0.42) compared to PLB. The decrease in total fat mass was related 
to a reduction in FPG, HbA1c, HOMAIR and triglycerides and an increase in HDL-
cholesterol. In conclusion, VAL diminished total body fat and leg fat mass, which 
was paralleled by improved metabolism and insulin sensitivity.
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Introduction
The association between insulin resistance, type 2 diabetes (T2DM) and 
inappropriate activation of the renin-angiotensin system (RAS) has been described 
extensively [1]. This was confirmed in several clinical trials, where RAS blockade, 
with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor 
blocker (ARB), lowered the risk for T2DM [2]. Previously, we demonstrated that the 
ARB valsartan (VAL) improved insulin secretion and insulin sensitivity [3]. However, 
the underlying mechanisms in humans remain unclear, but involvement of adipose 
tissue, which expresses compounds of the RAS, has been described [4]. As such, 
in vitro, RAS activation has been related to increased lipogenesis, resulting in 
increased adipose tissue mass in both murine and human adipocytes. In rodents, 
ACEi decreased body weight and reduced fat mass [5,6]. Similarly, ARB prevented 
dietary-induced weight gain in rats [7] and attenuated accumulation of visceral 
(VAT) and subcutaneous adipose tissue (SAT) and liver fat content [8]. Together, 
these alterations may contribute to improved insulin sensitivity.
Notwithstanding evidence in rodents, limited data is available regarding the 
effect of RAS blockade on body weight, body composition and fat distribution in 
humans. The aim of the present study was to investigate the effect of 26-weeks 
VAL or placebo (PLB) treatment on body weight, body composition, VAT, SAT, liver 
and pancreatic fat content in individuals with impaired glucose metabolism (IGM). 
Furthermore, we examined the relation between alterations in body fat content and 
distribution and glucose homeostasis. 
Methods
The current study was conducted within the framework of the PRESERVE study 
(PancREatic beta-cell dySfunction rEstoRed by Valsartan Effects); a randomized-
controlled trial, carried out in Amsterdam and Maastricht, the Netherlands. Details 
on study design were reported previously [3]. The dual-energy X-ray absorptiometry 
(DEXA) scans were performed in both centers (n=79), whereas magnetic resonance 
imaging and spectroscopy (MRI and 1H-MRS, respectively) were performed in 
individuals participating in Amsterdam (n=37; VAL=19, PLB=18). 
Individuals with IGM, i.e. impaired fasting glucose (fasting plasma glucose (FPG) 
≥6.1 and <7.0 mmol/L or FPG ≥5.6 and <7.0 mmol/L and family history of T2DM), 
and/or impaired glucose tolerance (2h-plasma glucose (PG) level ≥7.8-11.1 mmol/L) 
were eligible. After randomization, participants received 160 mg QD VAL (n=40) 
or PLB (n=39) for 2-weeks. The dosage was doubled to 320 mg QD for 24-weeks. 
Participants were allowed to use statins (VAL:2.5%, PLB:10%). The study was 
approved by the local ethics committee and conformed to the principles outlined 
in the Declaration of Helsinki. All individuals gave their written informed consent.
Body composition was assessed using DEXA-scans (Delphi-A;Hologic,Waltham,MA) 
at baseline and after 26-weeks treatment. In the analyses, we used DEXA-derived 
fat and lean soft-tissue mass from total body, legs and trunk (abdominal). VAT and 
SAT were determined with MRI and liver- and pancreatic fat content were quantified 
with 1H-MRS [9]. 
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Data are expressed as mean±standard error of the mean (SE) or, in case of skewed 
distribution, as median (interquartile range). Baseline differences were tested by 
analysis of covariance (ANCOVA) with adjustment for gender, glucometabolic 
status and center. Treatment effects were assessed by ANCOVA with adjustment 
for center, gender, glucometabolic status and baseline measurements. Correction 
for statin use did not alter the results. With univariate correlations (Pearson) 
associations between changes in body composition, fat compartments and 
glucometabolic variables (FPG, 2h-PG level, fasting plasma insulin (FPI), HbA1c and 
homeostasis model assessment of insulin resistance (HOMAIR)) were examined. 
Statistical analyses were performed using SPSS for windows version 15.0 (SPSS, 
Chicago, IL, USA). A P-value <0.05 was considered statistically significant. 
Results
Valsartan (n=40) Placebo (n=39) P-value
Weight, kg 88.5 ± 1.9 88.0 ± 2.8 0.53
BMI, m/kg2 29.8 ± 0.6 29.5 ± 0.8 0.72
Waist, cm 101.8 ± 1.7 102.4 ± 2.0 0.99
SBP, mmHg 131 ± 1.6 130 ± 1.8 0.58
DBP, mmHg 83 ± 1.2 83 ± 0.9 0.87
FPG, mmol/L 6.4 ± 0.1 6.3 ± 0.1 0.24
2h-PG level, mmol/L 8.4 ± 0.4 8.1 ± 0.4 0.62
HbA1c, % 6.0 ± 0.1 5.9 ± 0.1 0.27
FPI, pmol/L 90.4 ± 8.0 87.4 ± 8.3 0.70
Total Cholesterol, mmol/L 5.4 ± 0.14 5.3 ± 0.17 0.83
HDL-C, mmol/L 1.26 ± 0.06 1.26 ± 0.06 0.65
LDL-C, mmol/L 3.49 ± 0.12 3.37 ± 0.13 0.61
Triglycerides, mmol/L 1.46 ± 0.12 1.43 ± 0.11 0.99
GGT, u/L 30.4 ± 2.5 34.7 ± 3.2 0.27
AST, u/L 24.6 ± 1.2 23.3 ± 1.2 0.45
ALT, u/L 28.5 ± 2.1 31.5 ± 1.7 0.34
Total body fat mass, kg 28.3 ± 1.2 27.4 ± 1.3 0.75
leg fat mass, kg 8.5 ± 0.4 8.2 ± 0.4 0.77
Trunk fat, kg 15.1 ± 0.7 14.8 ± 0.8 0.85
Total body lean mass, kg 57.4 ± 18.2 58.7 ± 19.3 0.85
Leg lean mass, kg 19.1 ± 0.6 19.0 ± 0.7 0.23
Trunk lean, kg 28.7 ± 0.9 29.6 ± 1.0 0.84
Liver fat content, % 10.2 ± 2.0 11.3 ± 2.8 0.63
Pancreatic fat content, % 16.0 ± 2.6 12.4 ± 2.8 0.41
SAT, cm2 287 ± 22 258 ± 19 0.36
VAT, cm2 185 ± 14 184 ± 20 0.95
Table 1. Baseline characteristics and baseline body composition and fat distribution. Data represent mean±SE. 
Abbreviations: ALT, alanine aminotranferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; 
FPG, fasting plasma glucose; FPI, fasting plasma insulin; HbA1c, glycated hemoglobin; HDL-C, HDL-cholesterol; 
LDL-C, LDL-cholesterol; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; 2h-PG load, 2h post-load 
glucose levels; VAT, visceral adipose tissue. 
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Before randomization, treatment groups were well-matched (Table 1). After 
26-weeks, body weight and waist circumference remained unchanged in both 
groups (change in body weight: 0.49±0.5 vs. 0.44±0.4 kg, P=0.92; waist: 0.71±0.72 
vs. 0.23±0.51 cm, P=0.53, VAL vs. PLB, respectively). However, VAL significantly 
reduced total body fat mass as compared to PLB (Figure 1A). In particular, leg fat 
mass was consistently reduced after VAL compared to the increase seen after PLB 
(Figure 1B). However, there were no between-group differences in trunk fat mass 
(Figure 1C) and total body-, leg- and trunk lean mass (Figure 1D-F). Finally, VAL did 
not alter VAT, SAT, liver and pancreatic fat content (Figure 1G-J). 
Figure 1. Effect of 26-weeks valsartan on body composition and fat distribution. Changes in DEXA-derived body 
composition (A-F) and MRI or 1H-MRS-derived fat distribution (G-J) after 26-weeks treatment with valsartan (grey 
bars) or placebo (white bars); Abbreviations: SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue. data 
represent mean ± SE.
With respect to glucose metabolism, 2h-PG level tended to increase after PLB 
treatment compared to VAL treatment (0.09±0.38 vs. 0.82±0.21 mmol/L, P=0.09; VAL 
vs. PLB). VAL did not affect FPG (VAL vs. PLB:-0.2±0.1 vs. 0.0±0.1 mmol/L, P=0.56), 
HbA1c (-0.05±0.02 vs. 0.05±0.01 %, P=0.32), FPI (-0.5±5.6 vs. 3.6±4.3 pmol/L, P=0.83), 
HOMA-IR (-0.19(-0.63-0.21) vs. -0.01(-0.62-0.75), P=0.55). In univariate analysis, 
treatment-related changes in total body fat mass were associated with a reduction 
in FPG (r=0.353, P=0.003), HbA1c (r=0.303, P=0.006), HOMAIR (r=0.321, P=0.006) 
and triglycerides (r=0.314, P=0.008) and an increase in HDL-cholesterol (r=-0.253, 
P=0.035). Changes in leg fat content were positively associated with FPG (r=0.234, 
P=0.05) and 2h-PG levels (r=0.241, P=0.038). 
P P P
PPP
P P P P
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Conclusion
VAL did not alter body weight but reduced total body fat mass, with lower leg 
fat mass in individuals with IGM. The changes in fat mass were associated with 
improvements in glucose and lipid metabolism and insulin sensitivity. 
Consistent with our data, previous studies in humans did not find a change in 
body weight after ACEi or ARB treatment [11], although one study reported a small 
weight reduction after ARB treatment [10]. This is the first study showing a VAL-
induced reduction in total body fat mass. Interestingly, this was accompanied 
by a decrease in leg fat mass. Although leg fat mass consists for 90% out of 
subcutaneous fat, a reduction in leg fat mass, may also involve reduced skeletal 
muscle fat content. Unfortunately, DEXA assessment does not allow discrimination 
between these various fat compartments. Whether ARB treatment affects skeletal 
muscle fat content, which is strongly related to peripheral insulin resistance, should 
be addressed in future studies, using proton-MRS. 
The alterations in fat mass were related to improvements in glucose and lipid 
metabolism. These findings may contribute to improvements in insulin sensitivity 
after RAS blockade [3]. The effects of RAS blockade on body composition may be 
due to decreased lipogenesis [6]. Furthermore, RAS blockade may directly affect 
adipose tissue lipid buffering capacity, since an upregulation of RAS in adipose 
tissue has been related to adipose tissue dysfunction [4], with reduced capacity 
to store lipids. Alternatively, RAS blockade increased adipose tissue lipolysis and 
improved the adipocytokine profile and adipose tissue blood flow [6]. 
The reduced adipocyte capacity to store lipids may increase systemic lipid overflow 
thereby increasing fat storage in non-adipose tissues such as liver and pancreas, 
and contribute to insulin resistance and beta-cell failure [12]. In the current study, 
VAL did not affect VAT, SAT, liver- and pancreatic fat content. This finding might be 
explained by treatment duration and/or the used compound, since the effect of 
other ARB, possibly via PPAR-γ activation, might be more pronounced [7]. 
In conclusion, VAL reduced total body fat mass, with lower leg fat mass in subjects 
with IGM, but had no effect on body fat distribution. The changes in fat mass were 
related to improvements in glucose and lipid metabolism, which is consistent with 
the VAL-induced improvement in insulin sensitivity. 
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The natural history of type 2 diabetes (T2DM) is characterized by glucometabolic 
abnormalities that may develop during 5-10 years prior to the diagnosis of the 
disease [1]. In susceptible individuals, mostly in the setting of overweight or obesity, 
blood glucose levels may rise into the pre-diabetic range over time, resulting in 
either impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, as 
defined by a standardized 75-g oral glucose tolerance test (OGTT) [2]. Furthermore, 
these individuals are not only at high risk to develop T2DM, but also exhibit 
increased cardiovascular disease risk [3,4]. In general, the annual risk of individuals 
with impaired glucose metabolism (IGM) to progress to T2DM ranges from 5-10% 
[5]. However, the risk to develop T2DM, differs between individuals with IFG, IGT 
and combined IFG/IGT [6-8]. As such, individuals with IFG showed the lowest risk 
to develop T2DM, followed by individuals with IGT, whereas individuals with IFG/
IGT were most likely to progress to T2DM (Figure 1) [6,8,9]. These differences in 
T2DM risk outline that these conditions are not uniform. Similarly, although it has 
been established that individuals with IGM already manifest the characteristic 
defects of T2DM, i.e. reduced insulin sensitivity and impaired islet-cell function 
[10,11], the pathophysiological features of individuals with IFG, IGT or both, show 
distinct differences and only partly overlap. In Part 1 of this thesis we measured 
insulin sensitivity as well as insulin secretion with various techniques, including 
the gold-standard hyperinsulinemic-euglycemic clamp and hyperglycemic clamp 
with arginine stimulation, and specifically addressed the relation between impaired 
lipid metabolism, insulin sensitivity and beta-cell dysfunction in individuals with 
IFG and/or IGT who are at high risk to develop T2DM.
Insulin sensitivity in IFG, IGT and combined IFG/IGT
As stated, IFG, IGT and combined IFG/IGT are characterized by increased resistance 
to the action of insulin [10]. However, at tissue level, variation in insulin resistance 
has been described that may account for the pathophysiological differences 
[6,11,12]. As such, previous studies have found normal levels of endogenous glucose 
production (EGP) in the presence of increased basal insulin levels in IFG [6,13]. 
Furthermore, individuals with IFG showed an increase in homeostasis model of 
assessment-insulin resistance (HOMAIR), which is thought to predominantly reflect 
hepatic insulin resistance [14]. However, the presence of hepatic insulin resistance 
could not be confirmed in a study using the accurate tracer technique [15]. As 
described in Chapter 4 of this thesis, we could not establish differences in HOMAIR 
between IFG, IGT or IFG/IGT. A possible explanation for these seemingly conflicting 
results might be due to differences in clinical staging (e.g. number of years with 
IFG). Future tracer studies should clarify whether hepatic insulin resistance is 
indeed the predominant disorder in IFG.
In addition, it has been hypothesized that an increase in fasting plasma glucose 
may result from combined pancreatic beta-cell and alpha-cell dysfunction [16], 
with increased levels of glucagon. As such, in patients with T2DM increased alpha 
cell mass [17] as well as disproportionate glucagon levels [18,19] have been 
reported. Very limited studies investigated glucagon secretion in IGM. Although 
abnormalities in alpha-cell function have been reported in these studies [16,20], 
increased glucagon levels have been described in both IFG and IGT [15,21,22]. 
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Consequently, the differences between fasting and postprandial glucose levels 
between these groups could not be explained by differences in glucagon levels 
[15,23]. 
Figure 1. Conversion rates to type 2 diabetes in the Botnia study (follow-up 7-8 years) for individuals with normal 
glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and combined IFG/IGT.
In IGT, impaired peripheral skeletal muscle insulin sensitivity has been described 
as the principal disorder responsible for the rise in postprandial glucose levels 
[6,12,15,24]. In Chapter 4, we measured insulin sensitivity during the gold-standard 
hyperinsulinemic-euglycemic clamp (glucose infusion rate: M-value, mg·kg-1·min-1) 
[25]. This test is regarded as an accurate measure of whole-body insulin sensitivity, 
which is mainly determined by insulin-mediated glucose uptake in skeletal muscle. 
In our study, clamp-derived insulin sensitivity was impaired in individuals with 
IGM, including IGT, as compared to normoglycemic controls. In a small sub-
study including IFG and IGT subjects, we additionally derived postprandial insulin 
sensitivity after consumption of a standardized high-fat mixed meal. In line with 
clamp-derived skeletal muscle insulin sensitivity, meal-derived insulin sensitivity 
was diminished in both IFG and IGT. Meal-derived insulin sensitivity is the result 
of complex metabolic, humoral, neuronal and vascular (splanchnic) changes that 
occur in the postprandial state and have additionally been elicited by a multi-nutrient 
challenge and not only by e.g. glucose. Furthermore, after a meal the liver plays 
a larger role than during the clamp, since during a hyperinsulinemic-euglycemic 
clamp, EGP is almost fully suppressed [25], whereas during a meal, insulin levels 
are lower and EGP is less suppressed [26]. In healthy individuals, hepatic insulin 
sensitivity accounted for one-third, whereas peripheral insulin sensitivity accounted 
for two-third of glucose disposal after a meal [27]. Consequently, although the 
hyperinsulinemic-euglycemic clamp is the gold-standard for measuring peripheral 
insulin sensitivity, a mixed meal is a more physiologic test and gives additional 
information. In conclusion, individuals with IGM are characterized by insulin 
resistance, either assessed with the hyperinsulinemic-euglycemic clamp, the 
OGTT or derived from fasting measurements. However, we could not establish 
differences in insulin sensitivity at tissue level between IFG and/or IGT. 
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The pathophysiological pathways that ultimately lead to insulin resistance may 
include impaired fatty acid metabolism in adipose tissue and skeletal muscle [28,29]. 
According to the ‘lipid overflow’ hypothesis, under insulin resistant conditions, 
the capacity of the adipose tissue to store lipids (especially in the postprandial 
state) becomes insufficient, which may lead to an increased supply of non-
esterified fatty acids (NEFA) and triacylglycerol (TAG) to non-adipose tissues such 
as skeletal muscle and the liver [25,26]. These ectopic lipid depositions have been 
related to impaired insulin sensitivity [30,31]. Besides lipid overflow, also intrinsic 
disturbances in skeletal muscle fatty acid handling may contribute to ectopic fat 
accumulation. Subjects with impaired glucose tolerance or T2DM show a metabolic 
inflexibility to adjust fat oxidation to fatty acid supply as compared to obese or 
lean normoglycemic controls [32,33]. This is reflected by an impaired capacity to 
increase fat oxidation during fasting conditions and an impaired capacity to switch 
from fat to carbohydrate oxidation in the postprandial state [28]. Together, this may 
lead to increased skeletal muscle lipid accumulation, which is closely related to 
insulin resistance [30,31]. In Chapter 4, both IFG and IGT subjects showed increased 
plasma TAG concentrations after the mixed-meal, which was accompanied by 
increased TAG extraction across the skeletal muscle. Since in the postprandial state, 
insulin resistant individuals are characterized by hyperinsulinemia, the higher TAG 
extraction may result from insulin-induced upregulation of the fatty acid transporter 
CD36 [34] as well as higher skeletal muscle lipoprotein lipase activity [35]. Together, 
the increase in TAG supply as well as TAG extraction may contribute to skeletal 
muscle lipid accumulation and insulin resistance in individuals with IGM. 
Beta-cell dysfunction in IFG and/or IGT
In the presence of hepatic and/or peripheral insulin resistance, pancreatic beta-cells 
will increase insulin secretion by increasing beta-cell mass and function to maintain 
glucose levels within the normal range. However, when insulin demand exceeds 
beta-cell capacity, glucose levels will rise into the pre-diabetic states. Therefore, 
beta-cell dysfunction is a prerequisite in the progression of normal glucose 
tolerance to IGM and T2DM. The presence of beta-cell dysfunction in individuals 
with IGM has been described previously [15,24]. In Chapter 3 and 4, we further 
clarified the quantitative differences in beta-cell dysfunction between these groups. 
As such, first-phase C-peptide secretion was impaired in individuals with IFG, IGT 
and combined IFG/IGT, whereas only individuals with both IFG and IGT showed 
defects in second-phase glucose-stimulated and arginine-stimulated C-peptide 
secretion. This observation may partly explain the increased risk of individuals with 
combined IFG/IGT to develop T2DM, as compared to individuals with isolated IFG 
or IGT.
Chronically elevated NEFA have been implicated in the pathogenesis of both 
insulin resistance (as discussed above) and beta-cell dysfunction [36]. As reviewed 
in Chapter 2, prolonged exposure of beta-cells to elevated levels of NEFA in 
vitro resulted in decreased insulin gene expression, blunted glucose-stimulated 
insulin secretion (GSIS) and increased apoptosis [37,38], also referred to as 
lipotoxicity [39,40]. In vivo, while acute infusion of intralipid was shown to enhance 
GSIS [36,41], opposite effects were seen for prolonged infusion of intralipid 
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[36,42]. As stated above, in the presence of adipose tissue dysfunction and the 
subsequent systemic lipid overflow, triglycerides may accumulate in non-adipose 
tissues and impair organ function. Similarly, it could be hypothesized that the 
accumulating lipids in the pancreas may act as a source of NEFA or other lipid-
derived metabolites, which impair beta-cell function through lipotoxic pathways. 
However, as stated in Chapter 3, conflicting results have been published whether 
lipid accumulation in pancreatic islets occurs independently of factors such as 
aging and obesity, and whether this contributes to beta-cell dysfunction in vivo 
in metabolically compromised humans. In Chapter 3, we demonstrated that the 
impairments in beta-cell function as seen in individuals with IGM, are accompanied 
by lipid accumulation, as measured by proton 1H-MRS in the pancreas compared 
to age- and BMI-matched normoglycemic controls. The lipid accumulation in the 
pancreas was positively associated with post-load glucose levels, which delineates 
the reciprocal association of glucose and fatty acid metabolism. This is in line with 
the data regarding glucose and fatty acid handling in skeletal muscle as presented 
in Chapter 4, and confirms that in glucometabolic disorders both hyperglycemia 
and hyperlipidemia may contribute to organ dysfunction. 
Despite the relation between lipid accumulation and glucose metabolism, a direct 
relation between pancreatic fat accumulation and beta-cell dysfunction could not 
be established, as described in Chapter 3. Unfortunately, current techniques do 
not allow discrimination between intra- and inter-islet fat in vivo [43]. Since beta 
cells constitute only 2% of the total pancreas mass [44], 1H-MRS measured lipid 
deposition in the pancreas is most likely located outside beta cells. Consequently, 
with 1H-MRS it is impossible to tease out the direct from the indirect role of lipids 
and their toxic intermediates in vivo. Furthermore, it has been suggested that 
triglyceride depositions reflect a protective buffer, diverting excess NEFA from 
metabolic pathways leading to lipotoxicity. Instead, based on mainly pre-clinical 
data, NEFA are supposedly channelled into lipid stores in non-adipose tissue, 
including the pancreas. Therefore, although pancreatic lipid content reflects 
derangements in lipid metabolism, the location, i.e. intra- or inter-islet, and function 
of the accumulated pancreatic lipids is still unknown. 
In summary, Part 1 of this thesis provides more insight into the underlying 
pathophysiology of IGM, specifically focusing on mechanisms related to insulin 
resistance and beta-cell dysfunction and the contribution of alterations in lipid 
handling in these two key defects leading to T2DM.
Part 2 The role of the renin-angiotensin system
In addition to impairments in glucose metabolism, individuals with IGM often display 
several concurrent cardiometabolic abnormalities, including hyperinsulinemia, 
dyslipidemia and hypertension. Consequently, obese insulin-resistant individuals 
are often treated with lipid lowering and antihypertensive medication. With respect 
to the latter, retrospective analyses of clinical trials showed that diuretics and beta-
blockers increased the risk of new onset T2DM in individuals with IGM [45,46]. 
In contrast, blood pressure lowering medication that block the renin-angiotensin 
system (RAS), i.e. angiotensin converting enzyme inhibitors (ACEi) or angiotensin 
Discussion and future perspectives
10
Opzet Proefschrift-def 25052011.indd   167 25-05-11   16:27
168
receptor blockers (ARB) have been related to delayed onset of T2DM in non-
diabetic subjects with or without hypertension [47-50]. In Part 2 of this thesis we 
investigated whether the diabetes-preventing effects of RAS blockade may be 
related to improved insulin sensitivity and/or beta cell function and investigated 
several of the underlying mechanisms. 
RAS blockade and beta-cell function
In insulin resistant conditions like obesity, an upregulation of RAS has been related 
to impaired beta-cell function [51], thereby possibly contributing to the development 
of T2DM. The findings in Chapter 6 are consistent with a role of RAS in beta-cell 
dysfunction, since blocking the RAS with the ARB vasartan for 26 weeks improved 
beta-cell function, with an increase in both first- and second-phase C-peptide 
secretion. The underlying mechanisms of improved beta-cell function after RAS 
blockade have been reviewed in Chapter 5. In short, pancreatic islets express RAS 
components with the AT1R specifically localized on beta cells [52,53]. In rodents, 
the presence of hyperglycemia increased RAS components in pancreatic islets 
[52]. In addition, AngII diminished islet blood flow and impaired insulin secretion 
[54,55]. These deleterious effects were counteracted by RAS blockade with an 
ACEi or ARB, resulting in increased insulin secretion and glucose tolerance [55-
58]. Molecular mechanisms explaining these observations have been addressed 
in vitro and in vivo in animal models of T2DM and may include reduced oxidative 
stress, inflammation and islet fibrosis in pancreatic islets, resulting in improved islet 
structure, mass and function with increased insulin secretion [58-60]. Our study is 
the first to measure the effect of RAS blockade on beta-cell function using the gold-
standard hyperglycemic clamp with subsequent arginine stimulation in vivo in 
humans. The improvement in beta-cell function was not related to blood pressure 
changes, which supports the data from rodents showing that RAS blockade directly 
affects beta cells, thereby increasing insulin secretion. However, the suggested 
processes underlying RAS blockade-induced improvements in beta-cell function 
are based on rodent data and should preferably also be established in humans. 
RAS blockade and insulin sensitivity
In addition to the effects of RAS blockade on beta-cell function, we were able to 
confirm ARB-induced improvement in insulin sensitivity in Chapter 6. Despite 
changes in insulin secretion and action, there were no significant changes in fasting 
plasma glucose and HbA1c, whereas 2-h post-load glucose tended to improve after 
valsartan compared to placebo. This lack of changes in clinical variables of glucose 
metabolism has been reported previously [61], and may be due to the treatment 
duration of these studies, which all last less than 6 months.
The underlying processes involved in improved insulin sensitivity have been 
reviewed extensively in Chapter 5 and may include effects on both adipose tissue 
as well as skeletal muscle.
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RAS and adipose tissue
In line with a local tissue RAS in the pancreas, adipose tissue expresses many 
components of the RAS [62], which expression is up-regulated in insulin resistant 
states [63]. The increased expression of RAS components may contribute to an 
impaired adipose tissue function [63,64]. As such, an up-regulation of RAS has 
been related to impaired adipocyte differentiation, leading to large insulin resistant 
adipocytes [65,66], impaired adipose tissue blood flow [67,68] and, finally, altered 
adipokines with increased expression of pro-inflammatory cytokines and decreased 
adiponectin [69-71]. Another characteristic of adipose tissue dysfunction is impaired 
lipid buffering and lipid handling resulting in lipid overflow in the circulation and 
an increased lipid supply to and increased fat storage in non-adipose tissues 
[29]. Consequently, as reviewed in Chapter 5, RAS blockade may improve insulin 
sensitivity via improved adipose tissue function.
RAS blockade, adipocyte size and adipose tissue function 
In rodent and in vitro cell-culture studies, RAS blockade promoted the recruitment 
and differentiation of (pre)adipocytes, resulting in an increased number of small 
insulin-sensitive adipocytes [65,66,72] and improved insulin sensitivity [72]. In 
Chapter 8, we describe that 26 weeks valsartan treatment may improve adipose 
tissue function. Treatment with valsartan significantly reduced adipocyte size, which 
was associated with improved insulin sensitivity. Adipocyte hyperthrophy appears 
to be an independent marker of insulin resistance [73]. In fact, enlarged abdominal 
subcutaneous adipocyte size and insulin resistance appear to be independent and 
additive predictors of the development of T2DM [74]. The reason for this may be 
that hyperthropic adipocytes have a reduced lipid buffering capacity and show 
disturbances in adipokine expression and secretion, with a shift towards a more 
proinflammatory phenotype. Indeed, valsartan not only reduced adipocyte size 
but also significantly reduced adipose tissue gene expression of chemoattraction, 
macrophage infiltration and inflammatory markers, including monocyte 
chemotactic protein (MCP)-1 and tumor necrosis factor (TNF)-alpha. However, 
systemically, valsartan treatment did not result in alterations in circulating MCP-
1, TNF-alpha, leptin and adiponectin. Our data support a previous report where 
8-weeks treatment with the ARB losartan did not alter circulating leptin, TNF-alpha 
and adiponectin [75]. However, contrasting findings have also been reported. As 
such, treatment with an ACEi or ARB showed a significant decrease in systemic 
MCP-1, IL-6, high-sensitive C-reactive protein (HsCRP) and TNF-alpha in patients with 
diabetic nephropathy [76] or essential hypertension [77]. Furthermore, treatment 
with an ACEi or ARB has been shown to improve adiponectin in insulin resistant 
individuals with or without hypertension [78-82]. The different outcomes between 
these studies might be due to differences in study population, since individuals 
with hypertension or an increased inflammatory profile are more likely to benefit 
from RAS blocking agents. 
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One of the processes underlying the effects of how RAS blockade might decrease 
adipocyte size may involve peroxisome proliferator-activated receptor (PPAR)-γ 
activation [83,84], since PPAR-γ plays a role in glucose and lipid metabolism and 
PPAR-γ agonists can improve insulin sensitivity [85]. Both ACEi and ARB have been 
shown to have PPAR-γ-agonistic effects [61,86]. However, there might be effect 
differences with respect to the different compounds [87]. As such, consistent data 
exists regarding the PPAR-γ-agonistic effect of telmisartan [83,86], while this is less 
conclusive with respect to valsartan [86,88] and olmesartan [87]. In Chapter 8, we 
showed that despite a reduction in adipocyte size, 26 weeks valsartan reduced 
adipose tissue PPAR-γ expression. The adipocyte size might well be reduced weeks 
before the end of the study, and this may consequently explain the decrease in 
PPAR-γ gene expression. Unfortunately, we did not collect adipose tissue at different 
time points during the study to confirm this hypothesis. 
RAS blockade and adipose tissue blood flow
The positive effect of ARB treatment on adipose tissue lipid handling and adipose 
tissue function may include an increased adipose tissue blood flow. Reduced 
tissue blood flow impairs the clearance of locally produced metabolites from the 
interstitial space. This increases the probability of re-uptake and re-esterification 
of NEFA in adipose tissue [89]. Furthermore, impaired adipose tissue blood flow 
reduces triglyceride clearance and leads to a rise in circulating triglycerides [29]. 
Consequently, alterations in (postprandial) adipose tissue blood flow may contribute 
to lipid overflow to non-adipose tissues and insulin resistance. Finally, decreased 
blood supply may lead to hypoxia in adipose tissue, which has been related to 
adipose tissue dysfunction and increased expression of inflammatory genes and 
decreased expression of adiponectin [90,91]. Short-term AngII infusion in humans 
reduced adipose tissue blood flow [67,68], which was restored after treatment with 
an ARB [92]. In Chapter 8, we describe for the first time the effect of prolonged 
RAS blockade on adipose tissue blood flow in vivo in humans. Twenty-six week 
treatment with valsartan improved adipose tissue blood flow. Furthermore, adipose 
tissue gene expression of angiogenesis and capillarisation markers were markedly 
reduced after valsartan treatment. This reduction may reflect a lower angiogenic 
response secondary to the increase in adipose tissue blood flow.
Overall, in Chapter 8, we demonstrate that 26-weeks valsartan treatment increased 
adipose tissue blood flow and reduced adipocyte size, with a shift towards a higher 
frequency of small adipocytes, in individuals with IGM. This was associated with 
decreased adipose tissue gene expression of adipogenesis, chemoattraction, 
macrophage infiltration and inflammatory markers, without affecting systemic 
markers of inflammation. Nevertheless, this improved adipose tissue function may 
contribute to the valsartan-induced improvement in insulin sensitivity.
RAS blockade, body composition and fat distribution
RAS activation has been related to increased lipogenesis, thereby increasing 
adipose tissue mass in rodent and human adipocytes. In line with these data, 
treatment with an ARB prevented dietary-induced weight gain in Sprague-Dawley 
rats [93] and attenuated the accumulation of visceral and subcutaneous adipose 
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tissue and liver fat content in Fischer-344 rats [94]. Furthermore, in rodents RAS 
blockade with an ACEi reduced body weight with reduced fat mass [95,96]. Up 
till now, limited data is available regarding the effect of RAS blockade on body 
weight, body composition and fat distribution in humans. In Chapter 9 we showed 
that 26 weeks valsartan did not alter body weight. However, valsartan altered body 
composition as it reduced DEXA-derived total body fat mass, with a lower leg 
fat mass in individuals with IGM. The changes in fat mass were associated with 
improvements in glucose metabolism, insulin resistance and blood lipid profile. 
Despite changes in fat mass, valsartan did not affect visceral and subcutaneous 
adipose tissue and fat deposition in the liver and pancreas. As stated in Chapter 9, 
this finding might be due to the relatively short treatment duration and/or the 
compound that was used. Future studies should clarify the underlying mechanisms 
as well as the clinical relevance in humans. 
In conclusion, as shown in Chapter 8 and 9, pharmacological treatment with an 
ARB may improve adipose tissue function and reduce total body fat mass; these 
alterations may partly explain the observed improvements in insulin sensitivity 
after RAS blockade. 
RAS and skeletal muscle
As the major tissue for insulin mediated glucose disposal, the skeletal muscle is 
crucial in the development of insulin resistance. Similar to adipose tissue and the 
pancreas, skeletal muscle expresses many components of the RAS, including AngII 
and AT1R [97]. As reviewed in Chapter 5, local RAS components may affect insulin 
sensitivity via changes in muscle blood flow but also directly via interference 
in insulin signaling. Furthermore, recently, a role for AngII-induced reduction 
in skeletal muscle mitochondrial content has been described [98], which may 
contribute to insulin resistance and T2DM [99,100]. RAS blockade may increase 
mitochondrial content and thereby improve insulin sensitivity. The latter should be 
clarified in future studies in relevant populations. 
A reduction in muscle blood flow contributes to insulin resistance, since it reduces 
nutrient, hormone and oxygen delivery, including glucose and insulin [101]. Similar 
to the improvements in adipose tissue blood flow, pharmacological blockade of RAS 
resulted in an increase in forearm blood flow [101,102], thereby possibly increasing 
glucose and insulin delivery to skeletal muscle, which in turn may lead to increased 
glucose utilization. In rodents, AngII was shown to impair microvascular skeletal 
muscle blood flow and glucose uptake [103]. And, although assessed with different 
techniques, ARB treatment prevented or improved microvascular dysfunction in 
spontaneously hypertensive and Sprague-Dawley rats [104,105]. However, limited 
data is available regarding the effect of RAS blockade on the microcirculation 
in humans. In Chapter 7, we describe the presence of impaired microvascular 
structure and function in individuals with impaired glucose metabolism, compared 
to age- and BMI-matched normoglycemic controls. However, 26-weeks valsartan 
treatment did not alter unstimulated skin microvascular function and structure in 
this high risk population. This negative finding might be due to the drug class we 
used to interfere with the RAS, since more pronounced effects on microvascular 
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function have been reported after ACEi treatment [106]. Furthermore, the effect of 
RAS blockade on microvascular structure and function might be more pronounced 
in other populations, for instance (untreated) hypertensive patients, or after 
prolonged treatment duration. Thus, in addition to these considerations, the effect 
of long-term RAS blockade on stimulated microvascular function and structure, i.e. 
during hyperinsulinemia, should be addressed in future studies. 
Summary and future perspectives
In Part 1 of this thesis the pathophysiological characteristics of individuals with IGM 
are described, with a specific focus on pancreatic lipid accumulation in relation to 
beta-cell dysfunction and changes in skeletal muscle fatty acid handling in relation 
to IGM. Due to the increasing number of individuals with IGM and the high risk for 
these individuals to develop T2DM, there is an urgent need to develop strategies 
that may preserve or restore beta-cell function and insulin sensitivity. Lifestyle 
intervention has been shown to significantly delay the onset of T2DM. However, 
successful continuation of lifestyle changes is extremely difficult and a significant 
number of individuals still progress to IGM and T2DM. Recently, one study reported 
a protective effect of the thiazolidinedione pioglitazone on new onset T2DM in 
individuals with IGM [107]. However, up till now no successful pharmacological 
strategy has been addressed in the prevention of the disease. Consequently, older 
and established blood-glucose lowering agents (i.e. sulphonylurea, metformin 
and/or insulin) that relieve the symptomatic burden of T2DM, but do not prevent 
the progression of the disease are still first-choice drugs in the treatment of T2DM. 
In recent years, blockade of the RAS has been related to delayed onset of T2DM. 
In Part 2 of this thesis, we confirm the mechanisms possibly accounting for the 
protective effect of RAS blockade with an ARB in the onset of T2DM in individuals 
with IGM, since 26-weeks treatment improved both insulin sensitivity as well as 
beta-cell function. The underlying mechanisms addressed in this thesis include 
improvement in beta-cell function and adipose tissue function. In addition, based 
on rodent data, RAS blockade may additionally improve insulin sensitivity via direct 
effects on skeletal muscle insulin signaling or mitochondrial function. 
Individuals with IGM often display concurrent cardiometabolic abnormalities, 
including hypertension. Accordingly, antihypertensive drugs with neutral or positive 
side effects on glucose and lipid metabolism may be of clinical importance. This 
thesis outlines the positive glucometabolic effects of pharmacological blockade 
of the RAS, using an ARB. The clinical translation of these findings could be that 
physicians, when prescribing blood-pressure lowering therapy in individuals with 
hypertension and concurrent glucometabolic derangements, may consider ARB or 
ACEi as first-choice therapy, provided that there are no specific indications to use 
beta-blockers or diuretics. Given their beneficial metabolic actions, on top of the 
anti-hypertensive effects, agents that interfere with the RAS may help to prevent or 
delay the onset of T2DM in these high-risk individuals.
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Type 2 diabetes (T2DM) vormt bijna overal ter wereld een serieuze bedreiging voor 
de volksgezondheid. Dit wordt veroorzaakt doordat de ziekte naast complicaties aan 
ogen, nieren en zenuwen, samen gaat met een sterk verhoogd risico op het krijgen van 
hart- en vaatziekten [1]. De wereldgezondheidsorganisatie (World Health Organization) 
schat het aantal mensen dat in 2005 overleed aan de gevolgen van T2DM op 1.1 miljoen 
en waarschijnlijk is dit zelfs nog een onderschatting [2]. Daarnaast is de verwachting 
dat het aantal mensen met T2DM zal verdubbelen tussen 2000 en 2030 [3]. T2DM 
ontstaat door een aantal factoren, waaronder genetische aanleg, omgevingsfactoren en 
leefgewoonten. Met betrekking tot het laatste zijn met name overmatige en ongezonde 
voeding en verminderde beweging van belang, wat samen leidt tot overgewicht. 
Deel 1: Onderliggende verstoringen bij mensen met een hoog risico op T2DM
T2DM wordt gekenmerkt door een verminderde gevoeligheid van het lichaam voor de 
werking van het hormoon insuline (insuline resistentie). Insuline zorgt ervoor dat de 
glucose uit het bloed wordt opgenomen in de spieren en daar als brandstof gebruikt 
kan worden. Insuline wordt gemaakt in de alvleesklier in de zogeheten beta cellen. 
Mensen met overgewicht ontwikkelen insuline resistentie. De alvleesklier compenseert 
voor deze insuline resistentie door extra insuline aan te maken [4]. Wanneer de beta 
cellen deze extra vraag niet meer aan kunnen zal de insuline productie onvoldoende 
zijn en de glucose spiegel in het bloed stijgen [5,6]. Al 5-10 jaar voordat de diagnose 
T2DM wordt gesteld is de functie van deze beta-cellen achteruit gegaan (beta-cel 
dysfunctie) en is de gevoeligheid van het lichaam voor insuline verminderd [5,6]. 
Dit leidt tot een verhoging van de bloed glucose waarde. Wanneer deze waarde licht 
verhoogd is, wordt het een voorstadium van T2DM genoemd: de “pre-diabetes” fase. 
Dit stadium kent drie verschillende vormen. Allereerst kan de nuchtere glucose waarde 
verhoogd zijn (impaired fasting glucose, IFG), ten tweede kan de glucose waarde na 
een maaltijd verhoogd zijn (impaired glucose tolerance, IGT) en tot slot kan er sprake 
zijn van een combinatie van deze twee waarbij zowel de nuchtere glucose waarde 
alsmede de glucose waarde na een maaltijd verhoogd zijn (IFG/IGT). De onderliggende 
mechanismen, die deze verstoringen veroorzaken, lijken te verschillen tussen deze drie 
groepen. Over het algemeen hebben mensen met een glucose waarde passend bij 
de pre-diabetes fase een absoluut jaarlijks risico van 5-10% om T2DM te ontwikkelen 
[7]. Tussen de groepen verschilt dit risico waarbij de gecombineerde groep (IFG/IGT) 
het hoogste risico heeft op progressie naar T2DM [6,8,9]. Het hoge risico dat deze 
mensen lopen op T2DM vormt de basis voor dit proefschrift. Deel 1 van dit proefschrift 
beschrijft de onderliggende verstoringen bij mensen met een hoog risico op T2DM, 
waarbij onder andere is gekeken naar verschillen tussen de drie groepen. 
Insuline gevoeligheid in IFG, IGT en IFG/IGT
Mensen met een hoog risico op T2DM zijn insuline resistent ten opzichte van gezonde 
controles, zoals besproken is in hoofdstuk 4. In dit hoofdstuk hebben we de insuline 
gevoeligheid gemeten op diverse manieren om inzicht te krijgen in de verschillende 
vormen van insuline resistentie en om te meten of er sprake is van een verschil 
in insuline gevoeligheid tussen de groepen IFG, IGT en IFG/IGT. De verschillende 
metingen toonden consistent insuline resistentie aan bij deze drie groepen. Echter, 
in tegenstelling tot andere onderzoeksgroepen hebben wij geen verschillen gemeten 
tussen de groepen onderling.
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Mensen met een voorstadium van T2DM hebben niet alleen verstoringen in het 
glucose metabolisme maar ook vaak verstoringen in het vetmetabolisme [10]. Zo 
kunnen verstoringen in de vetstofwisseling leiden tot verminderde vetstapeling 
in vetweefsel en een toename van vetstapeling in andere organen, bijvoorbeeld 
spieren, lever en/of alvleesklier [11,12]. Vetstapeling in deze organen is gerelateerd 
aan een verminderde functie van deze organen. Zo kan vetstapeling in spieren 
en lever leiden tot ongevoeligheid voor insuline [11,13]. Ook veranderingen in 
de vetstofwisseling in de spieren zelf kunnen leiden tot vetstapeling in de spier, 
wat bijdraagt aan insuline resistentie en T2DM. Mensen met IFG en IGT hebben 
inderdaad een verstoorde verwerking van vetten, wat kan bijdragen aan vetstapeling 
in de spier, insuline resistentie en T2DM, zoals besproken is in hoofdstuk 4. 
Beta-cel functie in IFG, IGT en IFG/IGT
Zoals beschreven zal in de aanwezigheid van insuline resistentie, ter compensatie 
de insuline productie verhoogd worden, om de glucose waarden binnen de normale 
grenzen te houden. Wanneer de productie ontoereikend is, volgt een verhoging van 
de glucose spiegel. Daarom is het ontstaan van beta-cel dysfunctie essentieel in 
de ontwikkeling van T2DM. De insuline productie blijkt reeds gestoord bij mensen 
met IFG, IGT en IFG/IGT, zoals beschreven in hoofdstuk 3 en 4. Daarbij werden de 
meest uitgesproken verstoringen in beta-cel functie gezien bij mensen met zowel 
IFG alsmede IGT. Dit kan een verklaring vormen voor het hoge risico dat deze groep 
loopt op progressie naar T2DM. 
De relatie tussen vetstapeling in spieren en de lever is gerelateerd aan insuline 
resistentie in deze organen [11,13]. Daarnaast zijn er studies die vetstapeling in de 
alvleesklier beschrijven. Het is onduidelijk of vetstapeling in de alvleesklier plaats 
vindt onafhankelijk van overgewicht en veroudering. In hoofdstuk 3 beschrijven 
we voor de eerste keer dat mensen met een gestoord glucose metabolisme, 
onafhankelijk van de leeftijd en het gewicht, vetstapeling hebben in de alvleesklier 
ten opzichte van gezonde controles. Echter, een directe relatie tussen vetstapeling 
in de alvleesklier en de functie van de alvleesklier kon niet worden aangetoond. 
De huidige technieken maken het niet mogelijk de locatie van het vet in de 
alvleesklier te bepalen [14]. Dit vet kan opgeslagen zijn in de beta cellen zelf of 
eromheen. Aangezien maar 2% van de alvleesklier bestaat uit beta cellen [15] is 
het vet waarschijnlijk buiten de beta cellen gelegen. Ondanks dat er een verband 
bestaat tussen vetstapeling in de alvleesklier en afwijkingen in het glucose- en 
vetmetabolisme, blijft de locatie en rol van dit vet onbekend. 
Samenvattend geeft deel 1 van dit proefschrift meer inzicht in de verstoringen 
in de glucose stofwisseling bij mensen met een hoog risico op T2DM. Daarbij is 
specifiek gekeken naar insuline gevoeligheid en beta-cel functie en de bijdrage van 
veranderingen in de vetstofwisseling in deze twee belangrijke factoren leidend tot 
het ontstaan van T2DM. 
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Deel 2: De rol van het renine-angiotensine systeem
Mensen met een verstoring in de glucosestofwisseling hebben vaak bijkomende 
problemen, zoals een verstoring in de vetstofwisseling en een hoge bloeddruk. 
Dit heeft tot gevolg dat mensen met overgewicht (en insuline resistentie) vaak 
behandeld worden met vetverlagende medicatie en bloeddrukverlagende 
middelen. Verschillende bloeddrukverlagende medicijnen verhogen het risico op 
T2DM [16,17]. Daarentegen is uit meerdere studies gebleken dat medicijnen die de 
bloeddruk verlagen via blokkade van het renine-angiotensine systeem (RAS) juist 
het ontstaan van T2DM kunnen vertragen [18-21]. Men denkt dat dit komt door een 
gunstige werking van deze medicijnen zowel op de insuline gevoeligheid alsmede 
op de insuline producerende beta-cellen. 
In dit proefschrift wordt beschreven wat de effecten zijn van het geneesmiddel 
valsartan (een geneesmiddel dat het RAS remt) op insuline gevoeligheid en de 
functie van de insuline producerende beta-cellen in de alvleesklier bij mensen 
met een hoog risico op T2DM, dus IFG en/of IGT (hoofdstuk 6). Daarnaast wordt 
onderzocht wat de effecten van dit middel zijn op de bloedvaten (hoofdstuk 7), op 
vetweefsel (hoofdstuk 8) en op de lichaamsvetverdeling (hoofdstuk 9). 
RAS blokkade en beta-cel functie
Bij mensen met overgewicht en insuline resistentie is een overmatige activering 
van het RAS geconstateerd en dit is gerelateerd aan beta-cel dysfunctie [22]. In 
dit proefschrift (hoofdstuk 6) bevestigen we een relatie tussen RAS activatie en 
beta-cel dysfunctie, aangezien een half jaar behandeling met een RAS blokker 
(valsartan) de insuline productie verbetert. Het onderliggende mechanisme is 
gebaseerd op dierstudies zoals beschreven in hoofdstuk 5. Kort geformuleerd, de 
verbetering in insuline productie na RAS blokkade kan het gevolg zijn van een 
verbeterde doorbloeding van de alvleesklier, waardoor een betere signalering van 
een hoge glucose waarde plaats vindt en de insuline beter wordt afgevoerd [23-26]. 
Daarnaast vermindert RAS blokkade mogelijk ontstekingsreacties in de beta-cellen 
en verbetert het de structuur van de alvleeskliercellen. Samen zorgt dit voor een 
toename in beta-cel massa en functie met een verhoogde insuline productie [26-
28]. 
RAS blokkade en insuline gevoeligheid
Naast een toename van de insuline productie verbeterde tevens de insuline 
gevoeligheid na een half jaar behandeling met een RAS blokker, zoals beschreven 
in hoofdstuk 6. Echter, aan het einde van de studie was er geen verschil in klinische 
parameters zoals het HbA1c, de nuchtere glucose spiegel en de glucosespiegel 
na een maaltijd. Het is mogelijk dat een langere behandelduur nodig is om 
veranderingen in deze parameters te meten. De mechanismen die kunnen leiden 
tot een verbetering in insuline gevoeligheid na behandeling met RAS blokkers, 
inclusief effecten op vet en spierweefsel, zijn beschreven in hoofdstuk 5.    
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RAS en vetweefsel
Net als in de alvleesklier, is er ook sprake van verhoogde RAS activatie in vetweefsel 
bij mensen met insuline resistentie [29]. Deze verhoogde activatie van het RAS 
leidt tot gestoorde ontwikkeling van vetcellen [30,31], gestoorde doorbloeding 
van vetweefsel [32,33] en verhoogde ontstekingsparameters in vetweefsel [34-
36]. Samen leidt dit tot een verstoring van de functie van het vetweefsel. Zoals 
beschreven in deel 1 van dit proefschrift kan een verstoring in vetweefselfunctie 
leiden tot insuline resistentie. In hoofdstuk 8 beschrijven we hoe behandeling met 
een RAS blokker de ontwikkeling van vetcellen verbetert, wat leidt tot een toename 
in het aantal kleine goed-ontwikkelde vetcellen. De verandering in vetcel grootte na 
RAS blokkade is gerelateerd aan een toename in insuline gevoeligheid. Grote minder-
ontwikkelde vetcellen hebben een verminderde functie, waardoor de vetopslag 
is afgenomen en verhoogde ontstekingsparameters worden uitgescheiden. RAS 
blokkade deed de expressie van deze ontstekingsparameters afnemen, wat kan 
bijdragen aan een verbetering van de vetweefselfunctie en insuline gevoeligheid. 
Een goede doorbloeding is essentieel voor een goede functie van vetweefsel. 
Verminderde doorbloeding kan leiden tot een vermindering van vetopslag met 
als gevolg een verhoging van circulerende vetdeeltjes in het lichaam [11]. Deze 
kunnen, zoals eerder beschreven, stapelen in andere organen dan vetweefsel en 
daar leiden tot insuline resistentie. Daarnaast kan verminderde doorbloeding leiden 
tot hypoxie, dit betekent dat het vetweefsel niet voorzien wordt van voldoende 
zuurstof. Daaropvolgend ontstaat er vetweefsel dysfunctie en ontsteking in 
het vetweefsel [37,38]. Een half jaar behandeling met valsartan verbeterde de 
vetweefseldoorbloeding, zoals beschreven in hoofdstuk 8. Daarnaast verminderde 
de parameters voor vaatnieuwvorming, passend bij een verminderde behoefte aan 
vaatnieuwvorming bij een verbeterde doorbloeding van het vetweefsel. 
RAS blokkade, lichaamssamenstelling en vetverdeling
In dierstudies is aangetoond dat verhoogde RAS activatie kan leiden tot een 
toename in vetmassa. Omgekeerd, voorkwam RAS blokkade dat deze dieren in 
gewicht aankwamen en dat vet werd opgeslagen in vetweefsel rondom de organen 
en in de lever [39]. In hoofdstuk 9 beschrijven we voor het eerst het effect van 
RAS blokkade op lichaamssamenstelling en vetverdeling bij mensen. 26 weken 
behandeling had geen effect op het lichaamsgewicht. Daarentegen verlaagde 
RAS blokkade de totale lichaamsvetmassa (gemeten middels een DEXA-scan), 
waarbij de afname voornamelijk gezien werd in de benen. De veranderingen in 
vetmassa zijn gerelateerd aan veranderingen in de glucose- en vetstofwisseling. De 
verschillende vetcompartimenten in de buik (onderhuidsbuikvet, buikvet rondom 
de organen, levervet en pancreasvet) toonden geen veranderingen na valsartan 
behandeling. 
Samenvattend, zoals beschreven in hoofdstuk 8 en 9, kan behandeling met 
RAS blokkade de vetweefselfunctie en vetmassa verbeteren. Deels kunnen deze 
veranderingen bijdragen aan een verbetering in insuline gevoeligheid. 
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RAS en spierweefsel
Onder invloed van insuline vormt de spier de grootste opslagplaats van glucose 
en spierweefsel is dan ook essentieel in het ontstaan van insuline resistentie. 
RAS blokkade kan de insuline gevoeligheid in de spier verbeteren via effecten op 
de doorbloeding van de spier, maar ook direct via veranderingen in de insuline 
signalering en werking in de spiercellen. Een verbetering in de doorbloeding van de 
spier zal bijdragen aan een toename in afgifte van insuline en glucose uit het bloed 
aan de spiercellen. In dierstudies verbeterde een behandeling met RAS blokkade 
de doorbloeding van de kleinste vaatjes in de spier [40,41]. In dit proefschrift is de 
doorbloeding van de vaatjes onder de nagelriem bekeken. De doorbloeding van 
deze vaatjes bleek in eerdere onderzoeken een goede relatie te laten zien met de 
vaatjes in de spier. In hoofdstuk 7 wordt beschreven dat deze kleine vaatjes in de 
vinger een verminderde structuur en functie hebben bij mensen met een gestoorde 
glucosestofwisseling ten opzichte van gezonde controles. Echter, behandeling met 
valsartan had geen effect op deze vaatjes. Het kan zijn dat een langere behandeling 
met een RAS blokker nodig is om een dergelijk effect te bewerkstelligen. Daarnaast 
kunnen andere patiëntenpopulaties meer baat hebben bij deze behandeling, 
bijvoorbeeld mensen met een hoge bloeddruk. Toekomstige studies zijn nodig om 
hierover meer inzicht te geven.
Toekomstperspectieven
Het toenemende aantal mensen met (een hoog-risico op) T2DM, noodzaakt het 
vinden van een behandeling welke de achteruitgang van beta-cel functie en 
insuline gevoeligheid kan tegen gaan en zo nodig de reeds bestaande verstoringen 
kan herstellen. Leefstijlveranderingen, gezonder eten en meer bewegen, hebben 
bewezen het ontstaan van diabetes aanzienlijk te kunnen uitstellen. Helaas blijkt het 
erg moeilijk een gezonde leefstijl te continueren, waardoor een groot deel van de 
mensen alsnog T2DM ontwikkelt. Nieuwe glucose-verlagende therapieën kunnen 
helaas de ziekte ook niet voorkomen. Dit heeft tot gevolg dat oudere veelgebruikte 
medicatie die de klachten verlichten, maar niet de progressie voorkomen, middelen 
van eerste keuze blijven. Recente grote studies laten zien dat RAS blokkade mogelijk 
de ziekte kan uitstellen. Deel 2 van dit proefschrift beschrijft de onderliggende 
mechanismen die hier mogelijk aan bijdragen, waarbij een verbetering in insuline 
gevoeligheid (o.a. via verbeterde vetweefselfunctie) en beta-cel functie voorop 
staan.  
Mensen met een gestoorde glucosestofwisseling hebben frequent bijkomende 
problemen, zoals een hoge bloeddruk. Derhalve is bloeddrukverlagende medicatie 
met een neutraal danwel positief effect op de glucose- en vetstofwisseling 
wenselijk. In dit proefschrift wordt het positieve effect van RAS blokkade op de 
glucose- en vetstofwisseling beschreven. Dit proefschrift kan er aan bijdragen 
dat artsen, bij het voorschrijven van bloeddrukverlagende medicatie aan mensen 
met een hoge bloeddruk en bijkomende verstoringen in de stofwisseling zonder 
specifieke indicaties voor beta-blokkers en diuretica, overwegen als eerste keuze 
een RAS blokker voor te schrijven.
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Introductie
De meeste mensen die een proefschrift ontvangen bladeren meteen door naar 
het dankwoord. Dit is het hoofdstuk dat voor iedereen goed te begrijpen is, waar 
de andere hoofdstukken vaak toch wat lastiger zijn. Daarnaast is het leuk om te 
lezen wie er allemaal bedankt worden. Om de hoofdstukken voor het dankwoord 
wat begrijpelijker te maken, schrijf ik het dankwoord in de vorm van een artikel. 
In het kort vertel ik wat er over het algemeen besproken wordt in de betreffende 
sectie. Zo bevat de introductie een algemene achtergrond van het onderzoek. Er 
wordt beschreven wat er reeds bekend is over een bepaald onderwerp en welke 
problemen/onduidelijkheden er nog bestaan. De introductie eindigt meestal met de 
doelstelling van het onderzoek. In dit geval is de introductie de plek om de mensen 
te bedanken die vanaf het begin nauw betrokken zijn geweest bij mijn onderzoek; 
mijn promotoren en de ‘PRESERVERS’. 
Prof. dr. Diamant, beste Michaela, jij staat aan de basis van de PRESERVE studie 
en samen met Rob aan de basis van mijn carrière binnen het diabetes centrum. 
Je staat bekend als iemand die bijzonder gedreven en perfectionistisch is. Ik heb 
enorm veel bewondering voor je brede vakkennis, waarmee je feilloos aanvoelt 
waar nieuwe mogelijkheden liggen voor onderzoek. Met je kritische houding 
probeer je altijd je promovendi verder te helpen en ik heb dan ook waanzinnig veel 
van je geleerd de afgelopen jaren. Daarnaast hebben we in de afgelopen 8 jaar een 
bijzondere band opgebouwd en ik heb de persoonlijke betrokkenheid van Manon 
en jou enorm gewaardeerd. Ik zal de congresreisjes missen!
Prof. dr. Blaak, beste Ellen, samen met Michaela ben jij de motor achter dit 
proefschrift. Ik heb je begeleiding gedurende de studie als zeer prettig ervaren en 
ik wil je bedanken voor het vele meedenken over de resultaten en je waardevolle 
commentaren op mijn stukken. Bedankt dat je altijd bereid was op korte termijn 
input te leveren zodat ik weer verder kon. 
 
Chantalle, partner-in-crime, samen hebben we de klus geklaard! Je hebt een hele 
moeilijke tijd achter de rug, waar je je knap doorheen hebt geslagen. Ik bewonder 
je relativerings- en doorzettingsvermogen en de manier waarop je het onderzoek 
weer hebt opgepakt. Bedankt voor de fijne samenwerking, de heerlijke klaaguurtjes 
en je lieve mailtjes en kaartjes. Ik ben er van overtuigd dat ook jij op korte termijn 
je proefschrift zal afronden!
Gijs, ik durf hier te erkennen dat je het niet altijd makkelijk hebt gehad met 
Chantalle en mij ☺. Je kritische bijdrage binnen de PRESERVE studie heb ik erg 
weten te waarderen. Bedankt voor de goede samenwerking en veel succes met je 
toekomstige projecten. 
Materiaal en Methode
In dit deel wordt uitgelegd hoe het onderzoek is uitgevoerd (bijvoorbeeld de 
onderzoekspopulatie, gebruikte technieken en analysemethoden). Dit is onder 
andere belangrijk voor de betrouwbaarheid van het onderzoek. Ook kan deze 
informatie erg bruikbaar zijn voor andere wetenschappers die een soortgelijk 
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onderzoek willen uitvoeren. 
Dit proefschrift zou er niet zijn geweest zonder de deelnemers aan mijn studie. 
Wat hebben Jeannette en ik veel tijd doorgebracht met jullie op testkamer 5! Ik kijk 
met heel veel plezier terug op deze periode, waar iedere dag weer anders werd 
ingekleurd. Ik wil jullie enorm bedanken, niet alleen voor de bereidheid om de 
(intensieve) testdagen te ondergaan onder een strak regime van vroeg opstaan 
en nuchter komen, maar ook voor ieders vertrouwen en betrokkenheid bij mijn 
promotietraject. 
De testen zijn zoals gezegd grotendeels uitgevoerd op testkamer 5, met als grote 
steun Jeannette Boerop. Lieve Jeannette, wat heb je ongelooflijk veel voor me 
gedaan de afgelopen jaren. Naast het feit dat je ontzettend goed bent in je werk, 
ben je ook een prachtig mens die oog heeft voor haar omgeving en altijd voor 
iedereen klaar staat. Ontzettend bedankt voor de fijne tijd samen en ik kijk uit naar 
het glas witte wijn dat we samen gaan drinken op de afronding!
Daarnaast wil ik Ans, Nicolette, Sandra, Ingrid, Mariëlle, Greetje, Lilian, Louise en 
Jennifer bedanken voor hun hulp op de afdeling. Bedankt dat jullie altijd bereid 
waren bij te springen waar dat nodig was!
Voor het onderzoek maakten we ’s ochtends heel vroeg (het voelde meestal als 
midden in de nacht) MRI-scans. Ton, bedankt voor al je hulp en nogmaals sorry 
voor alle keren dat ik jou of je vrouw uit bed heb gebeld als het apparaat weer eens 
niet volgens mijn protocol werkte… Petra, het analyseren van de MRI-data was 
nooit gelukt zonder jouw hulp. Je bent de koningin van de sneltoetsen en ik ben 
me dan ook blijven verbazen over de ongekende snelheid waarmee jij bestanden 
bewerkt. Bedankt voor je tijd (‘tuurlijk, loop maar even langs, ik ben er…’), hulp en 
betrokkenheid bij mijn onderzoek. 
Sander, ontzettend bedankt voor alle tijd en energie die je hebt gestoken in het 
ontwerpen en vormgeven van mijn proefschrift, Studio Hartveld it is!
Resultaten
In het hoofdstuk resultaten wordt uitgelegd wat de bevindingen van het onderzoek 
zijn. Vaak wordt de data weergegeven in tabellen en grafieken. Voordat je data 
echter geanalyseerd is en het in het artikel staat, is er vaak heel wat afgemopperd; 
je SPSS loopt vast op een cruciaal moment, GraphPad werkt niet en komt er nou uit 
wat je verwacht had of gaat het toch de andere kant op? Je kamergenoten zorgen 
voor de eerste opvang van deze problemen…
Daniël Henry, dr D., wat een geluk dat we tegelijk aan ons promotietraject begonnen 
zijn, jij als AMC-autist en ik als VU-nerd! Ik heb waanzinnig veel van je geleerd 
op onderzoeksgebied en wil je bedanken voor al je kritische kanttekeningen en 
relativerende opmerkingen. Daarnaast hebben we een ontzettend gezellige tijd 
gehad, niet alleen op de VU, maar ook tijdens de congressen en de etentjes met 
Boudewijn en Lisette. Na L048 en 3A69 is het nu tijd om weer klinisch te gaan 
werken!
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Renate, Naat, op 3A69 kwam jij bij ons op de kamer en dat bleek een hit! Jouw 
cynische opmerkingen uit de hoek zijn legendarisch, je voorliefde voor skihuthits 
ongeëvenaard en je dans-moves als je je iPod aan hebt zijn waarschijnlijk de beste 
remedie tegen RSI-klachten. Bedankt voor alle bijklets-uurtjes op de VU en gezellige 
biertjes aan de bar, waarbij jouw teksten alleen maar beter werden gedurende de 
avond!
Alle collega’s van het diabetes centrum: Maarten, Mathijs, Luuk, Roger, Annemarie, 
Larissa, Mariska, Diane, Weena, Eelco, Liselotte en Jennifer, bedankt voor onze 
discussies, lunches, vrimibo’s en alle mooie momenten tijdens de congressen (club 
Level, de pool-party, EASD lapdance, Joe’s ride of joy en het dakterras in Rome!). 
Ook Remco, Michiel, Carolien, Rick, Mirjam, Christa, Trynke, Nienke, Marcel, Kelly 
en Ton wil ik bedanken voor de gezellige tijd. Succes met jullie onderzoek! 
Discussie
Dit deel bevat de belangrijkste bevindingen van het onderzoek. Daarnaast wordt 
beschreven hoe deze bevindingen passen bij de bestaande literatuur en wat nog 
onduidelijkheden zijn binnen het onderzoeksgebied. Er wordt ook kritisch gekeken 
naar de eigen bevindingen. Samen leidt dit tot een uiteindelijke conclusie van het 
onderzoek. 
Mijn onderzoek is kritisch beoordeeld door de leescommissie. Ik wil derhalve 
prof. dr. Bilo, prof. dr. Blom, prof. dr. Lips, prof. dr. Nijpels, dr. Rustemeijer en dr. 
Serné hartelijk danken voor het kritisch beoordelen van mijn proefschrift en hun 
bereidheid zitting te nemen in mijn promotiecommissie. 
Prof. dr. Heine, beste Rob, mijn eerste gesprek bij het diabetes centrum was met jou 
vanwege mijn onderzoeksstage. Daarop volgde een prachtige stage bij het Joslin 
Diabetes Center in Boston. Ik heb genoten van deze periode en daar is tevens mijn 
interesse ontstaan voor een promotieonderzoek. Ik wil je ontzettend bedanken 
voor de kansen die je me hebt geboden, je betrokkenheid bij mijn onderzoek en de 
inspirerende gesprekken die we samen hebben gevoerd. Bedankt dat ook jij zitting 
wilde nemen in mijn leescommissie. 
Tijdens mijn onderzoeksperiode heb ik veel steun gehad van vrienden en familie 
om mij heen. En ook al gingen de discussies en gesprekken vaak niet over het 
onderzoek, dit is toch de plek waar ik jullie wil bedanken. Senatus, lieve Nicci, Reiner, 
Willem en Bunnik, ik geniet iedere keer van de avonden en weekenden samen, 
dat er nog velen mogen volgen. Lieve Rosa, bedankt voor je fijne vriendschap en 
alle healthy food en sapjes de afgelopen jaren! Lieve Nely, je Friese nuchterheid 
wist menig promotieprobleem te relativeren, bedankt voor alle gezellige bakkies 
samen. Lieve Jose, Sas en Nien, kookpunt, bedankt dat jullie er altijd voor me zijn, 
op nog vele (heerlijke) avonden! PL-vriendinnen: Jungst, Buuf, Eefje, Guusje, Mies, 
Dochter, PvA en SvS wat is het fijn om jullie al 13 jaar als vriendinnen te hebben! 
O&N club: Hans en Fardo, Martin en Reina, Tjeerd en Emmely, Rob en Agnes, 
ontzettend bedankt voor jullie lieve betrokkenheid en gezellige weekenden!
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Lieve paps, mams, Niels, Eline, Koen en Seth, ook jullie hebben de afgelopen jaren 
veelvuldig voor me klaar gestaan. Bedankt voor jullie warme betrokkenheid en de 
vele gezellige momenten samen. Ik kijk er naar uit straks met onze kleine naar 
Schoorl te komen! Paps, ook wij zijn nu eindelijk collega’s ☺.
Lourens, lieve bro, je weet hoe bijzonder je voor me bent, op nog vele uren samen 
in een zeilboot of aan de bar! Fenneke, lieve sis, ik bof met een zus die altijd voor 
me klaar staat en betrokken is bij alles wat ik doe. Onze hechte band betekent heel 
veel voor me. Marieke en Mike, wat fijn dat jullie bij ons in de familie zijn, kan me 
geen betere schoonzus en zwager wensen! Taeke, Annelieke, Yfke en Marije, jullie 
zorgden voor heerlijke ontspanning en afleiding tussen het drukke promovendus 
bestaan door.
Lieve pap en mam, jullie hebben me altijd gesteund in mijn beslissingen, zo ook in 
het besluit om te promoveren. Wat fijn te weten dat jullie er altijd voor me zijn, ik 
geniet van onze gesprekken in Norg of Sneek onder het genot van een heerlijk glas 
wijn. Bedankt voor alles!
Lieve Bous, jij verwoordde het zo mooi met het liedje ´Alles´ van Herman van Veen 
op ons huwelijk. Ik wil je bedanken voor je onvoorwaardelijke liefde en steun. Ik 
geniet van al onze momenten samen en kijk uit naar de toekomst!   
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Nynke van der Zijl werd geboren op 19 september 1979 in Assen. Na de basisschool ‘de 
Hekakker’ in haar woonplaats Norg, volgde ze de VWO opleiding aan het Dr. Nassau 
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